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Abstract 
 
Flavonoids form a family of well known natural products present in most of the plant 
families. More than 8000 different flavonoids have been isolated from their natural source to 
date. The structural variations of these flavonoids are associated with many different 
biological and pharmacological activities, including anticancer activity, protection against 
cancer formation (chemo-protection), antioxidant activity, cardiovascular and hepatic 
protection, antibacterial, antifungal and antiviral activity. Flavonoids have also been reported 
to play an important role in hormone-related female diseases, such as breast cancer and 
menopausal syndrome. Natural flavonoids have therefore been subjected to many chemical 
modifications in order to improve their activity. As part of this thesis, I have added moieties 
such as an amino alkyl chain, selenium and tellurium containing moieties. As part of an 
approach to generate flavonoid derivatives more active and specific toward cancer cells, 
addition of a chromene ring (ring D) to the flavonoid core structure resulted in chromene-
flavone derivative. Aromatase is a group of cytochrome P450 enzymes responsible for the 
biosynthesis of estrogen, the main stimulant of breast cancer cell growth. Some of the 
flavonoid derivatives tested (natural as well as synthetic) turned out to be good aromatase 
inhibitors and may be studied further in the treatment of breast cancer. Ten natural products in 
addition to 38 synthetic flavonoid derivatives were subjected to various in vivo and in vitro 
bioassays in order to understand the various antioxidant, cytotoxic and aromatase inhibiting 
properties associated with these compounds. 
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Kurzdarstellung 
 
Die Familie der Flavonoide ist als Naturprodukte sehr gut bekannt und findet sich in 
einem Großteil der Pflanzenfamilie wieder. Mehr als 8000 verschiedene Flavonoide wurden 
zum jetzigen Zeitpunkt aus Quellen natürlichen Ursprungs isoliert. Die strukturellen 
Unterschiede dieser Flavonoide, sowie deren Wirkung gegen Krebs, Schutz vor 
Krebsentstehung, Antioxidantien-Aktivität, kardiovaskulärer und hepatischer Schutz sowie 
antibakterielle, antifungizide als auch antivirale Aktivität, spiegeln sich in verschiedenen 
biologischen und pharmakologischen Aktivitäten wider. Flavonoide spielen zudem bei 
hormonell bedingten Erkrankungen, die überwiegend bei Frauen auftreten, wie z.B. 
Brustkrebs oder das menopausale Syndrom, eine wichtige Rolle. Aus diesem Grund wurden 
natürliche Flavonoide 
für diese Studien ausgesucht, die chemisch modifiziert worden sind, um deren Aktivität 
erhöhen zu können. Als Teil dieser Doktorarbeit wurden verschiedene Reste, wie z.B. 
Aminoalkylketten, Selen sowie auch Tellur hinzugefügt. 
Um eine höhere Aktivität sowie Spezifität der Flavonoid-Derivate gegenüber 
Krebszellen erzielen zu können, wurde das Flavonoid-Grundgerüst mit einem Chromen-Ring 
(Ring D) ergänzt. 
Aromatase gehört zur Gruppe der Cytochrom P450 Enzyme, die für die Biosynthese 
von Östrogen verantwortlich sind, einem wichtigen Förderer des Wachstums von Brustkrebs-
Zellen. 
Sowohl natürliche als auch synthetische Flavonoid-Derivate stellten sich als gute 
Aromatase-Inhibitoren heraus and könnten später vielleicht in der Brustkrebs-Therapie 
eingesetzt werden. 
Zehn natürliche Produkte sowie 38 auf synthetischem Wege hergestellte Derivate 
wurden in verschiedenen in vivo und in vitro Bioassays eingesetzt, um die antioxidativen, 
cytotoxischen, als auch die Aromatase inhibierenden Eigenschaften besser verstehen zu 
können. 
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Abreviations 
 
A Unlabeled androstenedion 
ANS Anthocyanin synthase 
ATP Adenosine triphosphate 
br s Broad singlet 
Brine Saturated solution of sodium chloride 
calcd Calculated  
cAMP Cyclic adenosine monophosphate 
CC Column chromatography 
CDCl3 Chloroform 
CH2CL2 Dichloromethane 
CHI Chalcone isomerase 
CHS Chalcone synthase 
13C NMR Carbon Nuclear magnetic resonance 
COSY Correlation spectroscopy 
d Duplet 
dd Duplet of duplet 
DFR Dihydroflavone-4-reductase 
DMF Dimethyl formamide 
DMSO Dimethyl sulfoxide 
DPPH 1,1-Diphenyl-2-picrylhydrazyl 
ER Estrogen receptor 
EtOAc Ethyl acetate 
EtOH Ethanol 
FCS Fetal calf serum 
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Fig Figure 
FLS Flavone synthase 
FSH Follicle stimulating hormone 
g Gram 
G6P Glucose-6-phosphate 
G6PDH Glucose-6-phosphate dehydrogenase 
3HA Labeled androstenedione 
HDL High density lipoprotein 
HMBC Heteronuclear multiple bond correlation 
1H NMR Proton Nuclear magnetic resonance 
HR-MS High resolution-mass spectroscopy 
hrs Hours 
HSQC Heteronuclear single quantum coherence 
IC50 50 % inhibition concentration 
IFS Isoflavone synthase 
Kg Kilograms 
L Litre 
LC-MS Liquid chromatography-mass spectroscopy 
LDL Low density lipoprotein 
m/z Mass to charge ratio 
m Multiplet 
mCi Millicurie 
MeOH Methanol 
mg Milligrams 
min Minutes 
mL Millilitres 
MMP Matrix metallo protein 
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mp Melting point 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NADPH Nicotinamide adenine dinucleotide phosphate 
n.d. Not determined 
NMR Nuclear magnetic resonance 
OS Oxidative stress 
PBS Phosphate buffered saline 
PgR Progesterone receptor 
PLA Phenylalanine amminolyase 
ppm Part per million 
q Quartet 
RNO Reactive nitrogen species 
ROS Reactive oxygen species 
RPMI 1640 Roswell Park Memorial Institute 1640-medium 
r.t. Room temperature 
s Singlet 
SERM Selective estrogen receptor modulator 
t Triplet 
TLC Thin layer chromatography 
TNFα Tumor necrosis factor α 
δ Chemical shift 
% Percent 
µCi Microcurie 
µM Micro molar 
µL Micro litre 
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Chapter I: Introduction 
 
Natural, mainly plant-derived constituents have long been sources of drugs, and a large 
proportion (30–40%) of the pharmaceuticals available in modern medicine is directly or 
indirectly derived from natural sources. Natural products are also of great interest in the 
process of drug discovery. Due to their large diversity in nature, they permit the identification 
of leading molecules of interest for the development of new therapeutic agents. Furthermore 
they provide biochemical and molecular tools needed to clarify complex cellular and 
molecular mechanisms of action involved in most physiological and pathological processes. 
Ultimately, a growing world-wide interest in the use of phytopharmaceuticals as 
complementary or alternative medicine, either for the prevention or treatment of many 
diseases, has been noted in recent years. It is believed that about 80% of world’s population 
uses plants as their primary source of medicinal agents. Flavonoids in particular are 
considered to be one of the most important natural products and one of the most commonly 
used compounds around the world. 
 
1.1. Flavonoids 
 
1.1.1. Flavonoids in nature 
 
Flavonoids are a group of naturally occurring polyphenolic compounds ubiquitously 
found in plants [1]. Considering the means of defense and communication that plants acquired 
through evolution, flavonoids form one of the most important chemical classes of natural 
products. Flavonoids first appeared in green algae 500 million years ago, resulting from the 
fusion of two biogenetic pathways, namely the cinnamate and the ancient polyketide route. 
They have then become more and more complex with plant evolution [2]. 
We can attribute a large biological importance to flavonoids, not only for the vegetal 
kingdom itself, but also for humans and animals. Flavonoids are increasingly thought to be 
responsible for the longer life expectancy of populations with well-balanced and healthy diets. 
Such a diet consist of a high amount of fruit and vegetables as well as beverages from 
vegetable origin, particularly tea and juice, which make it rich in flavonoids and other 
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polyphenols [3, 4]. This nutritious phenomenon has often been referred to as the ‘French 
paradox’ [5]. French paradox is the observation that the French suffer a relatively low 
incidence of coronary heart disease. The phenomenon was first noted by Irish physician 
Samuel Black in 1819. The term French paradox was coined by Dr. Serge Renaud, a scientist 
from Bordeaux University in France in 1992 [6]. 
Flavonoids generally occur in plants as glycosylated derivatives, and they contribute to 
the brilliant shades of blue, scarlet, yellow and orange, in leaves, flowers, and fruits [7]. Apart 
from various vegetables and fruits, flavonoids are found in seeds, nuts, grains, spices, and 
different medicinal plants as well as in beverages, such as wine (particularly red wine), tea, 
and at lower levels also in beer [8]. 
Over 8000 different naturally occurring flavonoids have been discovered [9] and the list 
is still growing. Most of these structurally different flavonoids can be arranged in various 
classes, and differ in the level of oxidation of the C-ring of the basic benzo-γ-pyrone 
structure. Common family members of flavonoids include flavones, flavanes, flavonols, 
catechins, and anthocyanidins (Fig 1). The structural difference in each flavonoid family 
results from the variation in the number and substitution pattern of the hydroxyl groups as 
well as the extent of glycosylation of these groups [10]. 
 
 
Fig 1: Chemical structure of some flavonoid members. 
 
1.1.2. Biosynthesis of flavonoids [10, 11] 
 
The B-ring and part of the heterocyclic ring of the flavonoid skeleton are provided by a 
suitable hydroxy-cinnamic acid-CoA ester, usually 4-coumaroyl-CoA, whereas the A-ring 
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originates from three acetate units via malonyl-CoA (Fig 2). Both precursors are derived from 
carbohydrates. Malonyl-CoA is formed from acetyl-CoA and CO2 catalysed by acetyl CoA 
carboxylase. 4-Coumaroyl-CoA and related hydroxycinnamic acid esters are supplied by the 
first steps of the general phenylpropanoid pathway. This pathway starts from the aromatic 
amino acid phenylalanine, which is synthesized via the shikimate arogenate pathway. The key 
reaction is the deamination of phenylalanine catalysed by phenylalanine ammonialyase 
(PAL). This enzyme links the primary metabolism with the phenylpropanoid pathway. The 
product of the reaction, trans-cinnamate, is hydroxylated to 4-coumarate by cinnamate 4-
hydroxylase, a cytochrome P450 mixed-function monooxygenase. Activation of 4-coumarate 
by formation of the CoA ester is catalysed by 4-coumarate-CoA ligase. 4-Coumaroyl-CoA 
can be hydroxylated in position 3 to caffeoyl-CoA, which may serve as a substrate for 
chalcone formation besides 4-coumaroyl-CoA in some plant species. Three different enzyme 
activities have been demonstrated for caffeoyl-CoA formation from 4-coumaroyl-CoA. 
The key enzyme for the formation of the flavonoid skeleton is chalcone synthase 
(CHS), which catalyses the stepwise condensation of three acetate units from malonyl-CoA 
with 4-coumaroyl-CoA to the fifteen carbon intermediate 2´,4´,6´,4-tetrahydroxychalcone 
(Fig 2). The respective 6'-deoxychalcone, isoliquiritigenin, is likewise synthesized from 
malonyl-CoA and 4-coumaroyl-CoA by chalcone synthase but in coaction with a (reduced 
nicotinamide adenine dinucleotide phosphate) (NADPH)-dependent reductase. Both chalcone 
types may be the direct precursors for aurones and other diphenylpropanoids. The enzymes 
involved in these reactions are still unknown. But, in particular, the 6´-hydroxy- and 6´-
deoxychalcones are the immediate precursors for all flavonoid compounds. The stereospecific 
cyclization of the chalcone, catalysed by chalcone isomerase, provides 25-flavanones with the 
typical flavonoid skeleton (Fig 2). Two types of chalcone isomerases are known: one 
catalysing cyclization of 6´-hydroxy-chalcone to 5-hydroxyflavanone and another isomerizing 
both 6´-hydroxy- and 6´-deoxychalcone to 5-hydroxy-and 5-deoxyflavan-one, respectively. 
Flavanones are the direct precursors for other natural products, such as the large class of 
flavones, isoflavones that are involved in phytoalexin synthesis, and the two flavonoid 
intermediates, the flavan-4-ols and the dihydroflavonols. Flavones are synthesized from 
flavanones by introduction of a double bond between C-2 and C-3. Two types of enzymes, 
flavone synthase I, (a 2-oxoglutarate-dependent dioxygenase), and flavone synthase II, (a 
cytochrome P450 mixed-function monooxygenase), were found to catalyse this reaction. 
Formation of isoflavones from flavanones is catalysed by 2-hydroxy-isoflavanone synthase, 
Chapter I  Introduction 
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another cytochrome P450 mixed-function monooxygenase, coacting with a dehydratase 
protein. The enzyme accepts both 5-hydroxy- and 5-deoxyflavanones as substrates. The 
reaction involves an oxidative rearrangement of the flavanone, including a shift of the aryl 
ring from position 2 to 3.  
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Fig 2: Schematic overview of the major branch pathways of flavonoid biosynthesis, starting from carbohydrates 
and leading to twelve flavonoid groups adapted according to [10]. 
 
The reduction of the carbonyl group of flavanones gives rise to flavan-4-ols. The 
reaction is catalysed by flavanone-4-reductase and provides the immediate precursors for the 
formation of 3-deoxy-anthocyanins (Fig 2). 
Finally, flavanones can be hydroxylated in position 3 to dihydroflavonols, which are 
biosynthetic intermediates in the formation of flavonols, catechins, proanthocyanidins and 
anthocyanidins. This reaction is catalysed by flavanone 3-hydroxylase, a 2-oxoglutarate-
dependent dioxygenase. 
Dihydroflavonols are the direct substrates for most of the flavonols and flavan-3,4-diols, 
which are also known as leucoantho-cyanidins. Flavonols are formed from dihydroflavonols 
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by introduction of a double bond between C-2 and C-3. The reaction is catalysed by flavonol 
synthase, another 2-oxoglutarate-dependent dioxygenase. Reduction of dihydroflavonols in 
position 4, catalysed by dihydroflavonol-4-reductase, leads to flavan-2,3-trans-3,4-cis-diols, 
which are intermediates in catechin, proanthocyanidin and anthocyanidin formation. 
Catechins are synthesized from leucoanthocyanidins by further reduction in position 4. This 
reaction is catalysed by flavan-3,4-cis-diol-reductase. Proanthocyanidins probably originate 
from leucoanthocyanidins and catechins by a condensation reaction. The enzyme catalysing 
this reaction is not yet known (Fig 2). 
The formation of the glycosidic linkage(s) is catalyzed by transferases which are also 
highly specific, as far as the substrate and the glycosylation positions are concerned. These 
enzymes require the presence of uridine diphospho-saccharides (UDP-saccharides). Acyl-
transferases are also specific enzymes for the acylation of some glycosides such as 
anthocyanins. 
 
1.1.3. Metabolism of flavonoids 
 
During metabolism of flavonoids, hydroxyl groups are added (Phase I 
biotransformation), and then methylated, sulfated or glucuronidated (Phase II 
biotransformation). In food, flavonoids exist primarily as 3-O-glycosides and polymers [12]. 
Several types of higher structures exist, and polymers comprise a substantial fraction of 
dietary flavonoid intake [13]. Enzymatic oxidation of green tea leaves during fermentation to 
black tea results in polymerization of flavanols to tannins and other complex compounds [14]. 
The most common glycosidic unit is glucose, but other examples include 
glucorhamnose, galactose, arabinose, and rhamnose [15]. Not surprisingly, the β-linkage of 
these sugars resists hydrolysis by pancreatic enzymes, so it had long been assumed that 
intestinal microbiota were responsible for beta-hydrolysis of sugar moieties. However, two β-
endoglucosidases capable of flavonoid glycoside hydrolysis have since been characterized in 
the human small intestine, including lactase phlorizin hydrolase [16, 17] and a nonspecific 
cytosolic enzyme believed to deglycosylate flavonoids to allow a site for conjugation [18, 19]. 
Luteolin-7-glucoside, kaempferol-3-glucoside and quercetin-3-glucoside are hydrolyzed and 
absorbed by the small intestine, supporting β-glucosidase activity [20], but it’s also known for 
some flavonoid glycosides to be absorbed intact, e.g. anthocyanin glycosides [21]. 
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Absorption may also depend on dosage, vehicle of administration, antecedent diet, sex 
differences [22], and microbial population of the colon. For hydrolysis and absorption of 
some flavonoid glycosides, enteric bacteria are necessary. The requirement of colonic 
microflora for hydrolysis of rutinosides, for instance may explain the low bioavailability of 
rutin (quercetin-3-rutinoside) compared to quercetin-3-glucoside in human studies. 
Researches have shown that a glucose moiety increases absorption of quercetin in the 
small intestine to 52 %, compared to 24 % for the aglycone and 17 % for rutin. Quercetin 
glucoside, but not rutin, has been reported to interact with epithelial glucose transporters, 
offering a possible explanation for the rapid uptake and bioavailability of glucosides [23]. 
 
1.1.4. Distribution of flavonoids 
 
Flavonoids constitute one of the most important classes of compounds in higher plants. 
Many flavonoids are easily recognized as flower pigments in most angiosperm families 
(flowering plants). Their occurence is not restricted only to the flowers, but can be found in 
all parts of the plant. 
Flavonoids are present in all vascular plants but some classes are more widely 
distributed than others. While flavones and flavonols are universal, isoflavones and 
biflavonoids are found only in few plant families [24]. 
Bryophyte plants as well as certain types of green algae, particularly Nitella hookeri 
[24], fungi, such as Aspergillus candidus [25], and marine coral Echinophora labellosa [26], 
also have a biosynthetic ability to produce flavonoids. 
Out of all the plant families, the family Leguminosae is perhaps most endowed with 
flavonoid constituents, and many of such flavonoids are only found in Leguminosae plants 
[27]. Anthocynin pigments are widely distributed in the floral tissue of this family and many 
flavones and flavonol glycosides have been isolated from different leaves, bark, stems and 
roots of Leguminosae plants. A typical flavonol glycoside found in Leguminosae, for 
instance, is Robinin, which has first been recorded in the leaves of Robinia pseudoacacia 
[27]. Isoflavonoids are almost unique to the Leguminosae, and most of these compounds are 
restricted to the sub family Papilionoideae [27]. 
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1.2. Botanical general characters of family Leguminosae 
 
The family Leguminosae includes trees, shrubs, woody vines, and annual or perennial 
herbs. Leaves are usually alternate and compound–bipinnate, simple pinnate, or palmate, but 
rarely simple. Inflorescence is variously racemose, in simple racemes, panicles, spikes, or 
heads. Flower structure varies to the extent that 3 subfamilies (Mimosoideae, 
Caesalpinioideae, Papilionoideae) are recognized; corolla typically 5-parted; stamens 3-
many, mostly 10, free, or united by their filaments in various ways, pistil simple, free. The 
Fruit is characteristically a legume, dehiscent or indehiscent [28, 29]. 
Among the various leguminal plants we did select Delonix regia and Robinia 
pseudoacacia in this study in order to isolate the flavonoid constituents and so investigate 
their biological activities. 
 
1.2.1. Delonix regia 
 
Delonix regia is a species of flowering plant from the Fabaceae family (the new name 
of the family Leguminosae). This tree is native to Madagascar and is often grown as an 
ornamental tree in many countries around the world, consistently voted among the Top Five 
most beautiful flowering trees in the world. Delonix regia is also known as the Royal 
Poinciana or Flamboyant [32]. This plant was previously placed in the genus Poinciana, 
named after Phillippe de Longvilliers de Poincy (1583-1660), who is credited with 
introducing the plant to the Americas. 
 
Taxonomy  
Delonix regia is classified under class Dicotyledons, subclass Rosidae, order Fabales, 
family Fabaceae, genus Delonix and species regia. 
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1.2.2. General botanical character of Delonix regia 
 
The Royal Poinciana grows to a height of 9-15 meters with an elegant, wide-spreading, 
umbrella-like canopy which sometimes exceeds the height of the tree in diameter. Royal 
Poinciana is deciduous in climates that have a marked dry season, but in tropical areas (where 
the winter is not that much dryer than the summer), it is a semi-evergreen tree. 
The leaves are even-pinnate, alternate, and can grow up to 66 cm long, 10-25 pairs of 
opposite pinnate, and 12-40 pairs of small oblong leaflets. The flowers are Caesalpinaceous, 
can grow up to 12 cm wide, consisting of 5 red or yellow petals, or standard of red splashed 
with burgundy spots. They are arranged on racemes that can reach up to 25 cm long. The 
fruits are Pods, long, hard, flat, slightly curved and dehiscent [30, 31]. 
 
1.2.3. Destribution of flavonoids in Delonix regia  
 
Many publications take in consideration the Delonix regia fatty acids and sterols 
(Stigmasterol, γ-Sitosterol, β-Amyrin) as well as protein and lectin content. In contrast only 
two of these publications deal with the isolation and characterization of Delonix regia 
flavonoids [32, 34]. The flavonoids isolated from this plant are summaried in Table 1 and 
Table 2. 
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Table 1: Cyanidin glycosides isolated from Delonix regia [32, 33]. 
OHO
OH
O
O
H
OH
OH
H
H
H
HO
H
RO
R1
 
Compound R R1 
cyanidin 3-O-glucoside H OH 
cyanidin 3-O-rutinoside Rhamnoside OH 
pelargonidin 3-O-rutinoside Rhamnoside H 
cyanidin 3-O-gentiobioside, Glucoside OH 
 
 
Table 2: Flavone glycosides isolated from Delonix regia [34]. 
 
Compound R R1 R2 
Kaempferol-3-O-glucoside H H H 
Kaempferol-3-O-rutinoside H Rhamnoside H 
kaempferol -3-O- rhamnosyl 
neohesperidoside 
H Rhamnoside Rhamnoside 
Kaempferol-3-O-neohesperidoside H H Rhamnoside 
Quercetin-3-O-rutinoside OH Rhamnoside H 
 
1.2.4. Traditional uses of Delonix regia 
  
The extract of Delonix regia is known to have medicinal properties [35, 36]. This plant 
is used in several countries to prepare extracts with antimicrobial and antifungal activities [37] 
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and can be used as an antibiotic [38]. In Ivory Coast, for instance, traditional medicines are 
prepared from several parts of the tree, including the flowers. In rural areas, water extracts are 
generally homemade from Delonix regia flowers. 
 
1.2.5. Robinia pseudoacacia  
 
Robinia pseudoacacia, the black locust, is named after Jean Robin (1550-1629), and his 
son, Vespasian (1579–1662), the Royal Gardeners in Paris during the reign of Henry IV. 
According to one historical record, seeds of R. pseudoacacia were sent to Jean from Canada 
and cultivated by him on a large scale in 1601. Another record cites the planting of the seed 
by Vespasian in 1635, who was at that time the arborist to Louis XIII in the Jardin des 
Plantes, Paris [39]. 
The genus Robinia has 40 species native to temperate regions of north-east America and 
is noteworthy for its ability to tolerate frost. Robinia species have fragrant flowers and are a 
good source of pollens necessary to bee honey production. In the Danube Basin, this so-called 
acacia honey commands a higher price than other kinds of honey. 
 
Taxonomy  
Robinia pseudoacacia is classified under class Dicotyledons, subclass Rosidae, order 
Fabales, family Fabaceae, genus Robinia and species pseudoacacia. 
1.2.6. General botanical character of Robinia pseudoacacia 
 
The black locust is a medium-sized, native, deciduous tree belonging to Family 
Leguminosae. The height of a mature plant can range anywhere between 12-18 m. This 
deciduous plant can take the form of a shrubs or a tree, and can vary in size (from small to 
large). The trunks of the black locust tend to be long, straight and slender. Their branches are 
known to be slender, terete, angled, and zigzagged, and their bark is furrowed. The stipular 
spines grow on twigs and young branchlets. The leaves are imparipinnate and petioled while 
the leaflets consist of 6-20 pairs and are small, oblong, penniveined and petiolated. The 
stipules present are stipules setaceous, spinescent at maturity and are persistent. The flowers 
are white or pink, and present on long slender pedicels. The bracteoles are caduceus or absent. 
The calyx is campanulate and divided into 5 lobes, the upper 2 lobes are shorter than others. 
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The stamens are didelphous and around 10 in number. The ovary is linear-oblong and inserted 
at the base of the calyx [40]. 
 
1.2.7. Distribution of flavonoids in Robinia pseudoacacia 
 
As with Delonix regia, Robinia pseudoacacia contain many fatty acids, sterols, protein and 
lectins, which have reported, together with a large number of triterpenoidal saponins and 
carbohydrates [41-43]. Importantly Robinia pseudoacacia also contain several types of 
flavonoids which may exert significant health benefits. Tables 3-7 and Fig. 3 and Fig 4 
provide an overview of some of the flavonoids found in Robinia pseudoacacia.  
 
Table 3: Flavones and Flavonols isolated from Robinia pseudoacacia [44-50]. 
O
O
R5'
R4'
R7
H
R5
R
R3'
H
H
H
1
2
34
5
6
7
8
9
10
1`
2`
3`
4`
5`
6`
 
Compound R R5 R7 R3` R4` R5` 
4`,7-dihydroxyflavone H H OH H OH H 
Apigenin H OH OH H OH H 
Chrysoeriol H OH OH H OH OCH3 
Acacetin H OH OH H OCH3 H 
Robinetin OH H OH OH OH OH 
Fisetin OH H OH OH OH H 
Quercetin OH OH OH OH OH H 
Robinin A H O-Rha H H H 
Robtin Rha H Rha H H H 
A= Robinobioside (rhamnosyl(1to 6)galactose. 
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Table 4: Chalcones isolated from Robinia pseudoacacia [51-53]. 
H
O
R5
OH
HO
R2`
R3
6`
5`
4`
3`
2`
1` 

'
1
2
3
4
5
6
H
H
H
H
 
Compound R3 R5 R2` 
isoliquiritigenin H H H 
Robtein OH OH OH 
Butein OH H OH 
 
 
Table 5: Dihydroflavones and dihydroflavonols isolated from Robinia pesudoacacia [46, 49, 54, 55]. 
O
O
R5'
OH
HO
H
R5
R
R3'
H
H
H
1 2
34
5
6
7
8
9
10
1`
2`
3`
4`
5`
6`
 
Compound R R5 R3` R5` 
Chrysoeriol H OH H OCH3 
Dihydrofisetin OH H OH H 
Dihydrorobinetin OH H OH OH 
Naringenin H OH H H 
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Fig 3: Flavanes isolated from Robinia pesudoacacia [56].  
O
H
OH
HO
H
OH
OH
H
H
H
1
2
3
4
5
6
7
8
9
10
1`
2`
3`
4`
5`
6`
OH
H O
H
OH
HO
H
OH
OH
H
H
H
1
2
3
4
5
6
7
8
9
10
1`
2`
3`
4`
5`
6`
H
OH
H H
(+)-Catechin (-)-Catechin
 
 
 
 
Table 6: Isoflavones isolated from Robinia pseudoacacia [57]. 
 
Compound R5 R3´ R4´ R5´ 
3`-Methoxydaidzein H OCH3 OH H 
Formonetin H H OCH3 H 
Biochanin A OH OH OCH3 H 
Mucronulatol H OCH3 OH OCH3 
 
O
O
8
9
10
2
3
1'
6'
2'
R5
HO
H
R3'
R4'
R5'
7
6
H
H
H
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Table 7: Isoflavanes isolated from Robinia pseudoacacia [58]. 
O8 9
10
2
1'
6'
H
HO
H
R3'
R4'
R5'
R2'R
H
H
6
5
3
7
 
 
Compound R R2` R3` R4` R5` 
Isovestitol H OCH3 H OH H 
Isomucronulatol H OH OCH3 OCH3 H 
Secondifloran OH OH OH OCH3 -C(CH3)2 CH=CH2 
 
Fig 4: Pterocarpan isolated from Robinia pesudoacacia [59]. 
O
O
HO
OCH3
Medicarpin
4
3
7
4'
6'
 
 
 
1.2.8. Traditional uses of Robinia pseudoacacia 
 
Black locust flowers have a long tradition in the preparation of tea. Tonic, purgative, 
and emetic properties have been reported for the inner bark and roots of this tree [47]. 
 
1.3. Biological activities of flavonoids 
 
Flavonoids may have existed in nature for over 500 million years and thus have 
interacted with evolving organisms over the eons. Clearly, flavonoids serve important 
purposes in nature, having survived in vascular plants throughout evolution [2]. Flavonoids 
not only equip the plants themselves with unique properties (such as colors), but also exert an 
influence on animals living with plants. The long association of plant flavonoids with various 
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animal species and other organisms throughout evolution may account for the extraordinary 
range of biochemical and pharmacological activities of these chemicals in mammalian and 
other biological systems. 
First of all, we will consider the effects on the plant itself. Flavonoids have important 
roles in plant biochemistry and physiology, they act as antioxidants, enzyme inhibitors, and 
precursors of toxic substances, while they also take part in nitrogen fixation, and act as 
pigments and light screens [60]. In addition, these compounds are involved in 
photosensitization and energy transfer. Certain flavonoids also function as plant growth 
hormones and growth regulators. They are involved in the control of respiration, 
photosynthesis, morphogenesis, and sex determination, as well as defence against infections 
[61]. 
On the other hand, in humans and higher animals, flavonoids have long been recognized 
to possess anti-inflammatory, antioxidant, ant-allergic and hepato-protective properties. They 
are also believed to be antithrombotic, antibacterial, antifungal, antiviral, and cancer 
protective, and also to protect against cardiovascular disease [62-64]. 
 
Small alternations in the chemical structure of flavonoids may lead to significant 
changes in biological activities, e.g. chrysin is a poor antioxidant compared to quercetin (Fig 
5) -the latter has increased antioxidant activity due to the presence of three additional 
hydroxyl groups, yet chrysin is 20 times more effective in the inhibition of the human 
aromatase enzyme (see below) [65]. 
 
 
Fig 5: Chemical structure of chrysin and quercetin. 
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1.3.1. Antioxidant activities associated with flavonoids 
 
Numerous publications have investigated the antioxidant activities of flavonoids and 
how they can contribute to the treatment of several diseases. Considering these publications, 
they indicate that biological and pharmacological effects of flavonoids may depend upon their 
behavior as either antioxidants or as prooxidants. Some flavonoids can behave as both 
antioxidants and prooxidants, depending on concentration and the redox environment present. 
For instance, certain flavonoids act as antioxidants against free radicals, yet demonstrate 
prooxidant activity when a transition metal such as Cu2+is present [66]. 
Three important points must be illustrated in order to better understand antioxidant 
activity of flavonoids and the important role of flavonoids compounds in human biology: 
a. The role of oxidative stress in human diseases. 
b. The antioxidant structure-activity relationship of flavonoids. 
c. The structure characteristics of an effective flavonoid antioxidant. 
 
a. The role of oxidative stress in human diseases 
 
Oxidation is the transfer of electrons from one atom to another. It represents an essential 
part of our metabolism and aerobic life in general, since oxygen is the ultimate electron 
acceptor in the electron flow systems that transport energy in the form of ATP [67]. Problems 
may arise however when the electron flow generates free radicals, such as O2-centred free 
radicals, known as reactive oxygen species (ROS), and including superoxide (O2˙¯), peroxyl 
(ROO˙), alkoxyl (RO˙), hydroxyl (HO˙) and nitric oxide (NO˙) radicals. 
The contribution of free radical-mediated processes to the pathogenesis of human 
disease is indicated by biomarkers of oxidative damage to lipids, proteins, and DNA (Fig 6). 
Such markers have been identified in patients with atherosclerosis, certain cancers, 
neurodegenerative diseases, and lung disorders, especially those with an inflammatory 
component to their etiology. A range of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) have been implicated in the mechanisms of damage associated with disease 
development, including superoxide radical (O2˙¯), hydrogen peroxide (HOO˙), hypochlorite 
radical (ClO˙), ferryl heme protein species, lipid alkoxyl (RO˙) and peroxyl radicals (ROO˙), 
peroxynitrite (ONOO¯), nitric oxide (NO˙), and nitrogen dioxide radicals (NOO˙). 
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Reactive oxygen species (ROS) obey different rules in vivo. Some are involved in energy 
production, phagocytosis, regulation of cell growth and intracellular signaling, as well as 
recognizing of biologically important compounds [68]. 
  
Fig 6: Formation and impact of ROS on the human body. 
 
ROS may be very damaging, since they can attack lipids in cell membranes, proteins in 
tissues or enzymes, carbohydrates and DNA to induce oxidative modifications, which cause 
membrane damage, loss of protein function and DNA damage. This oxidative damage is 
considered to play a causative role in ageing and several degenerative diseases associated with 
it, such as heart disease, congestive dysfunction and cancer. Humans have evolved antioxidant 
systems to protect against free radicals. These systems include some antioxidants produced in 
the body (endogenous antioxidants) and others obtained from the diet (exogenous 
antioxidants). 
Defense systems against damage induced by ROS fall into three categories: 
 
 Preventative antioxidants that suppress free radical formation. 
 Radical-scavenging antioxidants that inhibit initiation of chain reactions and intercept 
chain propagation, including catalytic antioxidants. 
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 Antioxidants involved in repair processes. 
 
b. The antioxidant structure-activity relationship of flavonoids 
 
Flavonoids are polyphenolic substances that are based on the flavan nucleus which 
consists of 15 carbon atoms arranged in three rings (C6–C3–C6) (Fig 7). The rings are labeled 
A, B and C. 
 
Fig 7: Flavan skeleton. 
 
The major flavonoid classes include flavonols, flavones, flavanones, isoflavones 
flavanols, chalcones and aurones. Differences between the flavonoid classes are mostly 
limited to the pyrone ring (absence or presence of double bond, presence of 3-hydroxy and/or 
4-oxy groups) and in the number of hydroxyl groups in rings A and B (Fig 8).  
O
O
Flavone
O
O
OH
Flavonol
O
O
OH
Flavanol
"dihydroflavonol"
O
O
Flavanone
"dihydroflavone"
O
O
Isoflavone
O
Chalcone
O
Flavane
O
OH
OH
O
Aurone
HO
A C
B1
2
3
45
6
7
8
9
10
1´
2´
3´
4´
5´
6´
 Fig 8: Various classes of flavonoids which differ in the degree of oxidation and substitution. 
 
Flavonoids may be monomeric, dimeric, or oligomeric and vary greatly in molecular 
weight. Polymeric derivatives, called tannins, are divided into two groups relating to their 
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structure, i.e. condensed and hydrolysable. Condensed tannins are polymers of flavonoids and 
hydrolysable tannins contain gallic acid. 
 
Fig 9: Chemical structure of condensed and hydrolysable tannins. 
 
In order for a phenol to be classified as an antioxidant it must possess two properties: 
firstly, it should be oxidized properly when present in low concentrations compared to the 
substrate, hence delaying or preventing the autoxidation or free radical-mediated oxidation; 
secondly, the phenol free radical formed after scavenging must be stable (through 
intramolecular hydrogen bonding) to further oxidation and can not act as oxidant in its own 
right [67, 69]. Oxidisable substrates include almost all organic molecules found in food and 
living tissues including lipids, carbohydrates, proteins and DNA. 
The chemistry of the flavonoids is predictive of their free radical scavenging activity as 
the reduction potentials of flavonoids and the consequently radical form, are lower than those 
of alkyl peroxyl radicals and the superoxide radical, which therefore means the flavonoids 
may inactivate these radical species and prevent the deleterious consequences of their 
reactions [70-73]. 
The electron/H-donating properties of flavonoids are considered to be the basis of their 
antioxidant action. Their free radical scavenging properties are best approached through 
structure-antioxidant activity relationships. The ability of flavonoids to act as antioxidants by 
electron donation depends directly on the reduction potentials, and inversely on the reactivity 
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of the flavonoid molecules with dioxygen, as the generation of peroxyl radicals will propagate 
oxidative reactions. These concepts have been reviewed [74]. 
 
In essence, three types of structural properties have been recently known to appear to 
increase the antioxidant activity of the flavonoids; 
1- The ortho-dihydroxy structure in the B ring [75], which confers higher stability to the 
radical form and participates in electron delocalization. 
2- The 2,3 double bond in conjugation with a 4-oxo function in the C ring is responsible 
for electron delocalization from the B ring [69]. The antioxidant potency is related to 
structure in terms of electron delocalization of the aromatic nucleus. When these 
compounds react with free radicals, the phenoxyl radicals produced are stabilized by 
the resonance effect of the aromatic nucleus. 
3- The 3,5-OH and 4-oxo functional groups in the A and C rings are required for 
maximum radical scavenging potential. 
  
c. The structure characteristics of an effective flavonoid antioxidant. 
Quercetin is perhaps the best example of a flavonoid that displays these three structural 
properties, and so efficiently captures free radicals. 
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Fig 10: Delocalization and resonance of quercein radical. 
 
Quercetin has five free hydroxyl groups which can donate electrons and a complete 
resonance system which can stabilize the quercetin radical (Fig 10). Furthermore the hydroxyl 
groups at position 3, 5, 3´ and 4´ have a specific configuration that enables the quercetin 
molecule to bind with up to three metal ions (Fig 11) such as Cu2+ or Fe3+. These redox active 
metal ions may contribute to ROS production [76], via a Fenton-type radical generating 
chemistry. Sequestration of such adventitious metal isons may therefore also be considered as 
an antioxidant activity, as previously shown for the chelator desferoxamin [77] 
 
 
Fig 11: Metal binding site of quercetin. 
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1.3.2. Flavonoids and cancer therapy 
 
Cancer is the second most abundant cause of death in the United States and in many 
other western countries. According to the annual report of German cancer research center, 
over 450,000 new cases are diagnosed in Germany with 270,000 cancer-related deaths each 
year in females alone. The prognosis for a patient with metastatic carcinoma of the lung, 
colon, breast, or prostate remains a concerning issue and accounts for more than half of all 
cancer deaths [78]. 
Cancer may be controlled by a variety of means, including suppression, blockage, and 
transformation. Suppressing agents prevent the formation of new cancers from 
procarcinogens; blocking agents prevent carcinogenic compounds from reaching critical 
initiation sites; and transformation agents act to facilitate the metabolism of carcinogenic 
components into less toxic materials or prevent their biological actions. Flavonoids can act in 
all three ways [79]. 
Flavonoids may act at the different development stages of malignant tumors by 
protecting DNA against oxidative damage, inactivating carcinogens, inhibiting the expression 
of the mutagenic genes and enzymes responsible for activating procarcinogenic substances, 
and activating the systems responsible for xenobiotic detoxification [80]. 
Although most flavonoids appear to be nontoxic to humans and animals, they have been 
demonstrated to inhibit proliferation in many kinds of cancerous cell lines. For instance, it has 
been reported that flavonoids (quercetin and taxifolin) have antiproliferative effects on 
squamous cell carcinoma HTB43 [81]. Quercetin at 10 μM shows an antiproliferative activity 
against meningioma cells [82] and against colon cancer cells (Caco-2 and HT-29), with a 
dose-dependent effect [83]. Diosmin, another important Citrus flavonoid, which is on the 
market as a venotonic, has shown antiproliferative activity in Caco-2 and HT-29 colon cancer 
cell lines (IC50 203 µM), although with less efficacy than quercetin [84]. 
Comparison to the structure of the flavonoids shows that the presence of a double C2-
C3 bond in polyhydroxylated flavonoids increases the antiproliferative activity against certain 
cancer cell lines [85, 86]. Another structural element that may influence antiproliferative 
activity is the number and position of the substituents in the flavonoid base structure. Taking 
quercetin and myricetin as an example, the presence of one additional hydroxyl group in the 
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B-ring of myricetin leads to greater activity of this flavonol compared to quercetin when 
tested in B16F10 and Melan-A cell lines [87, 88]. 
Various mechanisms have been proposed to explain the antiproliferative activity of 
flavonoids. Flavonoids have been shown to inhibit several kinases involved in signal 
transduction, such as protein kinase C, tyrosine kinases, PI 3 kinases, or S6 kinase [89]. They 
can also interact with estrogen type-II binding sites [90, 91]. Flavonoids have been found to 
arrest cell-cycle progression at either the G1/S or the G2/M transition. 
Flavonoids have also been shown to affect formation of the metastases. Metastases form 
when cancer cells invade beyond the boundaries of the primary site and establish new tumors 
in distant organs, an bent considered to be a major cause of cancer death [92]. The invasion of 
surrounding tissues by cancer cells involves several steps, including matrix metalloproteinase 
(MMP) secretion, migration, invasion, and adhesion. Flavonoids have shown beneficial 
influences on all of these steps. The flavonoids quercetin and apigenin, for instance have been 
reported to possess the ability to inhibit lung colonization by the melanoma B16-BL6 cell line 
in a dose-dependent manner in vivo [93]. 
A particularly interesting influence on cell proliferation is observed in breast cancer. 
This type of cancer is the most common cancer among women in the Western world, with 
about 40,000 deaths from breast cancer in the US alone in 2000 [94]. 
Around 94 % of breast cancer cases are diagnosed at the early stage of the disease. The 
primary aim of treatment for early breast cancer is to maximize local control and to prevent 
the progression of the disease to metastatic sites as metastatic breast cancer is currently 
incurable [95]  
Approximately 75 % of breast cancers are positive for the estrogen receptor (ER) and/or 
progesterone receptor (PgR). As estrogen is the main stimulant in the development and 
growth of these tumors, the deprivation of estrogenic signaling has been the main form of 
hormonal therapy for patients with ER-positive and/or PgR-positive disease. Tamoxifen, 
which works by blocking the tumor’s ability to respond to estrogen stimulation, has been the 
main hormonal therapy used. Furthermore, aromatase inhibitors help to prevent the growth of 
these tumors by lowering the amount of estrogen in the body. This approach has recently 
attracted considerable attention. 
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1.3.3. Aromatase and estrogen biosynthesis 
 
Aromatase is an enzyme responsible for a key step in the biosynthesis of estrogens. It is 
a cytochrome P450 enzyme and belongs to family 19, subfamily A, polypeptide 1. In humans, 
aromatase is expressed in both the granulosa and luteal cells of the ovary, and also in various 
extra-glandular sites including the placenta, brain, bone, testis and adipose tissue [96]. 
Aromatase is encoded by the CYP19 gene, which maps to chromosome 15q21.2 in humans 
[97]. The structure and hormonal regulation of CYP19 is complex: the gene spans 123 kb, 
with a coding region of 30 kb comprising nine translated exons [98-101]. A number of 
untranslated first exons, each driven by a unique promoter, exist upstream of exon II [102, 
103]. These are spliced to a common site in the 5’ untranslated region. Tissue-specific 
regulation of CYP19 expression is achieved through the use of these different promoters, each 
of which is regulated by distinct hormonal factors. In the ovary, CYP19 expression is 
regulated by Follicle-stimulating hormone (FSH) which acts (through cAMP) via promoter II 
[97], whereas in the placenta, promoter I.I regulates CYP19 expression in response to 
retinoids [104]. In contast, in bone and adipose tissue, a distal promoter (promoter I.4) drives 
CYP19 expression under the control of glucocorticoids, class 1 cytokines or TNFα [105-107]. 
Estradiol is the most potent endogenous estrogen. Estradiol is biosynthesized from 
androgens by the cytochrome P450 enzyme complex known as “aromatase” [108]. This 
enzyme complex is found in the endoplasmic reticulum of the cell and is comprised of two 
major proteins [108, 109]. One protein is cytochrome P450arom, a hemoprotein that converts 
C19 steroids (androgens) into C18 steroids (estrogens) that contain a phenolic A-ring [108, 
110]. The second protein is NADPH-cytochrome P450 reductase, which transfers reducing 
equivalents to cytochrome P450arom. 
Three moles of NADPH and three moles of oxygen are used in the conversion of one 
mole of androgen substrate into one mole of estrogen product (Fig 12). Aromatization of 
androstenedione, the preferred substrate, proceeds via three successive oxidation steps, with 
the first two being hydroxylation of the angular C-19 methyl group. The final oxidation step 
proceeds with the aromatization of the A ring of the steroid and loss of the C-19 carbon atom 
as formic acid. 
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Fig 12: Estrogen biosynthesis pathway catalysed by aromatase (Figure adaptaed according to [111]). 
 
1.3.4. Inhibitors of human aromatase enzyme 
 
Two primary approaches have been developed to reduce the growth-stimulatory effects 
of estrogens in breast cancer: firstly it is possible to interfere with the ability of estrogen to 
bind to its receptor. (The drug tamoxifen, which is widely used in the treatment of breast 
cancer acts via this pathway). Secondly, the circulating levels of estrogen may be decreased 
by inhibiting estrogen synthesis via aromatase inhibitors. This approach has been proven to 
be rather effective [111], and aromatase inhibitors have been developed as therapeutic agents 
for controlling estrogen-dependent breast cancer. Investigations on the development of 
aromatase inhibitors began in the 1970s and have greatly expanded over the past three 
decades [112-119]. Today, we can distinguish two types of aromatase inhibitors, namely 
steroidal and nonsteroidal inhibitors. 
 
1- Steroidal inhibitors represent competitive inhibitors which compete with the substrate 
androstenedione for noncovalent binding to the active site of the enzyme and thereby 
decrease the amount of estrogen product level. The development of steroidal inhibitors 
builds upon the basic androstenedione nucleus and incorporates chemical substituents at 
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varying positions on the steroid. This is illustrated by formestane and 1-methyl-ADD, two 
estoroidal aromatase inhibitors commonly used to treat breast cancer (Fig 13). These 
inhibitors bind to the aromatase cytochrome P450 enzyme in the same manner as the 
substrate androstenedione. [111]. 
 
 
Fig 13: Formestane and 1-methyl-ADD, two steroidal inhibitors of aromatase commonly used 
in the treatment of breast cancer. 
 
2- Nonsteroidal inhibitors 
a- First generation aromatase inhibitos: nonsteroidal aromatase inhibitors possess a 
heteroatom as a common chemical feature and interfere with steroid hydroxylation by 
the binding of this heteroatom to the heme iron of the cytochrome P450s. Initial 
nonsteroidal inhibitors were nonspecific to the enzyme and also inhibited other 
cytochrome P450-mediated hydroxylations of steroidogenesis which resultes in 
significant toxicity. Aminoglutethimide (Fig 14) is the prototype for nonsteroidal 
aromatase inhibitors [120]. This compound was originally developed as an antiepileptic 
agent but was removed from the market due to serious side effects. Aminoglutethimide 
also inhibites cytochrome P450SCC and other enzymes, yet is more selective for 
cytochrome P450arom. 
Because aminoglutethimide was the first aromatase inhibitor to be studied in patients, it 
is referred to as a first generation aromatase inhibitor. Aminoglutethimide has been used 
in the clinic with some success to treat patients with advanced breast cancer, but must be 
administered with corticosteroid due to the inhibitory effects on cortisol and aldosterone 
biosynthesis (see above) [120, 121]. 
b- Second generation aromatase inhibitors: the second generation inhibitors are represented 
by fadrazole (Fig 14) which is more selective than Aminoglutethimide. It is inhibitory 
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activity is 700 times more potent. Clinical studies using fadrazole have shown that this 
nonsteroidal inhibitor is effective in the treatment of some postmenopausal women with 
advanced breast cancer [111]. 
 
c- Third generation aromatase inhibitors: several nonsteroidal aromatase inhibitors 
containing a triazole ring have been successfully developed. Anastrozole (Fig 14) is a 
potent aromatase inhibitor with an IC50 of just 15 nM in human placental microsomes. 
In vitro, anastrozole is very specific and has no effect on other P450 enzymes such as 
P450SCC, 11β-hydroxylase, 18-hydroxylase, 17α-hydroxylase, and lanosterol-14α-
demethylase [111]. 
 
 
Fig 14: First, second and third generation aromatase inhibitors. 
 
d-   Flavonoid based aromatase inhibitors: several flavonoids demonstrate inhibitory 
activities against the aromatase enzyme, thus lowering estrogen biosynthesis and 
circulating estrogen levels [122]. Strong evidence for the binding of flavones to the active 
site of aromatase has been obtained by different spectral absorption studies [123], with 
7,8-benzoflavone displacing androstenedione from the aromatase active site and inducing 
a spectrum consistent with the low-spin state of iron. Binding of flavonoids to aromatase 
requires certain structural features. Reduction of the flavone 4-keto group for instance is 
detrimental to aromatase inhibition by these compounds [124]. Based on data obtained 
from site-directed mutagenesis studies and ligand docking into a homology model of the 
aromatase protein, a binding orientation has been predicted in which the A and C rings of 
the flavone mimic the C and D rings of the steroid substrate, respectively. The 2-phenyl 
substituent (ring B) is orientated in a region similar to that occupied by the A ring of the 
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steroid (Fig 15). This analysis places the flavone 4-keto functionality in the same 
position as the steroid 19-angular methyl group with respect to the heme iron [125]. 
 
Fig 15: Structural similarities between chrysin and aromatase substrate androstenedione (Figure 
adapted according to [125]) 
 
Generally, flavones and flavanones have higher aromatase inhibitory activity than 
isoflavones [111]. Furthermore medicinal chemistry approaches to develop synthetic 
flavonoids, chromones, or xanthone analogs with enhanced aromatase inhibitory activity have 
identified more selective and/or more potent agents for future development [126-128]. 
 
1.3.5. Receptor binding activities: Treatment of menopausal 
syndrome 
 
The estrogen receptor (ER) belongs to the steroid/thyroid nuclear receptor superfamily 
whose members act as transcriptional activators via a direct interaction with DNA sequences 
termed response elements [129]. Ligand (e.g. estradiol) binding to the ER induces a 
conformational change in the receptor important for the association of the receptor-DNA 
complex with transcriptional coactivators and the transcriptional components of the cell [130]. 
This association then culminates in the synthesis of estrogen-responsive genes and an 
estrogen-induced cell and/or tissue response. 
An apparent consequence of estrogen deficiency is the increase in short-term 
menopausal symptoms, including vasomotor hot flashes, urogenital atrophy and changes in 
psychological functioning. The "hot flash" is the classic sign of menopause and the primary 
clinical symptom experienced by women during this transitional stage [131]. 
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At menopause, an accelerated loss of bone mass takes place during the first five years, 
with changes in bone structure (3 %/year). Estrogen slows the rate of bone remodeling and 
protects against bone loss directly, through the estrogen Receptor (ER), and indirectly, 
through its effects on collagen. It has been suggested that in E2 deficiency, the loss of 
transcriptional effect on the lifespan of mature osteoclasts may be responsible for the 
imbalance between formation and resorption and the progressive loss of bone mass and 
strength [132]. 
The incidence of heart disease among pre-menopausal women is low compared with 
males, whereas the incidence among post-menopausal women approaches that of males. The 
administration of estrogen to post-menopausal women decreases the incidence of heart 
disease [133]. This protective effect of estrogen may partially be attributed to its influence in 
decreasing the ratio between LDL (low density lipoprotein) and HDL (high density 
lipoprotein) [134], on reducing thrombus formation and in improving vascular compliance.  
Not surprisingly, there is a great motive for women to start taking hormone replacing 
therapy (HRT), which among other things alleviates sleep problems, mood change, loss of 
drive and energy and hence, improves quality of life [135]. Unfortunately women taking 
estrogen have an increased risk of breast and epithelial ovarian cancers. Estrogen can 
stimulate malignant growths, and hence contributes to the development of estrogen-dependent 
tumors, such as breast and uterus cancer (see above) [136]. 
Phytoestrogens (Fig 16) are a group of polyphenolic non-steroidal compounds of plant 
origin. They function at least in part as selective estrogen receptor modulators (SERMs) and 
may influence the transcriptional response to estrogens [137, 138]. These phytoestrogens are 
thought to act as estrogen agonists (or antagonists) and may promote a significant 
advancement in the prevention of some diseases caused by estrogen deficiency in post 
menopausal women compared to conventional hormonal therapy [139]. 
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Fig 16: Chemical structure of selected phytoestrogens. 
 
Shared structural features of phytoestrogens include a pair of hydroxyl groups and a 
phenolic ring, which is required for binding to estrogen receptors ER-α and ER-β, with the 
position of these hydroxyl groups appearing to be an important factor in determining their 
ability to bind to ERs and activate transcription [140]. Four main classes of compounds are 
currently recognized as phytoestrogens, i.e. the isoflavones, stilbenes, coumestans, and 
lignans [141, 142]. These phytochemicals are some of the most prevalent compounds found in 
fruits, vegetables, legumes, and tea and are generally concentrated in the fruit skin, bark, and 
flowers of plants [141]. Among them, Resveratrol, daidzein, quercetin, and genistein 
represent four of the most commonly ingested and most intensely studied phytoestrogens. 
 
1.4. Chemistry of flavonoids  
 
Flavonoids are formed in plants from the aromatic amino acids phenylalanine and 
tyrosine, and malonate. As already mentioned, the basic flavonoid structure is the flavan 
nucleus, which consists of 15 carbon atoms arranged in three rings (C6-C3-C6), labeled A, B, 
and C (Fig 7). 
The various classes of flavonoids differ in the degree of oxidation and pattern of 
substitution of the C-ring, while individual compounds within each class differ in the pattern 
of substitution of the A and B-rings. The flavonoid classes include flavones, flavanones, 
isoflavones, flavonols, flavanonols, flavan-3-ols, and anthocyanidins, biflavones, chalcones, 
aurones (Fig 8), and most of these classes are present in plants as glycosides. 
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Synthesis, redox behavior and electrochemistry 
Flavonoids represent a well-known family of compounds and their synthesis has been 
the object of a great number of studies. In general, procedures for laboratory synthesis of 
flavonoids are still based on the approaches originally developed by Robinson [143], with 
other methods including the Baker–Venkataraman rearrangement [144, 145], synthesis via 
chalcones [146], and synthesis via an intramolecular Wittig reaction [147]. Despite the 
number of steps often involved in these methods, they constitute the most popular 
methodologies used nowadays for the preparation of flavonoids. The synthesis of flavonoid 
derivatives is also an area of significant interest and many synthetic routes have been used to 
add moieties to the natural flavonoids nucleus. The Mannich reaction, for instance, is used for 
the addition of alkyl amine derivatives [148]. The Aldol condensation reaction is used either 
for the synthesis of natural flavonoids or for the addition of alkyl or benzyl moieties [149]. 
Many puplications covering flavonoid biotransformations also focus on oxidation, 
methylation, glucosidation [150-152], and halogenation [153]. 
The biochemical reaction activities of flavonoids and their metabolites depend on their 
chemical structure and the relative orientation of the various moieties present in the molecule. 
The shape of the flavonoid is important as flavones and flavonols have a planar 
benzopyranone skeleton whereas the dihydroflavonols have a less planar 
dihydrobenzopyranone skeleton. Chrysin has a double bond between C-2 and C-3, and the 
conjugation within the molecule is causing ring B to be a coplanar with the rings A and C. 
Saturation of this double bond, as in taxifolin, will destroy conjugation and coplanarity [155]. 
The antioxidant property of flavonoids may be investigated using electrochemical 
methods. The ability to act as chemical defence agents by donating an electron to an oxidant 
frequently depends on the redox potentials of the flavonoid and the corresponding radical 
[154]. 
The mechanism of action as antioxidants seems to involve the ability of phenols to 
scavenge radicals with an H-atom, or by an electron transfer process in which the phenol is 
converted into a phenoxyl radical resulting in the formation of the semiquinone, which can 
donate a further electron to form the quinone (Fig 17) [156]. Electrochemical measurements 
lead to physicochemical parameters for antioxidants, which help in evaluating their 
antioxidative abilities [157–159], and understanding their reaction mechanisms. 
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Fig 17: Quinone formation in ring B by oxidation with free radicals. 
 
Some information regarding the mechanism of polyphenol oxidation is provided by 
comparing the redox potentials at different pH. An increase in pH is often associated with 
deprotonation of the OH groups and a decrease of the oxidation potential [155]. 
Studies of the electrochemical properties of flavonoids have provided useful 
information about the redox potential and strongly support the antioxidant structure-activity 
relationship of different flavonoids which may also be measured by different biological and 
bioassay methods. Electrochemical analysis of quercetin, (±)-catechin, galangin, rutin, and 
taxifolin show that quercetin, with a 3´,4´-dihydroxy subistitution in B-ring and double bond 
between C2 and C3 has the lowest redox potential of all [75, 160]; it can therefore be assumed 
that quercetin has the highest antioxidant activity of the compounds tested. 
 
1.5. The objectives of this project 
 
Flavonoids form a group of natural products present in most plant families. They 
reportedly play an important role in plant growth and defense mechanisms. More than 8000 
different flavonoids have been isolated from natural sources todate, and scientists still 
endeavor to find new flavonoid structures. 
Scientists were also trying to synthesise these flavonoids to make it then available in 
high amounts or to add some more functional groups that may enhance the biological or 
pharmacological behavior. Biotransformation of the flavonoids is also a current area of 
interest to obtain novel biologically and pharmacologically active flavonoid compounds. 
Thousands of publications underline this interest in the different biological activities 
and pharmacological behavior (absorption, metabolism, excretion) of the various flavonoid 
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classes. There is hardly any flavonoid structure without a biological use of interest, and 
structural variations between flavonoids may be related to the different activities observed in 
diseases in the humans and animals body. 
Quercetin for instance is a well known flavonoid isolated from many plant families. It 
has a unique structural feature that enables it to play a significant role as an antioxidant in 
addition to many other roles in the protection against cancer and coronary heart diseases. 
Chrysin, another well known flavonoid natural product, is reported to possess interesting 
biological activities, such as an aromatase inhibitor and certain cytotoxicity toward cancer cell 
lines. 
The synthesis of novel quercetin and chrysin derivatives, based on the Mannich reaction 
may be a good strategy to introduce changes in the biological behavior of quercetin and 
chrysin, e.g. by addition of alkyl amine moieties. Such changes may enhance the cytotoxic 
and aromatase inhibiting activity of the quercetin, and, at the same time, may also improve the 
antioxidant activity of this compound. 
Chrysin and most other flavonoids are able to mimic the substrate of aromatase (i.e. 
androgen), due to the similarity between rings A and C in flavonoids and the C and D rings of 
the aromatase substrate. Addition of one more ring to chrysin may enhance this aromatase 
inhibiting activity. It was therefore decided to synthesise a set of novel chromene-flavone 
compounds that consist of both a flavone (chrysin) and a chromene nucleus in the same 
molecule. 
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Chapter II: Materials and Methods 
2.1. Isolation and characterization of natural products  
 
The plant materials used in this work are the roots of Delonix regia (growing in Egypt 
and collected in July 2007, from the garden of Al-Azhar University, Nasr city, Cairo, Egypt), 
and Robinia pseudoacacia (growing in Germany and collected in August 2008 from the forest 
of Saarbrücken, near to the Waldhaus, Saarbrücken, Germany). Delonix regia plants were 
kindly identified by Dr. Nabil El-hadidy, Professor of Plant Taxonomy, Faculty of Science, 
Cairo University, and by Engineer Badeia Hassan Aly Dewan, Consultant of Egyptian Flora, 
Agricultural Museum, Dokki, Giza, Egypt. Robinia pseudoacacia were kindly identified by 
Professor Rüdiger Mues, professor of Molecular Plant Biology and Botany, Saarland 
University, Saarbrücken, Germany. 
 
2.1.1. Chromatographic studies 
 
Thin layer chromatography (TLC): 
Silica gel 60 F254 (with fluorescent indicator) pre-coated sheets 20 x 20 cm wide and 0.2 
mm thick (Merck, Germany) were used for TLC analysis in the synthesis and isolation of 
natural products. The solvent systems used for TLC were mixtures of methanol in 
dichloromethane or ethyl acetate in petroleum ether (40-65 °C) in different concentrations. 
Vanillin/H2SO4 (TLC spraying reagent) was applied to the TLC, as a means of detection 
[161]. Vanillin/H2SO4 are generally used to visualize hydrocarbon compounds, especially 
flavonoid glycosides. Vanillin powder (1 g) was dissolved in 100 mL of H2SO4 and then the 
mixture was heated at 100 °C for 5 min. 
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Column Chromatography (CC): 
Silica gel 60 (0.063-0.200 mm) 70-230 mesh (Merck, Germany) and Sephadex LH-20 
(Pharmacia, Germany) were used as stationary phases for column chromatography. The 
solvent system applied for the Silica gel column was a mixture of methanol and 
dichloromethane or mixture of ethyl acetate and petroleum ether (40-65 °C) in different 
concentrations. The solvent used for the Sephadex column was pure methanol. 
 
Solvents used for NMR spectroscopy:  
DMSO-d6, CDCl3 and CD3OD were the solvents used for 1H and 13CNMR spectroscopy. 
  
2.1.2. Extraction 
 
Delonix regia: The extraction of Delonix regia is shown in Fig 18. 3000 g of air-dried 
powdered roots were subjected to exhaustive extraction with 5×10 L ethanol (70 %). The 
combined ethanol extracts were concentrated under vacuum (Vakuum, PC2001 VARIO, 
Germany) at 40 °C to dryness (This yields 370.0 g of dried ethanol extract). The dried ethanol 
extract was then suspended in distilled water (500 mL) and filtered through filter paper. 
The water soluble portion (255.0 g) was extracted with petroleum ether (3×500 mL) to 
remove the fat and nonpolar compounds. The combined petroleum ether extract were 
concentrated under vacuum at 40 °C to dryness (166.0 g).  
The resulting crude extract (defatted water extract) was partitioned several times with 
ethyl acetate, and then with n-butanol. The combined ethyl acetate and n-butanol extracts 
were concentrated under vacuum at 40 °C to produce 12.0 g of ethyl acetate extracts, and 20.4 
g of n-butanol extracts respectively. 
Robinia pseudoacacia: The extraction of Robinia pseudoacacia is shown in Fig 19. 850 
g of air-dried powdered roots were subjected to exhaustive extraction with 5×4 L ethanol (70 
%). The combined ethanol extracts were concentrated under vacuum at 40 °C to dryness (95.0 
g). The concentrated ethanol extract was then suspended in distilled water (200 mL) and 
filtered through filter paper.  
Chapter II  Materials and Methods 
36 
 
The water soluble portion (62 g) was defatted with petroleum ether (3×200 mL), and the 
combined petrol extracts were concentrated under vacuum at 40 °C to dryness (35.0 g).  
The defatted water crude extract was partitioned several times with ethyl acetate, and 
then with n-butanol. The combined ethyl acetate and n-butanol extracts was concentrated 
under vacuum at 40 °C to produce 5.0 g of ethyl acetate extracts, and 8.5 g of n-butanol 
extracts respectively. 
 
2.1.3. Isolation 
 
Sequential percolation of the powdered roots of Delonix regia and Robinia 
pseudoacacia with petroleum ether, ethyl acetate and n-butanol yielded the respective crude 
extracts. Chromatographic purification of the ethyl acetate fraction is shown in Fig 18 and 
Fig 19. 
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Delonix regia roots 3000 g
Delonix regia constituents isolation
Extraction (70 % ethanol)
(5x10 L)
The water soluble part of ethanol extract (255g)
i)Petrol (166 g)
ii)EtOAc (12 g)
iii) n-BuOH (20.4 g)
Silica gel CC
CH2Cl2 : MeOH
(10 : 0 7 : 3)
TLC CH2Cl2 : MeOH (80 : 20)
------------------------------------------------------------------------------------------------------------
Fr. A Fr. C Fr. E
395 mg 940 mg 560 mg
Fr. B Fr. D
60 mg 98 mg
Silica gel CC
CH2Cl2 : MeOH (100 : 0
TLC
CH2Cl2 : MeOH (80 : 20)
-----------------------------------------------------------------------------------------------------
Fr- A-1
200 mg
Fr- C-1
780 mg
Fr- D-1
65 mg
Fr- E-1
340 mg
i) Silica gel CC
CH2Cl2 : MeOH
9.5 : 0.5 8.5 : 1.5
ii) Sephadex LH-20
MeOH 100%
85 : 15)
Several runs of
Compound 1d
50 mg
Compound 2d
23 mg
Compound 3d
66 mg
Compound 4d
30 mg
Compound 5d
55 mg
 
Fig 18: Separation procedure for Delonix regia root constituents. 
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Robinia pseudoacacia roots 850 g
Robiniapesudoacacia constituents isolation
Extraction (70% ethanol)
(5x4 L)
The water soluble part of ethanol extract (62 g)
i)Petrol (35 g)
ii)EtOAc (5 g)
iii) n-BuOH (8.5 g)
Silica gel CC
CH2Cl2 : MeOH
(100 : 0 80 : 20)
TLC CH2Cl2 : MeOH (80 : 20)
-----------------------------------------------------------------------------------------------------
Fr. F Fr. G Fr. H Fr. JFr. I
33 mg 120 mg 60 mg 700 mg 530mg
i) Silica gel CC
CH2Cl2 : MeOH
9.5 : 0.5 8.0 : 2.0
ii) Sephadex LH-20
MeOH 100%
36 mg 55 mg 521 mg 435 mg
Fr. I-1 Fr. J-1
i) Silica gel CC
CH2Cl2 : MeOH
9.5 : 0.5 8.0 : 2.0
ii) Sephadex LH-20
MeOH 100%
Compound 1r
15 mg
Compound 2r
23 mg
Compound 3r
150 mg
Compound 4r
177 mg
Compound 5r
34 mg
Fr. G-2Fr. G-1
 
 
Fig 19: Separation procedure for Robinia pseudoacacia root constituents. 
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2.2. Synthesis of compounds 
 
2.2.1. Mannich reaction 
 
This reaction is named after Carl Mannich [162]. The Mannich Reaction is an important 
carbon-carbon bond forming reaction that is commonly employed in the synthesis of alkaloid 
natural products and is involved in a number of biosynthetic pathways [163]. The reaction 
uses three components: An amine, a non-enolizable aldehyde, and a compound containing an 
enolizable carbonyl moiety. 
In short, compounds with an active hydrogen atom are treated with aldehyde and 
ammonia or a primary or secondary amine, thereby replacing the active hydrogen with an 
amino alkyl group (Fig 20) [164]. 
 
Fig 20: General scheme of Mannich reaction.  
 
Materials and analytical methods 
 
Flavonoids used in the reactions, i.e 5,7-dihydroxyflavone (chrysin), and 3,5,7,3´,4´-
pentahydroxyflavone (quercetin), and all other starting materials used in synthesis were 
purchased from Aldrich, Acros, Lancaster, Merck, or Fluka and were used without further 
purification. Reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-
Nagel). Melting points were measured on a Mettler FP1 melting point apparatus and are 
provided uncorrected. 
1H and 13C NMR spectra were recorded on a Bruker DRX-500 instrument. Chemical 
shifts are given in parts per million (ppm), and tetramethylsilane (TMS) was used as the 
internal standard. All coupling constants (J) are given in Hertz. Mass spectra (LC-MS) were 
measured on a TSQ Quantum (Thermo Electron Corporation) instrument with a RP18 100-3 
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column (Macherey Nagel) and with water/acetonitrile mixtures as eluents. HR-MS was 
measured with a Finnigan MAT 95S mass spectrometer. 
 
General synthetic procedure for the Mannich reaction 
The primary or secondary amine (1.5 mmol), was added to a solution of flavones (1 
mmol) and aldehyde (1.5 mmol) in EtOH (10 mL) at r.t. The mixture was then heated to 40–
65 °C, depending on the flavonoid and secondary amine (Fig 21 and Fig 22), and progression 
of the reaction was monitored by TLC. 
After the reactants were consumed, EtOAc (30 mL) and diluted HCl (30 mL, pH 3) 
were added to the mixture. The aqueous layer was separated and the pH was adjusted to 7-8. 
The aqueous phase was then extracted with EtOAc (3 × 15 mL). The combined extracts were 
dried over anhydrous Na2SO4, the solvent was removed under vaccum. The crude product was 
subsequently purified by silica gel column chromatography using a mixture of ethyl acetate 
and petroleum ether (40-65 °C) as eluent. 
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Fig 21: Amines and aldehydes used in the Mannich reaction employing chrysin. The temperatures needed for the 
reaction are provided. 
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Fig 22: Amines and aldehydes used in the Mannich reaction employing quercetin. The temperatures needed for 
the reaction are provided. 
 
 
2.2.2. Chromene-flavone reaction 
 
By reacting a flavonoid with alkyl isocyanides and dialkyl acetylenedicarboxylate it is 
possible to create new tricyclic compounds that contain both, flavone and chromene-like 
moieties. The new molecules may possess interesting biological and pharmacological 
activities. 
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General synthetic procedure for the chromene-flavone reaction 
The isocyanide derivative (1.5 mmol) was added drop-wise to a magnetically stirred 
solution of flavonoids (1.5 mmol) and dialkyl acetylene dicarboxylate (1.5 mmol) in 10 mL 
CH2Cl2 at -20°C over 10 min. The reaction mixture was then allowed to warm up to room 
temperature and was stirred for another 24-48 hrs, and progress of the reaction was monitored 
by TLC. The solvent was removed under reduced pressure and the residue was separated by 
silica gel column chromatography using a mixture of petroleum ether (40-65 °C) and ethyl 
acetate as eluent. 
 
2.2.3. Synthesis of 7-(3-phenyl selenide propan)-3-hydroxyflavone and 7-
(3-phenyl telluride propan)-3-hydroxyflavone 
 
General synthetic procedure 
 
A previously reported synthetic method was used for this synthesis [165]. In brief, 
diphenyl diselenide or diphenyl ditelluride (1 mmol) was dissolved in 30 mL of EtOH and 
cooled with an ice-water bath. Sodium borohydride 0.83g (21.9 mmol) and 1,3-
dibromopropane (400 mg, 2 mmol) were added to the solution under a nitrogen atmosphere, 
and the solution was stirred at room temperature for 3 hrs. The reaction mixture was poured 
into water, extracted with ether, and the organic portion was washed successively with 
aqueous Na2CO3 and brine. The ether fraction was dried over anhydrous Na2SO4, and the 
solvent was removed in vacuo. The crude products 1-bromo(3-phenyl selenide)-propane, or 1-
bromo(3-phenyl telluride)-propane, were used directly in the next step. 
A mixture of 5,7-dihydroxyflavone (1 mmol), 1-bromo(3-phenyl selenide)-propane, or 
1-bromo(3-phenyl telluride)-propane (1.5 mmol) and K2CO3 (5.0 g), in anhydrous acetone 
(25.0 mL) was stirred at 40 °C for 24 hrs. The insoluble material was filtered off, and the 
solvent was removed under reduced pressure. The residue was separated by silica gel column 
chromatography using a mixture of petroleum ether and ethyl acetate as eluent. 
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2.3. Cell culture 
 
HL-60 cell line as a model to measure the antioxidant/ cytotoxic activities of compounds 
 
Apparatus 
Multi-plate reader  Sunrise Absorption Reader, Tecan (Osterreich) 
Autoclave  Autoklavi Spa, Fedegari (Italien) 
Incubator Steri-Cycle CO2 Incubator Hepa Class 100, Thermo 
Cryobox Nalgene Cryo 1 °C Freezing Container 
Digital multichannel Pipette Finnipette, Thermo 
Electric Pipette Accu-jet pro, Brand 
Fine scale balance Mettler AE 50 
Microscope Axiovert 40 CFL, Zeiss 
pH-Meter HI 8314, Hanna 
Pipettes Pipettman, Gilson 
Stepper Handy-Step, Brand 
Sterile Workbench Biowizard Kojair, Axon 
Vortex Vortex Genie 2, Scientific Industries 
Waterbath Haake W13, Thermo 
Centrifuge Sigma 4-10, B.Braun 
Freezer (-80 °C) C660, New Brunswick scientic 
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Stock solution and media 
1- Phosphate buffered saline (PBS) 
8.00 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4 and 0.24 g of KH2PO4 were dissolved 
in distilled water (1000 mL) and the pH was adjusted to 7.4. The solution was then autoclaved 
in a stem autoclave at 120 °C for 20 min. It was opened only in a clean, sterile area. 
2- Hydrogen peroxide (H2O2) stock solution  
Freshly prepared 500 mM of H2O2 was used as a stock solution. 5 mM of final 
concentration was prepared by adding 10 µl from the stock solution to 990 µl of cell medium. 
3- Stock solution of the test compounds 
Serial dilutions of all compounds at 2.5, 10, 20, 30, 40, and 50 mM were prepared as 
stock solutions in pure DMSO. 4 µl from this stock solution in 996 µL of medium was used to 
prepare 1000 µl of 10, 40, 80, 120, 160 and 200 µM, respectively (please note: the DMSO 
concentration must not exceed 0.4 %). 
4- 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution 
50 mg of MTT solid powder was dissolved in 10 mL of PBS (5 mg/mL) and used 
directly without dilution. This solution was stored below 4°C, in the dark and was used within 
two weeks. 
HL-60 cell line culture 
Human promyelocytic leukemia HL-60 cells were kindly provided by Prof. Dr. 
Alexandra K. Kiemer (Dept. of Pharmaceutical Biology, Saarland University, Germany). 
Cells were maintained in RPMI1640 medium supplemented with 10% heat-inactivated fetal 
calf serum (Grand Island Biological Co., Grand Island, NY, USA), 100 U/mL penicillin G, 
100 µg/mL streptomycin, and 1 % l-glutamine (Sebac, Germany) in an atmosphere of 5 % 
CO2 in humidified air at 37 °C. In all experiments, exponentially growing cells were used. 
In order to establish the activity of the test compounds, 2-day experiments were set up. 
On the first day, one mL of cell suspension was added in a concentration of 9×105 cell/mL to 
Eppendorfs (size 1.5 mL or 2 mL, Greiner Bio-One). To each cell suspension, the compounds 
were added at different concentrations (with a DMSO concentration equal to 0.4%). DMSO 
was used as control. For the antioxidant assay, H2O2 was added to the mixture of cell 
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suspension and compounds in 5 mM final concentration. In contrast, samples prepared for the 
cytotoxicity test will not contain H2O2. To a 96 well plate (Greiner Bio-One) 100 µl of cell 
suspension with compounds were added. This micro plate was then incubated for 24 hours in 
an atmosphere of 5 % CO2 in humidified air at 37 °C. 
On the second day, 10 µl of MTT stock solution was added to each well (final conc. 0.5 
mg /mL), in the dark and under sterile conditions. The plate was then incubated at 37 °C for 2 
hrs in the dark. 200 µl of DMSO was then added in each well to dissolve the formazane 
formed. The plate was gently shaken and the color was immediately measured with a 
microplate reader at 550 nm (reference 690 nm). 
2.4. Nematode assay 
 
These assays were carried out together with Mr. Mohammed Badr Sarakbi, a Diploma 
student in Prof Jacob´s group who was supervised by me since February 2009. Nematodes, 
i.e. primarily Steinernema feltiae, were purchased as soft cake product used in gardening 
(from Schneckenprofi Hennstedt Ltd., Germany), and stored at 4 °C until the time of use (the 
viability of nematodes was checked prior to each assay; the viability must be more than 80 
%). A suitable suspension of the nematodes was prepared by mixing 2 g of the nematode soft 
cake with approximately 250 mL distilled water. The suspension was set aside at room 
temperature for 15-30 minutes before use. 
The compounds were dissolved in DMSO to prepare a stock solution of a desired 
concentration, and were then subjected to serial dilution with DMSO and distilled water. The 
samples were prepared by transferring 900 µL of the compound solution at each test 
concentration to an Eppendorf tube (1 mL). 100 µL of the prepared nematode suspension was 
added, resulting in 1 mL test solution containing 200-400 nematodes with final concentrations 
of 50, 100, 200, and 400 µM of the tested compounds, respectively (please note that the 
DMSO concentration in each tube must be 2 %). A blank of 2 % DMSO was used as negative 
control. 
Assay procedure: 
Three replicates were prepared for each concentration. For each replicate, four samples 
of 100 µL were transferred into 4 wells in a 96-well micro plate and immediately examined 
under a light microscope at 4 fold magnification. Only living (mobile) nematodes in each 
sample were counted, producing a combined total from the four samples. The micro plate was 
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then incubated in the dark, and re-examined after 24 and 48 hours. The viability (survival) 
percentage after each time period was calculated by the formula: 
Viability % = (At/A0) X 100 
Where A0 is the number of live nematodes at the beginning of the test, At is the number 
of live nematodes after the time period (24 and 48 hours). 
The test was conducted in two independent measurements, and the final result was 
estimated as the mean ± standard deviation. 
 
2.5. In vitro bioassay  
 
2.5.1. Aromatase assay 
 
Preparation of stock solution 
Sodium phosphate buffer 
6.00 g of Na2HPO4 and 8.90 g of NaH2PO4 were dissolved in 2000 mL of distilled water 
and the pH was adjusted to be 7.4. 
Labeled androstenedion solution (3HA-stock) 
100 µL of androsten-4-ene-3,17-dione,[1ß-3H(N)] (NET-926, 1,0 mCi) was diluted to 
1000 mL with ethanol (1 µL contain 1 µCi) 
Normal androstenedion stock solution (A-stock) 
6.945 mg of androstenedion was dissolved in 50 mL of ethanol. 
Normal androstenedion diluted solution 
250 µl of androstenedion stock solution was diluted in 50 mL of the cooled phosphate 
buffer. 
Mercuric chloride solution 
27.25 mg of HgCl2 was dissolved in 100 mL of dist. water (1mM). 
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Glucose-6-phosphate (G6P) 
120.56 mg of glucose-6-phosphate was dissolved in 4 mL of cooled sodium phosphate 
buffer. 
Nicotinamid adenine dinucleotide phosphate (NADPH) solution 
18.11 mg of NADP was dissolved in 1mL of cooled sodium phosphate buffer. 
Glucose-6-phosphate dehydogenase (G6PDH) solution 
4 µl of G6PDH solution (1 mL contain 40 units) was diluted in the cooled sodium 
phosphate buffer to a final volume of 1 mL. 
Aromatase  
Human aromatase was obtained from the microsomal fraction of freshly delivered 
human term placental tissue according to the procedure of Thompson and Siiteri [166]. In 
brief, freshly delivered human term placentas were washed in cold 0.15 M KC1, and adhering 
membranes and large blood vessels were removed by dissection. After thorough mincing with 
scissors, the tissue was weighed and 1 mL of cold 0.25 M sucrose was added per 1 g of tissue. 
Homogenization was accomplished and mitochondria, nuclei, and cell debris were removed 
by centrifugation at 20,000 rpm for 30 min. The postmitochondrial supernatant was then 
subjected to centrifugation at 148,000 rpm for 45 min to yield a microsomal pellet which was 
resuspended in 0.05 M potassium phosphate buffer, pH 7.4. The volume of this microsomal 
suspension was adjusted to 400 mL with the above buffer, after which the microsomes were 
resedimented at 148,000 rpm for 45 min. The microsomal pellet from the second high speed 
centrifugation was again resuspended in buffer and resedimented under the same conditions. 
Twice washed microsomes were finally suspended in a minimal volume of buffer and stored 
frozen at -80 °C in 1 mL Eppendorf tubes. Prepared in this manner, microsomes retained their 
full aromatase activity for at least 4 months. 
Working enzyme solution was prepared by dilution of the microsomes obtained by the 
above procedure with phosphate buffer (pH 7.4) (1: 50). This diluted enzyme preparation was 
stored in -80°C for several months. 
Charcol suspension 
2 g of charcol was suspended in 100 mL of dist. Water. 
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Assay procedure 
Pre test preparation 
1- 3HA/A: 20 µl of labeled androstenedione 3HA was dissolved in 1000 µl of cooled, 
diluted, unlabeled androstenedion and was mixed well for 10 min. 
2- Preparation of the regenerating system: G6P solution, NADP solution and G6PDH 
solution were mixed in 2:1:1 ratio respectively. 
3- Preparation of inhibitors (compounds under investigation): at least 3 different 
concentrations from each compound were used and all compounds were dissolved 
in DMSO (with the concentration of DMSO not exceeding 2 %), and dilution 
factor of 50 was used. 
Test procedure 
To each Eppendorf, 95 µl of phosphate buffer, 50 µl of the regenerating system, 5 µl of 
DMSO (control) or compound solution, and 50 µl of 3HA/A solution was added (the previous 
mixtures were added in only two Eppendorfs, except for the presence of DMSO or 
compounds solution, as they were used as a zero control). To each zero control, 200 µl of 
HgCl2 was added to stop the reaction. The diluted aromatase solution (1: 50) was removed 
from the -80 °C freezer and incubated with the prepared Eppendorf samples in 30 °C water 
bath (Grant, Type VAB18EU, England) for 5 min. The reaction was started by the addition of 
50 µl of diluted aromatase solution to each reaction tube; after thorough mixing (IKA-Vibrax-
VXR, Germany), these tubes were incubated for 14 min in a water bath at 30 °C. The reaction 
was stopped directly after the incubation period by the addition of 200 µl of HgCl2, and was 
then mixed well for 2-3 min. 200 µl of charcoal solution was added after vigorous mixing and 
the reaction tubes were shaken for at least 30 min before being centrifuged (Thermo scientific, 
Heraeus Fresco 17 centrifuge, Germany) for 5 min at 12500 rpm at 4 °C. 400 µl of 
supernatant from each tube was transferred to new tubes and again centrifuged for 5 min at 
12500 rpm at 4 °C. 200 µl of supernatant from each tube was then transferred to 2 mL 
Eppendorf tubes, followed by the addition of 1000 µl of Szintillator 212. All tubes were then 
mixed well. The 3H2O was measured using a ß-counter (WALLAC, Micro Beta Trilux, 
Finland). 
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2.5.2. 2,2-Diphenyl-1-picrylhydrazyl, 95 % (DPPH) assay 
 
Preparation of DPPH solution 
DPPH stock solution  
Dissolve 125 mg of DPPH in 100 mL of ethanol, sonicate for 10 minutes. The stock 
solution may be stored for 2 weeks in the refrigerator (–20 °C). 
DPPH working solution 
Dilute the stock solution 1: 10 (V/V) in ethanol. The concentration of DPPH in the 
working solution is 316 µM. 
Sample preparation 
Serial dilution of all compounds at 0.2, 1, 2, 4 and 8 mM was prepared in pure DMSO. 
10 µl from these dilutions was necessary to prepare 200 µl of 10, 50, 100, 200 and 400 µM 
respectively. Controls (D, L–α–tocopherol (vitamin E) and Trolox®) were prepared in the 
same concentration as test compounds. 
Assay procedure 
In a 96–well plate, 10 µL of test compounds stock solution sample was added to 190 µL 
of DPPH working solution. A blank control was prepared; where as 10 µL of DMSO was 
added to 190 µL of DPPH working solution. The final volume in each is therefore equal to 
200 µL. In final solution, the concentration of DPPH is 300 µM. The plate was then incubated 
in the dark for 30 minutes at room temperature. After incubation, the absorbance was 
measured using the microplate reader spectrophotometer (Wallac, Victor, 1420 multilabel 
counter) at 530 nm. 
 
Calculations 
Inhibition %= (1- Sample530/blank530) X 100 
The percentage of inhibition versus compound concentration was plotted on a graph. 
From the equation of the slope, I was able to calculate the test sample concentration required 
to reduce the absorbance at 520 nm by 50 % (IC50). 
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2.5.3. Electrochemistry 
 
The electrochemical behavior of the chromene-flavone compounds was studied by Ms. 
Elena Gurevich, a Diploma student in Jacob´s group. Studies were performed by using 
Differential Pulse Polarography (DPP) with a BAS 100W potentiostat. The compounds were 
at first solved in 5 % DMSO and then diluted in 33 % of methanol/water (v:v) and phosphate 
buffer pH = 7.4. to a final concentration of approximately 500 µM. The Polarogramms were 
recorded using a glassy carbon working electrode, a silver/silver chloride reference electrode 
and platium reference electrode. The potential range was between -1000 to 1500 mV with a 
scan rate of 10 mV/s, the puls amplitude was 80 mV, with a sample width of 45 ms and pulse 
width of 100 ms. For Cyclic Voltammetry (CV), the same experimental setup was used. The 
potential range was between -1500 mV to 1500 mV with scan rates of 100 mV/s and 500 
mV/s. 
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Chapter III: Results 
3.1. Characterization of natural product  
 
The water soluble portion of the ethanolic extracts of Delonix regia and Robinia 
pseudoacacia roots were fractionated by solvent partition (ethyl acetate and n-butanol). A 
successive silica gel column chromatography followed by further purification via Sephadex 
(LH-20) column chromatography allowed for the isolation of five compounds from Delonix 
regia root (two 3,4-flavandiols 1d, 2d, one legnan derivative 3d, one flavan-3-ol 4d, and one 
dihydroflavone 5d (Fig 23)), and five compounds from Robinia pseudoacacia root (one 
dihydroflavone 1r, three chalcones 2r, 3r, 4r, and one indol derivative 5r (Fig 24)). 
Identification of these compounds was based on extensive 1H, 13C NMR (1D and 2D), 
and mass spectroscopy data. 
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3.1.1. Isolated natural products from Delonix regia root 
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Fig 23: Chemical structure of natural compounds isolated from Delonix regia roots 
 
3.1.1.1. Compound 1d 
 
Compound 1d was isolated as a yellowish brown amorphous powder. On TLC, it 
resulted in a greenish black spot when treated with vanillin/H2SO4. According to IUPAC 
system, the compound was named as 2-(3,4-dihydroxyphenyl) chromane-3,4,7,8-tetrol (Fig 
23). Following the normal nomenclature of flavonoids, it can be also referred to as 7,8,3´,4´-
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teteahydroxy-3,4-flavandiol. After reviewing the literature, compound 1d has never been 
isolated from Delonix regia before, but was isolated from many other Leguminosae plants 
[167]. 
Compound 1d has a molecular formula C15H14O7. LC-MS-ESI: tR = 3.95 min, m/z calcd 
306.07, m/z found 290.96 [M-OH+H]+. 
1H, 13C NMR and mass spectroscopy were all compatible with the structure of 1d (see 
Table 8). 
 
3.1.1.2. Compound 2d  
 
Compound 2d was isolated as a yellowish brown amorphous powder. On TLC, it 
resulted in a greenish black spot when treated with vanillin/H2SO4. According to IUPAC 
system, the compound was named as 2-(3,4-dihydroxyphenyl)-4-methoxychromane-3,7,8-
triol (Fig 23). By the normal nomenclature of flavonoids, it can also be referred to as 
7,8,3´,4´-teteahydroxy-4-methoxy-flavan-3-ol. Compound 2d has been a known compound 
since July 2008, when its isolation from heartwood of Acacia confuse family Leguminosae 
was reported [168]. (NB, I isolated this compound for the first time in September 2007). 
The position of methoxy group is confirmed by the correlation of the methoxy protons 
and the carbons 3, 4 and 10. Whereas the stereochemistry of protons on the chiral carbons 2 
and 3 in addition to stereochemistry of the methoxy group is more complicated and still 
requires more analysis. 
Comound 2d has a molecular formula of C16H16O7, LC-MS-ESI: tR = 2.32 min, m/z 
calcd 320.09, m/z found 288.93 [M-OCH3+H]+. 
HRMS [M-H] negative mode calcd= 319.0817, found= 319.0823. 
1H, 13C NMR and mass spectroscopy were all compatible with the structure of 2d (see 
Table 8). 
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Table 8: 1H, 13C NMR and DEPT spectral data of compounds 1d and 2d. 
 
 
 
Compound 1d Compound 2d 
Position Nr. δ H δ C δ H δ C DEPT 
2 4.93, br. s. 69.50 4.97, br. s. 76.80 CH 
3 3.87, dd, J = 0.63, 3.99 67.48 3.95, dd, J = 0.80, 2.70. 69.47 CH 
4 4.84, d, J = 3.31 79.04 4.07, d, J = 3.30. 78.68 CH 
5 6.68, d, J = 7.95 118.34 6.67, d, J = 8.60. 123.32 CH 
6 6.36, d, J = 8.34 108.09 6.45, d, J = 8.60. 109.26 CH 
7 - 144.81 - 147.25 C 
8 - 131.92 - 133.84 C 
9 - 143.05 - 145.35 C 
10 - 114.28 - 112.61 C 
1´ - 130.34 - 131.44 C 
2´ 7.01, d, J =1.90 114.51 7.04, d, J = 1.96. 115.80 CH 
3´ - 144.71 - 146.09 C 
4´ - 144.63 - 146.08 C 
5´ 6.75, dd, J = 8.30, 0.90 115.73 6.77, d, J = 8.30. 116.02 CH 
6´ 6.81, dd, J = 8.34, 2.28 117.42 6.87, dd, J = 8.00, 2.20. 119.85 CH 
O-CH3 - - 3.45, s. 56.57 CH3 
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3.1.1.3. Compound 3d 
 
Compound 3d was isolated as a colorless amorphous powder. On TLC, it resulted in a 
greenish black spot when treated with vanillin/H2SO4. According to IUPAC system, the 
compound was named as 8-(4-dihydroxy-3,5 dimethoxyphenyl)-6,7-bis(hydroxymethyl)-1,3-
dimethoxy-5,6,7,8-tetrahydronaphthalene-2-ol (Fig 23). 3d is considered to be a lignin 
derivative and was isolated for the first time from the genus Delonix. It has also been isolated 
previously from Aphanamixis polystachya family Meliaceae [169] and given the name 
Lyoniresinol or (-)-Lyoniresinol, according to the configuration of the chiral center (C7). 
LC-MS-ESI: tR = 6.29 min, m/z calcd 420.18, m/z found 405.02 [M-Me]+. 
HRMS [M-H] negative mode calcd= 419.1705, found= 419.1716. 
1H and 13C NMR as well as HC-HMBC two dimensional correlations (Table 9) and 
mass spectroscopy were all compatible with the structure of 3d. 
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Table 9: 1D and 2D NMR data of compound 3d. 
Position Nr. δ 1H δ 13C DEPT HMBC 
1 - 139.31* C - 
2 6.28, s 106.91 CH C-1,3,4,6,7 
3 - 149.00 C - 
4 - 134.56 C - 
5 - 149.00 C - 
6 6.28, s 106.91 CH C-1,2,4,5,7 
7 4.20, d, J = 4.87 42.31 CH C-1,2,9,1´,6´,8´ 
8 1.85, m 48.00# CH C-1,7,9,8´,9´ 
9 3.40, d, J = 5.84 64.21 CH2 C-7,8,8´ 
1´ - 129.87 C - 
2´ 6.49, s 107.79 CH C-3´,4´,6´,7´ 
3´ - 148.67 C - 
4´ - 139.31* C - 
5´ - 147.71 C - 
6´ - 126.26 C - 
2.47, dd, J =11.54, 14.50,ax C-1´,6´,8´ 7´ 
 2.59, dd, J = 4.86, 15.05, eq 
33.30 CH2 
C-8,1´,6´,8´ 
8´ 1.50, m 40.91 CH - 
3.39, dd, J = 2.85, 8.50, ax C-8,7´,8´ 9´ 
 3.50, dd, J = 4.40, 10.82, eq 
66.80 CH2 
C-8,7´,8´ 
3,5-OCH3 3.65, s 56.61 CH3 C-3,5 
3`- OCH3 3.77, s 56.78 CH3 C-3´ 
5`- OCH3 3.28, s 60.16 CH3 C-5´ 
* Observed from HMBC correlations [139.31 ppm for C-1 and C-4´]. 
# Chemical shift obtained from HMQC, due to solvent interference. 
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3.1.1.4. Compound 4d 
 
Compound 4d was isolated as a yellowish white amorphous powder. On TLC, it 
resulted in a blueish spot when treated with vanillin/H2SO4. Compound 4d is a well known 
compound. It has a common name, (±) catechin. According to the IUPAC system, the 
compound was named as 2-(3,4-dihydroxyphenyl)chromane-3,5,7-triol (Fig 23). Following 
the normal nomenclature of flavonoids, it can be named 5,7,3´,4´-teteahydroxy–flavan-3-ol. 
After reviewing the literature, Compound 4d has never been isolated from Delonix regia, but 
it has been isolated from many other plants.  
Compound 4d has a molecular formula of C15H14O6, LC-MS-ESI: tR = 5.54 min, m/z 
calcd 290.08, m/z found 290.96 [M+H]+. 
1H, 13C NMR and mass spectroscopy were compatible with the structure of 4d and with 
the data published before (see Table 10) [170]. 
Table 10: 1H and 13C of compound 4d. 
Position Nr. δ H δ C DEPT 
2 4.64, d. J = 7.58 81.48 CH 
3 3.87, m 67.43 CH 
2.40, dd, J = 8.20, 16.30, ax 
4 
2.74, dd, J = 6.24, 16.30, eq 
27.14 CH2 
5 - 156.45 C 
6 5.82, d, J = 2.34 94.12 CH 
7 - 156.19 C 
8 5.75, d, J = 2.18 94.89 CH 
9 - 155.54 C 
10 - 99.45 C 
1´ - 130.85 C 
2´ 6.73, d, J = 2.06 113.86 CH 
3´ - 144.85 C 
4´ - 144.83 C 
5´ 6.66, d, J = 8.24 114.70 CH 
6´ 6.61, dd, J = 2.60, 8.31 118.64 CH 
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3.1.1.5. Compound 5d 
 
Compound 5d is a well known compound. It’s known as Isookanin. According to the 
IUPAC system, the compound was named as 2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-2,3-
dihydro-4H-chromen-4-one (Fig 23). Following the normal nomenclature of flavonoids, is 
referred to 7,8,3´,4´-teteahydroxy–dihydroflavone.  
After reviewing the literature, compound 5d has never been isolated from Delonix regia 
before, but it has been isolated from many other Leguminosae plants [171]. 
Compound 5d has a molecular formula of C15H14O6, LC-MS-ESI: tR = 2.68 min, m/z 
calcd 288.06, m/z found 289.00 [M+H]+. 
1H, 13C NMR and mass spectroscopy were all compatible with the structure of 5d and 
with the data published before (see Table 11) [171]. 
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Table 11: 1H and 13C of compounds 5d and 1r. 
Compound 5d Compound 1r 
No 
δ H δ C DEPT δ H δ C DEPT 
2 5.35, dd. J = 2.79. 12.31 82.49 CH 5.28, dd. J = 2.90. 13.26 81.06 CH 
3 
3.04, dd, J =12.31, 16.72, ax 
2.70, dd, J =2.79, 16.72, eq 
45.96 CH2 
2.95, dd, J = 12.93, 16.91, ax 
2.59, dd, J = 2.99, 16.50, eq 
44.96 CH2 
4 - 194.94 C - 193.52 C 
5 7.27, d, J = 8.94 120.27 CH 6.25, d, J = 8.01 103.83 CH 
6 6.50, d, J = 8.82 111.85 CH 6.40, dd, J = 2.50, 8.60 111.77 CH 
7 - 155.04 C - 155.04 C 
8 - 134.95 C 7.63, d, J = 8.12 129.84 CH 
9 - 153.62 C - 158.98 C 
10 - 116.58 C - 114.98 C 
1´ - 132.86 C - 131.37 C 
2´ 6.96, d, J = 1.86 115.93 CH 6.72, d, J = 9.57 116.31 CH 
3´ - 147.41 C 7.22, d, J = 8.12 129.00 CH 
4´ - 147.85 C - 166.86 C 
5´ 6.76, d, J = 8.13 117.16 CH 7.22, d, J = 8.12 129.00 CH 
6´ 6.83, dd, J = 1.86, 8.13 120.51 CH 6.72, d, J = 9.57 116.31 CH 
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3.1.2. Isolated natural products from Robinia pseudoacacia root 
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Fig 24: Chemical structure of natural compounds isolated from Robinia pseudoacacia roots 
 
3.1.2.1. Compound 1r 
 
Compound 1r was isolated as a yellowish amorphous powder. On TLC, it resulted in a 
black spot when treated with vanillin/H2SO4. According to IUPAC system, the compound was 
named as 7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one (Fig 24). 
Following the normal nomenclature of flavonoids, it can be referred to as 7,4´-dihydroxy–
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dihydroflavone. After literature reviewing, compound 1r has never been isolated before from 
the Robinia pseudoacacia, but has been isolated from many other plants [172] 
Compound 1r has a molecular formula of C15H12O4, LC-MS-ESI: tR = 7.87 min, m/z 
calcd 256.07, m/z found 256.95 [M+H]+. 
1H, 13C NMR and mass spectroscopy were all compatible with the structure of 1r (see 
Table 11). 
 
3.1.2.2. Compound 2r 
 
Compound 2r was isolated as an intense yellow amorphous powder. On TLC, it resulted 
in a yellow spot when treated with vanillin/H2SO4. The proton and carbon pattern of NMR 
showed a complete chalcone skeleton [173], with only one OH group at position 2´. 
Compound 2r was named according to IUPAC system, as (2E)-1-(2-hydroxyphenyl)-3-
phenylprop-2-en-1-one. Following the flavonoid nomenclature it can referred to as 2´-
hydroxychalcone. 
Compound 2r has a molecular formula of C15H12O2, LC-MS-ESI: tR = 12.72 min, m/z 
calcd 224.08, m/z found 225.15 [M+H]+. 
1H, 13C NMR and mass spectroscopy were all compatible with the structure of 2r (see 
Table 12 and 13). 
 
3.1.2.3. Compound 3r 
 
Compound 3r was isolated as an amorphous powder with more intense yellow 
colouration than 2r. On TLC, it resulted in a yellow spot when treated with vanillin/H2SO4. 
Compound 3r was identified as a chalcone, with NMR data and comparison with compound 
2r indicating the presence of two more hydroxyl groups at positions 4 and 4´ [173]. 
Compound 3r was named according to IUPAC system as (2E)-1-(2,4-
dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one. Following the flavonoid 
nomenclature, it can be referred to as 4,4´,2´-trihydroxychalcone. 
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Compound 3r has a molecular formula of C15H12O4, LC-MS-ESI: tR = 13.85 min, m/z 
calcd 256.07, m/z found 257.04 [M+H]+. 
1H, 13C NMR and mass spectroscopy were all compatible with the structure of 3r and 
with the data obtained from the literature (see Table 12 and 13) [173]. 
 
3.1.2.4. Compound 4r 
 
Compound 4r was isolated as a yellow amorphous powder. On TLC, it resulted in a 
yellow spot when treated with vanillin/H2SO4. Compound 4r was identified as a chalcone, 
with NMR data and comparison with compounds 2r and 3r indicating the presence of two 
more methoxy groups at positions 2 and 3. Two dimensional NMR, HMBC and HMQC 
spectra also confirm this structure. After reviewing the literature, this compound appears to be 
a new natural product isolated for only the second time from the plant. I isolated this 
compound during my master work from leaves of Robinia pseudoacacia and recorded this 
isolation in my MSc. thesis. N.B: Compound 4r is known in literature however as a synthetic 
product [174, 175]. It is used to prepare other chalcons by the process of biotransformation 
[176]. 
Compound 4r can be named according to the IUPAC system as (2E)-3-(2,3-
dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one. Following the flavonoid 
nomenclature, it can also be referred to as 2´-hydroxy-2,3-dimethoxy chalcone. 
Compound 4r has a molecular formula of C17H16O5, HRMS calcd = 284.1048, found = 
284.1055[M]+. 
1H, 13C NMR (Table 12 and 13) in addition to COSY, HMQC and HMBC as well as 
mass spectroscopy were all compatible with the structure of 4r. 
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Table 12: 1H NMR spectral data of compounds 2r, 3r, 4r. 
Position 
Nr. 
δ H compound 2r δ H compound 3r δ H compound 4r 
1 - - - 
2 7.90, m 6.74, d, J = 8.90 - 
3 7.48, m 7.51, d, J = 8.90 - 
4 7.48, m - 7.00, m 
5 7.48, m 7.51, d, J = 8.90 7.12, dd, J = 2.68, 6.65 
6 7.90, m 6.74, d, J = 8.90 7.00, m 
Α 8.04, d, J = 15.57 7.56, d, J = 15.95 8.07, d, J = 15.83 
Β 7.84, d, J = 15.57 7.51, d, J = 15.95 7.98, d, J = 15.59 
Β´ - - - 
1´ - - - 
2´ - - - 
3´ 8.24, dd, J = 1.16, 7.95 6.18, d, J = 2.00 8.19, dd, J = 1.50, 8.22 
4´ 7.86, m - 7.17, m 
5´ 7.01, m 6.31, dd, J = 2.60, 8,82 7.56,ddd, J = 1.62, 1.62, 8.43 
6´ 7.01, m 7.86, d, J = 8.29 7.17, m 
2´-OH 12.55, s 12.89, s 12.39, s 
4´-OH - 10.12, s - 
4 -OH - 10.35, s - 
2-OCH3 - - 3.81, s 
3-OCH3 - - 3.84, s 
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Table 13: 13C NMR spectral data of compounds 2r, 3r, 4r. 
compound 2r compound 3r compound 4r 
Position Nr. 
δ C DEPT δ C DEPT δ C DEPT 
1 134.42 C 127.87 C 127.99 C 
2 128.92 CH 131.80 CH 148.51 C 
3 128.50 CH 116.94 CH 153.77 C 
4 130.96 CH 161.60 C 115.39 CH 
5 129.16 CH 116.94 CH 122.86 CH 
6 129.92 CH 131.80 CH 124.42 CH 
α 117.68 CH 118.40 CH 117.70 CH 
β 144.70 CH 145.58 CH 138.68 CH 
β- 193.62 C 193.48 C 193.55 C 
1´ 120.80 C 114.62 C 120.94 C 
2´ 161.84 C 166.76 C 161.72 C 
3´ 119.15 CH 103.88 CH 119.36 CH 
4´ 136.31 CH 167.56 C 136.25 CH 
5´ 121.86 CH 109.31 CH 119.17 CH 
6´ 130.84 CH 133.35 CH 130.77 CH 
2-OCH3 - - - - 61.00 CH3 
3-OCH3 - - - - 56.00 CH3 
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3.1.2.5. Compound 5r 
 
Compound 5r was isolated as a white amorphous powder. On TLC, it resulted in a black 
spot when treated with vanillin/H2SO4. 
Compound 5r was identified as a new indol derivative, with 1H, 13C and two 
dimensional NMR HMBC comparison used to confirm the indol derivative structure. This 
compound is a new natural product which has not been reported before, and is isolated the 
first time from the root of Robinia pseudoacacia. 
The chemical structure of compound 5r gave the typical NMR signals of a pterocarpan 
(Medicarpin) [177, 178], with one additional broad singlet proton at δH 4.99, indicating the 
presence of an NH group instead of oxygen at the bridge of the three member ring [179, 180]. 
Compound 5r was named according to IUPAC system as 9-methoxy-6,6a,11,11a-
tetrahydrochromeno[4,3-b]indol-3-ol  
Compound 5r has a molecular formula of C16H15NO3, LC-MS-ESI: tR = 12.55 min, m/z 
calcd 269.11, m/z found 269.1 [M]+. 
1H and 13C NMR and HMBC in addition to COSY, HMQC as well as mass 
spectroscopy were all compatible with the structure of 5r (see Table 14). 
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Table 14: 1H, 13C as well as HMBC spectral data of compound 5r. 
Position Nr. δ H H-C HMBC correlation δ C DEPT 
2 3.51, m, ax/ 4.21, m, eq C-2, 1´, 9 66.58 CH2 
3 3.60, t, J = 10.95 C-3, 4, 1´, 6´ 39.52 CH 
4 5.47, d, J = 6.85 C-2, 10, 8, 9 78.55 CH 
5 7.36, d, J = 8.50 C-9, 4 132.22 CH 
6 6.43,dd, J = 2.50, 8.50 C-5, 10 106.45 CH 
7 - - 161.15 C 
8 6.38, d, J = 2.50 C-9, 10 96.93 CH 
9 - - 157.01 C 
10 - - 112.70 C 
1´ - - 119.11 C 
2´ 7.11, d, J = 8.45 C-3´, 4´, 5´, 3 124.78 CH 
3´ 6.53,dd, J = 2.20, 8.45 C-1´, 3´, 4´, 5´ 109.75 CH 
4´ - - 160.71 C 
5´ 6.43, d, J = 2.20 C-1´, 3´, 4´, 5´ 103.69 CH 
6´ - - 156.67 C 
N-H 4.99, br.s C-10, 5´, 6´ - - 
O-CH3 3.74, s C-4´ 55.45 CH3 
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3.2. Mannich reaction  
 
Reaction of aldehydes and primary or secondary amines with the flavones (chrysin or 
quercetin) produced twenty-one compounds (1m-21m), all with different chemical, physical 
and biological characteristics. The resulting diversity may provide a better understanding of 
the structure-activity relationships of these compounds (Fig 26). 
Table 15 provides details of the compounds obtained from the Mannich reaction as well 
as the reaction conditions and yields associated with them. 
It should be noted that carbon number 6 in the flavone nucleus was the most reactive 
and usually involved in the reaction. In some instances carbon number 8 was also involved, 
thus creating 6,8-disubstituted flavones (Fig 25). 
 
 
Fig 25: Schematic overview of the Mannich reaction used to modify chrysin and quercetin. 
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Table 15: Components of the Mannich reaction, including reaction conditions and yields. 
No Aldehyde Amine Flavone Condition Reaction site Yield% 
1m Paraformaldehyde morpholin chrysin 24 h, 65 °C C6 42 
2m Paraformaldehyde morpholin chrysin 24 h, 65 °C C6, C8 22 
3m Paraformaldehyde thiomorpholin chrysin 8 h, 65 °C C6 21 
4m Paraformaldehyde thiomorpholin chrysin 8 h, 65 °C C6, C8 86 
5m Paraformaldehyde N-methyl piperazine chrysin 4 h, 65 °C C6 32 
6m Ethylglyoxalate morpholin chrysin 8 h, 65 °C C6 80 
7m Ethylglyoxalate morpholin chrysin 8 h, 65 °C C6, C8 12 
8m Ethylglyoxalate thiomorpholin chrysin 4 h, 65 °C C6 18 
9m Ethylglyoxalate N-methyl piperazine chrysin 4 h, 65 °C C6 80 
10m Ethylglyoxalate morpholin quercetin 4 h, 40 °C C6 72 
11m Ethylglyoxalate thiomorpholin quercetin 4 h, 35 °C C6 36 
12m Paraformaldehyde Phthalimide chrysin 4 h, 65 °C C6 10 
13m Ethylglyoxalate p-anisidine chrysin 4 h, 55°C C6 10 
14m Ethylglyoxalate p-anisidine quercetin 8 h, r.t. C6 39 
15m p-Methoxy penzaldehyde morpholin chrysin 24 h, 65 °C C8 42 
16m p-Methoxy penzaldehyde morpholin chrysin 24 h, 65 °C C6 18 
17m Benzaldehyde morpholin chrysin 24 h, 65 °C C6 47 
18m p-Nitro penzaldehyde morpholin chrysin 24 h, 65 °C C6 22 
19m p-Bromo penzaldehyde morpholin chrysin 24 h, 65 °C C6 15 
20m p-Chloro penzaldhyde morpholin chrysin 24 h, 65 °C C6 60 
21m p-Floro penzaldehyde morpholin chrysin 24 h, 65 °C C6 55 
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Fig 26: Chemical structure of synthetic compounds obtained via Mannich reaction. 
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Compound 1m: 5,7-Dihydroxy-6-(morpholinomethyl)-2-phenyl-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellow powder. Yield = 42 %. 
TLC (petrol ether: ethyl acetate = 7: 3): Rf = 0.61, melting point: 209 °C. 
1H NMR (CDCl3, 500 MHz): 12.70 (s, 1H), 7.83-7.71 (dd, 2H, J=1.49, 7.50 Hz,), 7.57-7.48 
(m, 3H), 6.61 (s, 1H), 6.27 (s, 1H), 3.98 (s, 2H), 3.86- 3.63 (br s, 4H), 2.83- 2.47 (br s, 4H) 
ppm. 
13C NMR (CDCl3, 125 Hz): 182.35 (s), 165.31 (s), 163.13 (s), 161.74 (s), 154.84 (s), 131.79 
(d), 131.53 (s), 129.19 (d, 2C), 126.07 (d, 2C), 105.91 (d), 104.84 (s), 100.25 (d), 97.97 (s), 
66.63 (t), 54.13 (t), 52.98 (t) ppm. 
LC-MS-ESI: tR = 7.07 min, m/z calcd 353.13, m/z found 354.61 [M+H]+. 
 
Compound 2m: 5,7-Dihydroxy-6,8-bis(morpholinomethyl)-2-phenyl-4H-chromen-4-one  
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellow powder. Yield = 22 %. 
TLC (petrol ether: ethyl acetate = 7: 3): Rf = 0.77, melting point: 172 oC. 
1H NMR (CDCl3, 500 MHz): 13.25 (s, 1H), 9.80 (br s, 1H), 7.80-7.95 (dd, 2H, J=2.00, 8.09 
Hz,), 7.54-7.47 (m, 3H), 6.63 (s, 1H), 3.82 (s, 2H), 3.81 (s, 2H), 3.75- 3.71 (t, 4H, J=4.40), 
3.71- 3.68 (t, 4H, J=4.40), 2.64- 2.55 (m, 4H)1.49 ppm. 
13C NMR (CDCl3, 125 Hz): 182.58 (s), 164.63 (s), 163.34 (s), 159.08 (s), 155.32 (s), 131.72 
(d), 131.58 (s), 129.11 (d, 2C), 126.15 (d, 2C), 105.48 (d), 104.03 (s), 103.92 (s), 101.31 (s), 
66.87 (t), 66.62 (t), 53.73 (t), 52.86 (t), 52.38 (t), 50.96 (t) ppm. 
LC-MS-ESI: tR = 6.09 min, m/z calcd 452.19, m/z found 453.63 [M+H]+. 
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Compound 3m: 5,7-Dihydroxy-2-phenyl-6-(thiomorpholinomethyl)-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as a dark yellow powder. Yield = 21 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.8, melting point: 226 °C. 
1H NMR (CDCl3, 500 MHz): 12.70 (s, 1H), 7.81-7.78 (dd, 2H, J= 1.54, 8.30 Hz,), 7.56-7.50 
(m, 3H), 6.61 (s, 1H), 6.27 (s, 1H), 3.99 (s, 2H), 3.00-2.83 (br s, 4H), 2.81-2.71 (br s, 4H), 
ppm. 
13C NMR (CDCl3, 125 Hz): 182.0 (s), 165.46 (s), 163.11 (s), 161.72 (s), 154.82 (s), 131.80 
(d), 131.53 (s), 129.20 (d, 2C), 126.06 (d, 2C), 105.91 (d), 104.82 (s), 100.31 (d), 98.05 (s), 
54.62 (t), 54.45 (t, 2C), 27.86 (t, 2C) ppm. 
LC-MS-ESI: tR = 7.84 min, m/z calcd 369.10, m/z found 370.49 [M+H]+. 
HRMS: [M]+, calcd 369.1034, found 369.1073. 
 
Compound 4m: 5,7-Dihydroxy-2-phenyl-6,8-bis(thiomorpholinomethyl)-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as a dark yellow powder. Yield = 86 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.64, melting point: 226 °C. 
1H NMR (CDCl3, 500 MHz): 13.34-12.95(br s, 1H), 10.58-948 (br s, 1H) 7.87-7.83 (dd, 2H, 
J=2.22, 7.67 Hz,), 7.52-7.47 (m, 3H), 6.61 (s, 1H), 3.79 (s, 4H), 2.88-2.81(m, 8H), 2.72-2.67 
(t, 4H, J=4.52 Hz), 2.67-2.63 (t, 4H, J=4.94Hz) ppm. 
13C NMR (CDCl3, 125 Hz): 182.49 (s), 164.63 (s), 163.25 (s), 158.99 (s), 155.23 (s), 131.67 
(d), 131.52 (s), 129.06 (d,2C), 126.09 (d, 2C), 105.42 (d), 104.01 (s), 103.95 (s), 101.45 (s), 
54.62 (t), 54.18 (t), 52.62 (t, 2C), 51.35 (t,2C), 27.82 (t, 2C), 27.54 (t, 2C) ppm  
LC-MS-ESI: tR = 7.57 min, m/z calcd 484.15, m/z found 485.55 [M+H]+. 
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Compound 5m: 5,7-Dihydroxy-6-((4-methylpiperazin-1-yl)methyl)-2-phenyl-4H-chromen-
4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as a dark yellow powder. Yield = 32 %. 
TLC (petrol ether: ethyl acetate = 7: 4): Rf = 0.64, melting point: 186 °C. 
1H NMR (CDCl3, 500 MHz): 12.69 (s, 1H), 7.80-7.77 (dd, 2H, J= 1.55, 7.75 Hz), 7.54-7.48 
(m, 3H), 6.59 (s, 1H), 6.25 (s, 1H), 3.97 (s, 2H), 2.97-2.32 (m, 8H), 2.30 (s, 3H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.32 (s), 165.64 (s), 163.04 (s), 161.58 (s), 131.73 (d), 131.53 
(s), 129.14 (d, 2C), 126.03 (d, 2C), 105.80 (d), 104.68 (s), 100.20 (d), 98.36 (s), 54.69 (t), 
53.68 (t), 52.60 (t), 45.79 (q) ppm. 
LC-MS-ESI: tR = 6.18 min, m/z calcd 366.16, m/z found 367.59 [M+H]+. 
HRMS: [M]+, calcd 366.1579, found 366.1577. 
 
Compound 6m: Ethyl 2-(5,7-dihydroxy-4-oxo-2-phenyl-4H-chromen-6-yl)-2-
morpholinoacetate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as a dark yellow powder. Yield = 80 %. 
TLC (petrol ether: ethyl acetate = 7: 3): Rf = 0.61, melting point: 199 °C. 
1H NMR (CDCl3, 500 MHz): 12.75 (s, 1H), 7.94-7.91 (dd, 2H, J= 1.50, 8.76 Hz), 7.55-7.50 
(m, 3H), 6.63 (s, 1H), 6.26 (s, 1H), 4.27 (s, 1H), 4.21-4.12 (m, 2H), 3.81-3.74 (t, 4H, J= 4.50), 
2.73-2.57 (m, 4H), 1.19-1.14 (t, 3H, J= 7.50) ppm. 
13C NMR (CDCl3, 125 Hz): 182.10 (s), 168.67 (s), 164.60 (s), 163.37 (s), 162.47 (s), 155.21 
(s), 131.84 (d), 131.30 (s), 129.14 (d, 2C), 126.23 (d, 2C), 105.91 (d), 105.00 (s), 100.47 (d), 
96.81 (s), 66.47 (d), 66.42 (t), 61.78 (t), 51.40 (t), 13.88 (q) ppm. 
LC-MS-ESI: tR = 7.67 min, m/z calcd 425.15, m/z found 426.01 [M+H]+. 
HRMS: [M+H]+, calcd 426.1552, found 426.1275. 
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Compound 7m: Diethyl 2,2'-(5,7-dihydroxy-4-oxo-2-phenyl-4H-chromene-6,8-diyl)bis(2-
morpholinoacetate) 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as a dark yellow powder. Yield = 12 %. 
TLC (petrol ether: ethyl acetate = 7: 3): Rf = 0.64, melting point: 124 oC. 
1H NMR (CDCl3, 500 MHz): 13.26 (s, 1H), 7.67-7.62 (dd, 2H, J= 2.2, 8.21 Hz), 7.29-7.22 
(m, 3H), 6.41 (s, 1H), 4.60 (s, 1H), 4.56 (s, 1H), 3.93-3.85 (m, 2H), 3.84-3.77 (m, 2H), 3.50-
3.40 (t, 8H, J= 4.50), 2.50-2.40 (m, 4H), 2.40-2.27 (m, 4H), 0.97-0.92 (t, 3H, J= 6.90), 0.90-
0.86 (t, 3H, J= 6.90) ppm. 
13C NMR (CDCl3, 125 Hz): 182.13 (s), 170.77 (s), 170.06 (s), 170.04 (s), 169.37 (s), 163.44 
(s), 163.07 (s), 162.93 (s), 160.51 (s), 154.97 (s), 131.82 (d), 131.94 (s), 129.04 (d, 2C), 
126.15 (d, 2C), 105.62 (d), 98.31 (s), 66.65 (t), 66.49 (t), 63.83 (d), 62.07 (d), 61.20 (t), 60.93 
(t), 50.70 (t), 50.53 (t), 13.90 (q), 13.79 (q) ppm. 
LC-MS-ESI: tR = 8.69 min, m/z calcd 596.24, m/z found 597.10 [M+H]+. 
HRMS: [M+H]+, calcd= 597.2448, found= 597.2416. 
 
Compound 8m: 6-(2-Ethoxy-1-morpholinoallyl)-5,7-dihydroxy-2-phenyl-4H-chromen-4-
one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a dark yellow powder. Yield = 18 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.61, melting point: 190 °C. 
1H NMR (CDCl3, 500 MHz): 12.77 (s, 1H), 7.94-7.91 (dd, 2H, J= 2.50, 7.14 Hz), 7.57-7.53 
(m, 3H), 6.64 (s, 1H), 6.29 (s, 1H), 4.79 (s, 1H), 4.19-4.14 (m, 2H), 2.96-2.86 (m, 4H), 2.80-
2.75 (m, 4H), 1.19-1.15 (t, 3H, J= 7.14) ppm. 
13C NMR (CDCl3, 125 Hz): 182.18 (s), 168.98 (s), 164.80 (s), 163.43 (s), 162.56 (s), 155.25 
(s), 131.92 (d), 131.89 (s), 129.23 (d, 2C), 126.30 (d, 2C), 106.03 (d), 105.08 (s), 100.67 (d), 
97.04 (s), 66.60 (d), 61.87 (t), 53.05 (t), 27.72 (t), 13.94 (q) ppm. 
LC-MS-ESI: tR = 8.74 min, m/z calcd 441.16, m/z found 442.66 [M+H]+. 
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Compound 9m: Ethyl 2-(5,7-dihydroxy-4-oxo-2-phenyl-4H-chromen-6-yl)-2-(4-
methylpiperazin-1-yl)acetate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as a dark yellow powder. Yield = 80 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.52, melting point: 166 °C. 
1H NMR (CDCl3, 500 MHz): 12.75 (s, 1H), 7.94-7.91 (dd, 2H, J= 1.75, 7.76 Hz), 7.55-7.50 
(m, 3H), 6.64 (s, 1H), 6.28 (s, 1H), 4.71 (s, 1H), 4.19-4.14 (m, 2H), 2.81-2.42 (m, 8H), 2.29 
(s, 3H), 1.19-1.14 (t, 3H, J= 7.15) ppm. 
13C NMR (CDCl3, 125 Hz): 182.19 (s), 168.99 (s), 165.00 (s), 163.37 (s), 162.24 (s), 155.15 
(s), 131.86 (d), 131.39 (s), 129.19 (d, 2C), 126.27 (d, 2C), 105.91 (d), 104.96 (s), 100.85 (d), 
97.36 (s), 66.35 (d), 61.73 (t), 54.63 (t), 51.02 (t), 45.69 (q), 13.93 (q) ppm. 
LC-MS-ESI: tR = 8.06 min, m/z calcd 438.18, m/z found 439.10 [M+H]+. 
 
Compound 10m: Ethyl 2-(2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-6-
yl)-2-morpholinoacetate 
The compound was purified by column chromatography on silica gel with dichloromethane: 
methanol = 95: 5. It was obtained as a brownish powder. Yield = 72 %. 
TLC (dichloromethane: methanol = 9: 1): Rf = 0.63, melting point: 250 °C. 
1H NMR (CH3OD, 500 MHz): 7.89-7.84 (br s, 1H), 7.75-771 (br s, 1H), 7.64-7.59 (d, 1H, J= 
8.67 Hz), 6.86-6.75 (s, 1H), 6.07 (s, 1H), 4.07-4.02 (m, 2H), 3.66-3.62 (t, 4H, J= 4.88), 2.60-
2.55 (m, 4H), 1.05-1.00 (t, 3H, J= 7.04) ppm. 
13C NMR (CH3OD, 125 Hz): 177.31 (s), 171.18 (s), 165.19 (s), 164.87 (d), 162.66 (s), 155.62 
(s), 148.79 (s), 148.14 (s) 146.31 (s), 137.42 (s), 124.04 (s), 122.21 (d), 116.32 (d), 104.76 (s), 
99.66 (d), 99.12 (s), 67.77 (t), 66.05 (d), 62.66 (t), 52.31 (t), 14.30 (q) ppm. 
LC-MS-ESI: tR = 6.74 min, m/z calcd 473.13, m/z found 474.02 [M+H]+. 
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Compound 11m: 2-(3,4-Dihydroxyphenyl)-6-(2-ethoxy-1-morpholinoallyl)-3,5,7-
trihydroxy-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with dichloromethane: 
methanol = 98: 2. It was obtained as a brownish yellow powder. Yield = 36 %. 
TLC (dichloromethane: methanol = 9: 1): Rf = 0.68, melting point: 211 °C. 
1H NMR (CH3OD, 500 MHz): 7.80-7.78 (d, 1H, J=2.23 Hz), 7.75-7.72 (dd, 1H, J=2.23, 8.36) 
7.02-6.98 (d, 1H, J=8.38 Hz), 6.28 (s, 1H), 4.81 (s, 1H), 4.21-4.13(m, 2H), 2.97-2.84 (m, 4H), 
2.80-2.74 (t, , 4H, J=4.47), 1.20-1.16 (t, , 3H, J=7.26) ppm. 
13C NMR (CH3OD, 125 Hz): 175.22 (s), 169.57 (s), 165.27 (s), 161.48 (s), 154.42 (s), 146.52 
(s), 145.44 (s), 143.80 (s), 135.89 (s), 123.69 (s), 121.81 (d), 115.77 (d), 114.95 (d), 103.50 
(s), 100.34 (d), 97.11 (s), 66.94 (d), 62.38 (t), 53.27 (t), 27.96 (t), 14.16 (q) ppm. 
LC-MS-ESI: tR = 7.06 min, m/z calcd 489.11, m/z found 490.63 [M+H]+. 
 
Compound 12m: 5,7-Dihydroxy-6-(hydroxymethyl)-2-phenyl-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as a yellow powder. Yield = 10 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.54, melting point: 118 °C. 
1H NMR (CH3OD, 500 MHz): 7.88-7.85 (dd, 2H, J= 2.26, 8.28 Hz), 7.49-7.42 (m, 3H), 6.64 
(s, 1H), 6.43 (s, 1H), 4.64 (s, 2H) ppm. 
13C NMR (CH3OD, 125 Hz): 184.04 (s), 165.60 (s), 165.03 (s), 161.18 (s), 158.72 (s), 133.05 
(d), 132.54 (s), 130.24 (d, 2C), 127.43 (d, 2C), 111.96 (s), 106.14 (d), 105.34 (s), 94.60 (d), 
53.68 (t) ppm. 
LC-MS-ESI: tR = 9.64 min, m/z calcd 284.07, m/z found 284.94 [M+H]+. 
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Compound 13m: Ethyl 2-(5,7-dihydroxy-4-oxo-2-phenyl-4H-chromen-6-yl)-2-(4-
methoxyphenylamino)acetate. 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellow powder. Yield = 10 %. 
TLC (petrol ether: ethyl acetate = 7: 3): Rf = 0.55, melting point: 152 °C. 
1H NMR (CDCl3, 500 MHz): 12.78 (s, 1H), 7.87-7.83 (dd, 2H, J= 1.50, 7.80 Hz), 7.54-7.50 
(m, 3H), 6.78-6.72 (m, 4H), 6.70 (s, 1H), 6.28 (s, 1H), 5.62 (s, 1H), 4.17-4.07 (m, 2H), 3.68 
(s, 3H), 1.13-1.08 (t, 3H, J= 6.75) ppm. 
13C NMR (CDCl3, 125 Hz): 182.37 (s), 170.55 (s), 164.50 (s), 163.43 (s), 162.18 (s), 155.33 
(s), 155.03 (s), 138.06 (s), 131.90 (d), 131.44 (s), 129.22 (d, 2C), 126.15 (d, 2C), 118.23 (d), 
114.96 (d), 106.10 (d), 105.62 (s), 100.96 (d), 99.11 (s), 62.76 (t), 56.43 (d), 55.49 (q), 13.91 
(q) ppm. 
LC-MS-ESI: tR = 10.47 min, m/z calcd 461.15, m/z found 461.95 [M+H]+. 
 
Compound 14m: Ethyl 2-(2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-6-
yl)-2-(4-methoxyphenylamino)acetate 
The compound was purified by column chromatography on silica gel with dichloromethane: 
methanol = 95: 5. It was obtained as a brownish black powder. Yield = 39 %. 
TLC (dichloromethane: methanol = 9: 1): Rf = 0.63, melting point: 120 °C. 
1H NMR (CH3OD, 500 MHz): 7.73-7.71 (d, 1H, J= 2.00), 7.59-7.55 (dd, 1H, J= 1.97, 7.87 
Hz), 6.81-6.79 (d, 1H, J= 8.66), 6.64-6.61 (dd, 2H, J= 1.97, 6.69 Hz), 6.59-6.55 (dd, 2H, J= 
1.97, 7.00 Hz), 6.12 (s, 1H), 5.64 (s, 1H), 4.11-4.01 (m, 2H), 3.54 (s, 3H), 1.04-1.00 (t, 3H, J= 
7.09) ppm. 
13C NMR (CH3OD, 125 Hz): 177.47 (s), 173.82 (s), 163.43 (s), 162.04 (s), 155.51 (s), 154.83 
(s), 148.96 (s), 148.30 (s) 146.33 (s), 142.08 (s), 137.29 (s), 124.06 (s), 121.80 (d), 117.70 (d), 
116.36 (d), 116.24 (d), 115.69 (d), 104.83 (s), 99.94 (d), 62.70 (t), 56.06 (q), 54.53 (d), 14.39 
(q) ppm. 
LC-MS-ESI: tR = 8.17 min, m/z calcd 509.13, m/z found 509.98 [M+H]+. 
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Compound 15m: 8-(Amino(4-methoxyphenyl)methyl)-5,7-dihydroxy-2-phenyl-4H-
chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as yellow powder. Yield = 42 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.54, melting point: 225 oC. 
1H NMR (CDCl3, 500 MHz): 13.79 (s, 1H), 12.68 (s, 1H), 7.79-7.75 (dd, 2H, J= 1.56, 8.24 
Hz), 7.56-7.52 (m, 3H), 7.39-7.35 (d, 2H, J= 8.20 Hz) 6.84-6.81 (d, 2H, J= 1.56, 8.24 Hz),  
6.54 (s, 1H), 6.34 (s, 1H), 4.49 (s, 1H), 3.73 (s, 3H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.22 (s), 164.17 (s), 163.38 (s), 161.54 (s), 159.73 (s), 154.81 
(s), 131.75 (d), 130.00 (s), 129.12 (d, 2C), 126.18 (d, 2C), 106.24 (d), 105.10 (s), 103.96 (s), 
100.73 (d), 68.31 (d), 55.23 (q) ppm. 
LC-MS-ESI: tR = 9.64 min, m/z calcd 389.13, m/z found 374.09 [M-NH2+H]+. 
HRMS: [M-CH3+H], calcd 375.1106, found 375.1076. 
 
Compound 16m: 6-(Amino(4-methoxyphenyl)methyl)-5,7-dihydroxy-2-phenyl-4H-
chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 7: 3. It was obtained as yellow powder. Yield = 18 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.49, melting point: 204 oC. 
1H NMR (CDCl3, 500 MHz): 14.00 (s, 1H), 13.08 (s, 1H), 7.85-7.81 (dd, 2H, J= 2.30, 7.60 
Hz), 7.51-7.45 (m, 3H), 7.42-7.38 (d, 2H, J= 8.56 Hz) 6.84-6.80 (d, 2H, J= 1.50, 8.20 Hz),  
6.56 (s, 1H), 6.45 (s, 1H), 4.87 (s, 1H), 3.74 (s, 3H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.28 (s), 163.99 (s), 163.66 (s), 159.42 (s), 159.25 (s), 157.02 
(s), 131.67 (d), 131.14 (s), 130.46 (s), 129.02 (d, 2C), 126.22 (d, 2C), 108.91 (s), 105.48 (d), 
104.56 (s), 94.95 (d), 67.74 (d), 55.20 (q) ppm. 
LC-MS-ESI: tR = 9.15 min, m/z calcd 389.13, m/z found 373.95 [M-NH2+H]+.  
HRMS: [M-OCH3+H], calcd 375.1106, found 375.1121. 
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Compound 17m: 6-(Amino(phenyl)methyl)-5,7-dihydroxy-2-phenyl-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellow powder. Yield = 47 %. 
TLC (petrol ether: ethyl acetate = 7: 3): Rf = 0.45, melting point: 195 oC. 
1H NMR (CDCl3, 500 MHz): 13.75 (s, 1H), 13.15 ( s, 1H), 7.85-7.81 (m, 2H), 7.56-7.51 (d, 
2H, J= 7.41 Hz), 7.50-7.75 (m, 3H),7.35-7.30 (d, 2H, J= 7.92 Hz),7.30-7.25 (m, 1H),  6.58 (s, 
1H), 6.49 (s, 1H), 4.96 (s, 1H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.18 (s), 163.89 (s), 163.57 (s), 159.31 (s), 155.99 (s), 138.44 
(s), 131.60 (d), 131.27 (s), 128.93 (d, 2C), 128.11 (d), 126.11 (d, 2C), 108.55 (s), 105.41 (d), 
104.49 (s), 94.89 (d), 68.35 (d) ppm. 
LC-MS-ESI: tR = 8.99 min, m/z calcd 359.12, m/z found 344.07 [M-NH2+H]+. 
 
Compound 18m: 6-(Amino(4-nitrophenyl)methyl)-5,7-dihydroxy-2-phenyl-4H-chromen-4-
one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as yellow powder. Yield = 22 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.55, melting point: 292 oC. 
1H NMR (CDCl3, 500 MHz): 13.20 (s, 1H), 8.18-8.13 (d, 2H, J= 8.76 Hz), 7.84-7.80 (d, 2H, 
J= 7.76 Hz), 7.73-7.67 (d, 2H, J= 8.76 Hz), 7.52-7.45 (m, 3H), 6.58 (s, 1H), 6.47 (s, 1H), 5.04 
(s, 1H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.27 (s), 164.00 (s), 163.31 (s), 159.44 (s), 157.34 (s), 147.62 
(s), 145.83 (s), 131.85 (d), 131.18 (s), 129.07 (d, 2C), 126.24 (d, 2C), 124.13 (d) 107.26 (s), 
105.52 (d), 104.66 (s), 95.82 (d), 67.59 (d) ppm. 
LC-MS-ESI: tR = 16.91 min, m/z calcd 404.10, m/z found 390.05 [M-NH2+H]+. 
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Compound 19m: 6-(Amino(4-bromophenyl)methyl)-5,7-dihydroxy-2-phenyl-4H-chromen-
4-one  
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 85: 15. It was obtained as a dark yellow powder. Yield = 15 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.60, melting point: 163 °C. 
1H NMR (CDCl3, 500 MHz): 12.96 (s, 1H),  7.66-7.64 (dd, 2H, J=1.67, 7.68 Hz), 7.34-7.28 
(m, 3H), 7.26-7.23 (d, 2H, J=8.34Hz), 7.22-7.18 (d, 2H, J=8.68 Hz), 6.39 (s, 1H), 6.28 (s, 
1H), 4.71 (s, 1H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.54 (s), 164.05 (s), 163.89 (s), 159.60 (s), 157.41 (s), 137.80 
(s), 132.28 (d), 132.00 (d), 131.57 (s), 129.29 (d, 3C), 126.49 (d, 2C), 122.45 (s), 108.38 (s), 
105.77 (d), 104.86 (s), 95.33 (d), 67.98 (d) ppm. 
LC-MS-ESI: tR = 9.98 min, m/z calcd 437.01, m/z found 421.47 [M-NH2]+. 
 
Compound 20m: 6-(Amino(4-chlorophenyl)methyl)-5,7-dihydroxy-2-phenyl-4H-chromen-
4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 85: 15. It was obtained as a dark yellow powder. Yield = 60 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.60, melting point: 187 °C. 
1H NMR (CDCl3, 500 MHz): 13.11 (s, 1H), 7.80-7.77 (dd, 2H, J=1.95, 8.27 Hz), 7.47-7.37 
(m, 5H), 7.25-7.21 (d, 2H, J=8.35Hz), 6.53 (s, 1H), 6.42 (s, 1H), 4.86 (s, 1H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.28 (s), 163.80 (s), 163.66 (s), 159.34 (s), 157.15 (s), 137.03 
(s), 134.04 (s), 131.74 (d), 131.31 (s), 129.04 (d, 2C), 126.23 (d, 2C), 108.20 (s), 105.51 (d), 
104.60 (s), 95.07 (d), 67.95 (d) ppm. 
LC-MS-ESI: tR = 9.98 min, m/z calcd 393.06, m/z found 379.75 [M-NH2+H]+. 
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Compound 21m: 6-(Amino(4-fluorophenyl)methyl)-5,7-dihydroxy-2-phenyl-4H-chromen-
4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 85: 15. It was obtained as a dark yellow powder. Yield = 55 %. 
TLC (petrol ether: ethyl acetate = 6: 4): Rf = 0.57, melting point: 166 °C. 
1H NMR (CDCl3, 500 MHz): 12.15 (s, 1H), 7.87-7.77 (dd, 2H, J=1.98, 8.20 Hz), 7.54-7.39 
(m, 5H), 7.01-7.94 (dt, 2H, J=1.30, 7.14, 8.47 Hz), 6.57 (s, 1H), 6.46 (s, 1H), 4.91 (s, 1H) 
ppm. 
13C NMR (CDCl3, 125 Hz): 182.31 (s), 163.79 (s), 163.72 (s), 159.32 (s), 157.12 (s), 134.35 
(s), 134.32 (s), 131.73 (d), 131.35 (s), 129.04 (d, 2C), 126.23 (d, 2C), 108.49 (s), 105.52 (d), 
104.60 (s), 95.05 (d), 67.58 (d) ppm. 
LC-MS-ESI: tR = 9.26 min, m/z calcd 377.11, m/z found 362.53 [M-NH2]+. 
 
3.3. New type of synthesis of chromene-flavone compounds 
 
The reaction of chrysin with alkyl isocyanides and dialkyl acetylene dicarboxylate provided 
the foundation for the synthesis of fifteen new compounds (1f-15f). Each of these compounds 
shows a tricyclic nucleus containing features of flavones as well as chromenes as a common 
structural element (Fig 28). The reaction was performed at -20 °C during the isonitrile 
addition step. The reaction was completed at r.t. The solvent used was CH2Cl2 for all 
compounds (Fig 27). The reaction times varied (see Table 16). 
 
Fig 27: General scheme employed for the synthesis chromene-flavones. Please note that this is a general 
scheme only. Details can be found in table 16 and in the text. 
 
Chapter III  Results 
82 
 
Table 16 lists the isocyanide and acetylene dicarboxylate elements as well as reaction times 
used and yields obtained. 
Table 16: Individiual building blocks of the chromene-flavone reaction. Reaction times and yields are provided.  
Compound Nr R R1 Reaction time Yield % 
1f methyl t- butyl 24 hrs 63 
2f methyl c-hexyl 36hrs 76 
3f t-butyl t-butyl 24hrs 55 
4f t-butyl c-hexyl 36hrs 27 
5f ethyl t-butyl 24hrs 55 
6f ethyl c-hexyl 24hrs 65 
7f methyl i-propyl 24hrs 69 
8f ethyl i-propyl 24hrs 70 
9f methyl 1,1,3,3- tetramethyl butyl 36 hrs 85 
10f ethyl 1,1,3,3- tetramethyl butyl 36 hrs 82 
11f t-butyl 1,1,3,3- tetramethyl butyl 48 hrs 65 
12f methyl n-pentyl 36 hrs 25 
13f ethyl n-pentyl 36 hrs 33 
14f methy n-butyl 24 hrs 55 
15f ethyl n-butyl 24 hrs 33 
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Fig 28: Chemical structures of chromene-flavones. 
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Compound 1f: Dimethyl 2-(tert-butylamino)-5-hydroxy-6-oxo-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellowish powder. Yield = 63 %. 
TLC (petrol ether: ethyl acetate = 7: 3): Rf = 0.45, melting point: the compound decomposes 
at 170 °C. 
1H NMR (CDCl3, 500 MHz): 12.81 (s, 1H), 8.91-8.83 (br s, 1H), 8.10-8.05 (dd, 2H, J=2.00, 
7.69 Hz,), 7.61-7.56 (m, 3H), 6.76 (s, 1H), 6.57 (s, 1H), 5.11 (s, 1H), 3.77 (s, 3H), 3.63 
(s,3H), 1.49 (s, 9H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.12 (s), 170.32 (s), 166.91 (s), 162.92 (s), 158.96 (s), 158.65 
(s), 151.92 (s), 151.23 (s), 129.64 (d, 2C), 128.43 (s), 126.73 (d, 2C), 124.11(d),  105.70 (s), 
103.58 (d), 97.99 (s), 97.16 (d), 69.44 (s), 50.33 (q), 49.92 (s), 48.54 (q), 33.28 (d), 28.07 (q, 
3C) ppm. 
LC-MS-ESI: tR = 16.91 min, m/z calcd 479.16, m/z found 480.1 [M+H]+.  
HRMS: [M+H]+, calcd 480.1658, found 480.1754. 
 
Compound 2f: Dimethyl 2-(cyclohexylamino)-5-hydroxy-6-oxo-8-phenyl-4,6 
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellowish powder. Yield = 76 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.54, melting point: 224-228 °C 
1H NMR (CDCl3, 500 MHz): 12.78 (s, 1H), 8.77-8.59 (br s, 1H), 8.09-8.03 (dd, 2H, J=2.00, 
7.69 Hz), 7.59-7.54 (m, 3H), 6.74 (s, 1H), 6.53 (s, 1H), 5.08 (s, 1H), 3.84-3.77(m, 1H), 3.75 
(s, 3H), 3.60 (s, 3H), 2.06-1.99(m, 1H), 1.94-1.88 (m, 1H), 1.82-1.70 (m, 2H), 1.45-1.22 (m, 
6H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.65 (s), 172.95 (s), 169.36 (s), 164.60 (s), 161.13 (s), 160.09 
(s), 154.70 (s), 153.76 (s), 132.15 (d), 130.95 (s), 129.24 (d, 2C), 126.64 (d, 2C), 108.19 (s), 
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106.10 (d), 100.45 (s), 99.84 (d), 71.11 (s), 52.41 (q), 51.08 (q), 50.07 (d), 35.92 (d), 33.91 
(t), 33.47 (t), 25.46 (t, 2C), 24.50 (t), 24.42 (t) ppm. 
LC-MS-ESI: tR = 13.45 min, m/z calcd 505.17, m/z found 506.1 [M+H]+. 
HRMS: [M+H]+, calcd  506.1814, found 506.1849. 
 
Compound 3f: Di-tert-butyl 2-(tert-butylamino)-5-hydroxy-6-oxo-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellowish powder. Yield = 55 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.69, melting point: 115 °C. 
1H NMR (CDCl3, 500 MHz): 12.66 (s, 1H), 8.66-8.59 (br s, 1H), 8.08-8.05 (dd, 2H, J=1.65, 
8.24 Hz), 7.57-7.49 (m, 3H), 6.76 (s, 1H), 6.53 (s, 1H), 4.98 (s, 1H), 1.53 (q, 9H), 1.45(q, 9H), 
1.27 (q, 9H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.72 (s), 172.02 (s), 168.59 (s), 163.91 (s), 161.21 (s), 160.72 
(s), 154.75 (s), 153.35 (s), 132.15 (d), 130.82 (s), 129.08 (d, 2C), 126.56 (d, 2C), 107.96 (s), 
105.61 (d), 101.59 (s), 99.55 (d), 80.85 (s), 79.29 (s), 52.54 (s), 37.25 (d), 30.64 (q, 3C), 28.49 
(q, 3C), 27.94 (q, 3C) ppm. 
LC-MS-ESI: tR = 23.15 min, m/z calcd 563.25, m/z found 566.3 [M+3H]+. 
HRMS: [M+H]+, calcd 564.2597, found 564.2491. 
 
Compound 4f: Di-tert-butyl 2-(cyclohexylamino)-5-hydroxy-6-oxo-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellowish powder. Yield = 27 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.69, melting point: 167 °C. 
1H NMR (CDCl3, 500 MHz): 12.64 (s, 1H), 8.56-8.36 (br s, 1H), 8.09-8.03 (dd, 2H, J=1.92, 
8.19 Hz), 7.58-7.49 (m, 3H), 6.76 (s, 1H), 6.52 (s, 1H), 4.98 (s, 1H), 3.79-3.70 (m, 1H), 2.07-
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1.99 (m, 1H), 1.95-1.89 (m, 1H), 1.79-1.70 (m, 2H), 1.64-1.58 (m, 1H), 1.53 (s, 9H), 1.40-1.34 
(m, 1H), 1.27 (s, 9H), 1.25-1.22 (m, 4H) ppm. 
13C NMR (CDCl3, 125 Hz): 183.02 (s), 172.53 (s), 168.65 (s), 164.19 (s), 160.96 (s), 160.21 
(s), 155.34 (s), 153.63 (s), 132.43 (d), 131.12 (s), 129.36 (d, 2C), 126.85 (d, 2C), 108.22 (s), 
105.91 (d), 101.86 (s), 100.02 (d), 81.18 (s), 79.50 (s), 50.49 (d), 37.56 (d), 34.37 (t), 33.94 (t), 
29.93 (t), 28.80 (q, 3C), 28.23 (q, 3C), 25.79 (t), 25.04 (t), 24.97 (t) ppm. 
LC-MS-ESI: tR = 16.77 min, m/z calcd 589.27, m/z found 590.1 [M+H]+. 
HRMS: [M+H]+, calcd 590.2753, found 590.2752. 
 
Compound 5f: Diethyl 2-(tert-butylamino)-5-hydroxy-6-oxo-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8.5: 1.5. It was obtained as a yellowish powder. Yield = 55 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.61, melting point: 177 °C. 
1H NMR (CDCl3, 500 MHz): 12.73 (s, 1H), 8.84-8.73 (br s, 1H), 8.08-8.04 (dd, 2H, J=1.67, 
7.95 Hz), 7.58-7.51 (m, 3H), 6.75 (s, 1H), 6.54 (s, 1H), 5.08 (s, 1H), 4.27-4.21 (m, 1H), 4.19-
4.12 (m, 1H), 4.10-3.98 (m, 2H), 1.46 (s, 9H), 1.32-1.28 (t, 3H, J= 7.14 Hz), 1.12-1.09 (t, 3H, 
J= 7.14 Hz) ppm. 
13C NMR (CDCl3, 125 Hz): 182.64 (s), 172.72 (s), 168.98 (s), 164.31 (s), 161.39 (s), 161.03 
(s), 154.51 (s), 153.68 (s), 132.14 (d), 130.78 (s), 129.13 (d, 2C), 126.60 (d, 2C), 108.13(s), 
105.93 (d), 100.65 (s), 99.62 (d), 72.16 (s), 61.07 (t), 59.51 (t), 52.74 (d), 35.88 (d) 30.69 (q, 
3C), 14.53 (q), 13.90 (q) ppm. 
LC-MS-ESI: tR = 19.59 min, m/z calcd 507.19, m/z found 508.1 [M+H]+. 
HRMS: [M+H]+, calcd 508.1971, found 508.1844. 
Compound 6f: Diethyl 2-(cyclohexylamino)-5-hydroxy-6-oxo-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 85: 15. It was obtained as a yellowish powder. Yield = 65 %. 
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TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.72, melting point: 39-42 °C. 
1H NMR (CDCl3, 500 MHz): 12.74 (s, 1H), 8.71-8.56 (br s, 1H), 8.09-8.04 (dd, 2H, J=1.58, 
8.05 Hz), 7.57-7.52 (m, 3H), 6.75 (s, 1H), 6.53 (s, 1H), 5.08 (s, 1H), 4.27-4.21 (m, 1H), 4.18-
4.13 (m, 1H), 4.10-3.99 (m, 2H), 3.85-3.73 (m, 1H), 2.04-1.98 (m, 1H), 1.94-1.87 (m, 1H), 
1.81-1.70 (m, 2H), 1.64-1.55 (m, 2H), 1.44-1.32 (m, 4H), 1.32-1.28 (t, 3H, J=7.14 Hz), 1.13-
1.07 (t, 3H, J=7.14 Hz) ppm. 
13C NMR (CDCl3, 125 Hz): 182.68 (s), 172.91 (s), 168.97 (s), 164.35 (s), 161.02 (s), 160.03 
(s), 154.80 (s), 153.70 (s), 132.16 (d), 130.91 (s), 129.16 (d, 2C), 126.65 (d, 2C), 108.14 (s), 
105.91 (d), 100.63 (s), 98.83 (d), 71.34 (s), 61.06 (t), 59.26 (t), 50.04 (d), 36.03 (d), 33.89 (t), 
33.51 (t), 25.48 (t), 24.50 (t), 24.49 (t), 14.57 (q), 14.10 (q) ppm. 
LC-MS-ESI: tR = 17.15 min, m/z calcd 533.2, m/z found 534.58 [M+H]+. 
HRMS: [M+H]+, calcd 534.2127, found 534.2027. 
 
Compound 7f: Dimethyl 5-hydroxy-2-(isopropylamino)-6-oxo-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellowish powder. Yield = 69 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.58, melting point: 117 °C. 
1H NMR (CDCl3, 500 MHz): 12.79 (s, 1H), 8.65-8.45 (br s, 1H), 8.09-8.03 (dd, 2H, J=1.74, 
7.24 Hz), 7.59-7.54 (m, 3H), 6.75 (s, 1H), 6.53 (s, 1H), 5.08 (s, 1H), 4.15-4.08 (m, 1H), 3.75 
(s, 3H), 3.60 (s, 3H), 1.33-1.30 (d, 3H, J=6.38 Hz), 1.26-1.26 (d, 3H, J=6.96 Hz) ppm. 
13C NMR (CDCl3, 125 Hz): 182.66 (s), 172.94 (s), 169.37 (s), 164.63 (s), 161.16 (s), 160.13 
(s), 154.67 (s), 153.78 (s), 132.17 (d), 130.96 (s), 129.25 (d, 2C), 126.65 (d, 2C),  108.23 (s), 
106.12 (d), 100.94 (s), 99.84 (d), 71.21 (s), 52.42 (q), 51.09 (q), 43.44 (d), 35.90 (d), 23.82 (q), 
23.54 (q) ppm. 
LC-MS-ESI: tR = 14.44 min, m/z calcd 465.14, m/z found 466.58 [M+H]+. 
HRMS: [M+H]+, calcd 466.1501, found 466.1405. 
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Compound 8f: Diethyl 5-hydroxy-2-(isopropylamino)-6-oxo-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 8: 2. It was obtained as a yellowish powder. Yield = 70 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf 0.56, melting point: 123 °C. 
1H NMR (CDCl3, 500 MHz): 12.73 (s, 1H), 8.60-8.44 (br s, 1H), 8.09-8.05 (dd, 2H, J=2.12, 
7.30 Hz), 7.56-7.51 (m, 3H), 6.75 (s, 1H), 6.53 (s, 1H), 5.08 (s, 1H), 4.29-4.21 (m, 1H), 4.18-
4.00 (m, 4H), 1.32-1.28 (m, 6H), 1.26-1.23 (d, 3H, J=6.45 Hz), 1.12-1.08 (t, 3H, J=6.83 Hz) 
ppm. 
13C NMR (CDCl3, 125 Hz): 182.67 (s), 172.88 (s), 168.96 (s), 164.35 (s), 161.04 (s), 160.07 
(s), 154.57 (s), 153.70 (s), 132.16 (d), 130.90 (s), 129.15 (d, 2C), 126.64 (d, 2C), 108.16 (s), 
105.97 (d), 100.58 (s), 99.81 (d), 71.43 (s), 61.10 (t), 59.47 (t), 43.39 (d), 36.00 (d), 23.78 (q), 
23.57 (q), 14.55 (q), 144.09 (q) ppm. 
LC-MS-ESI: tR = 18.56 min, m/z calcd 493.17, m/z found 494.1 [M+H]+. 
HRMS: [M+H]+, calcd 494.1814, found 494.1807. 
 
Compound 9f: Dimethyl 5-hydroxy-6-oxo-8-phenyl-2-(2,4,4-trimethylpentan-2-ylamino)-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 85: 15. It was obtained as a yellowish powder. Yield = 85 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.75, melting point: 195-197 °C. 
1H NMR (CDCl3, 500 MHz): 12.80 (s, 1H), 8.96-8.77 (br s, 1H), 8.09-7.96 (dd, 2H, J=2.58, 
6.75 Hz), 7.59-7.49 (m, 3H), 6.73 (s, 1H), 6.54 (s, 1H), 5.08 (s, 1H), 3.74 (s, 3H), 3.58 (s, 3H), 
1.86-1.74 (q, 2H, J=15.11, 16.75 Hz), 1.51 (s, 3H), 1.49 (s, 3H), 0.98 (s, 9H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.59 (s), 172.70 (s), 169.34 (s), 164.56 (s), 161.29 (s), 161.12 
(s), 154.35 (s), 153.69 (s), 132.09 (d), 130.88 (s), 129.19 (d, 2C), 126.58 (d, 2C),  108.16 (s), 
106.00 (d), 100.53 (s), 99.57 (d), 71.58 (s), 56.29 (s), 53.33 (t), 52.29 (q), 51.06 (q), 35.78 (d), 
31.64 (s), 31.46 (q), 31.73 (q), 31.30 (q) ppm. 
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LC-MS-ESI: tR = 16.72 min, m/z calcd 535.22, m/z found 536.66 [M+H]+. 
HRMS: [M+H]+, calcd 536.2284, found 480.2370 [M-C(CH3)3+H]+. 
 
Compound 10f: Diethyl 5-hydroxy-6-oxo-8-phenyl-2-(2,4,4-trimethylpentan-2-ylamino)-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 90: 10. It was obtained as a yellowish powder. Yield = 82 %.  
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.75, melting point: 172-177 °C. 
1H NMR (CDCl3, 500 MHz): 12.77 (s, 1H), 8.91-8.75 (br s, 1H), 8.09-8.00 (dd, 2H, J=2.61, 
7.82 Hz), 7.56-7.51 (m, 3H), 6.74 (s, 1H), 6.54 (s, 1H), 5.09 (s, 1H), 4.27-4.20 (m, 1H), 4.19-
4.12 (m, 1H), 4.06-4.00 (m, 2H), 1.85-1.75 (q, 2H, J=14.99, 16.75 Hz), 1.52 (s, 3H), 1.47 (s, 
3H), 1.32-1.27 (t, 3H, J=7.17 Hz), 1.12-1.07 (t, 3H, J=7.17 Hz), 0.98 (s, 9H) ppm. 
13C NMR (CDCl3, 125 Hz): 182.63 (s), 172.55 (s), 169.00 (s), 164.34 (s), 161.17 (s), 161.02 
(s), 154.43 (s), 153.67 (s), 132.11 (d), 130.84 (s), 129.11 (d, 2C), 126.61 (d, 2C),  108.12 (s), 
105.87 (d), 100.67 (s), 99.54 (d), 71.86 (s), 60.99 (t), 59.43 (t), 56.23 (s), 53.34 (t), 35.96 (d), 
31.64 (q), 31.48 (s), 31.41 (q, 3C), 31.30 (q), 14.49 (q), 14,04 (q) ppm. 
LC-MS-ESI: tR = 16.73 min, m/z calcd 563.26, m/z found 564.18 [M+H]+. 
HRMS: [M+H]+, calcd 564.2597, found 564.2658. 
 
Compound 11f: Di-tert-butyl 5-hydroxy-6-oxo-8-phenyl-2-(2,4,4-trimethylpentan-2-
ylamino)-4,6-dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 90: 10. It was obtained as a yellowish powder. Yield = 65 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf 0.71, melting point: 82 °C. 
1H NMR (CDCl3, 500 MHz): 12.68 (s, 1H), 8.77-8.61 (br s, 1H), 8.09-8.05 (dd, 2H, J=1.64, 
8.06 Hz), 7.55-7.48 (m, 3H), 6.75 (s, 1H), 6.53 (s, 1H), 4.98 (s, 1H), 1.85-1.73 (q, 2H, J=15.12, 
16.75 Hz), 1.52 (s, 9H), 1.50 (s, 3H), 1.47 (s, 3H), 1.27 (s, 9H), 0.97 (s, 9H) ppm. 
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13C NMR (CDCl3, 125 Hz): 182.84 (s), 171.99 (s), 168.67 (s), 164.06 (s), 161.14 (s), 160.47 
(s), 154.74 (s), 153.53 (s), 132.15 (d), 130.94 (s), 129.08 (d, 2C), 126.57 (d, 2C),  108.02 (s), 
105.75 (d), 101.87 (s), 99.60 (d), 80.81 (s), 79.28 (s), 73.53 (s), 56.20 (s), 53.94 (t), 37.49 (d), 
31.76 (s), 31.68 (q), 31.49 (q, 3C), 31.23 (q), 28.49 (q, 3C), 27.96 (q, 3C) ppm. 
LC-MS-ESI: tR = 19.68 min, m/z calcd 619.31, m/z found 620.73 [M+H]+. 
HRMS: [M+H]+, calcd 620.3223, found 620.3194. 
 
Compound 12f: Dimethyl 5-hydroxy-6-oxo-2-(pentylamino)-8-phenyl-4,6-
dihydropyrano[3,2-g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 90: 10. It was obtained as a yellowish powder. Yield = 25 %. 
TLC (petrol ether: ethyl acetate = 7:3), Rf = 0.63, melting point: 167 °C. 
1H NMR (CDCl3, 500 MHz): 12.78 (s, 1H), 8.77-8.5 (br s, 1H), 8.11-8.98 (m, 2H), 7.59-7.53 
(m, 3H), 6.74 (s, 1H), 6.52 (s, 1H), 5.08 (s, 1H), 3.75 (s, 3H), 3.59 (s, 3H), 3.49-3.26 (m, 2H), 
1.66-1.54 (m, 2H), 1.45-1.33 (m, 4H), 0.93-0.87 (t, 3H J= 7.19 Hz) ppm. 
13C NMR (CDCl3, 125 Hz): 182.66 (s), 172.95 (s), 169.38 (s), 164.63 (s), 161.13 (s), 160.64 
(s), 154.61 (s), 153.78 (s), 132.16 (d), 130.94 (s), 129.24 (d, 2C), 126.65 (d, 2C), 108.22 (s), 
106.10 (d), 100.39 (s), 99.88 (d), 71.08 (s), 52.41 (q), 51.10 (q), 41.05 (t), 35.37 (d), 29.95 (t), 
28.93 (t), 22.29 (t), 13.92 (q) ppm. 
LC-MS-ESI: tR = 15.83 min, m/z calcd 493.17, m/z found 494.53 [M+H]+. 
HRMS: [M+H]+, calcd 494.1814, found 494.1788. 
 
Compound 13f: Diethyl 5-hydroxy-6-oxo-2-(pentylamino)-8-phenyl-4,6-dihydropyrano[3,2-
g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 85: 15. It was obtained as a yellowish powder. Yield = 33 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.61, melting point: 138 °C. 
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1H NMR (CDCl3, 500 MHz): 12.74 (s, 1H), 8.77-8.45 (br s, 1H), 8.10-8.05 (dd, 2H, J=1.69, 
7.95 Hz), 7.58-7.50 (m, 3H), 6.76 (s, 1H), 6.52 (s, 1H), 5.08 (s, 1H), 4.28-4.20 (m, 1H), 4.18-
4.12 (m, 1H), 4.10-3.98 (m, 2H), 3.48-3.37 (m, 2H), 1.66-1.58 (m, 2H), 1.40-1.33 (m, 4H), 
1.32-1.28 (t, 3H, J= 7.44 Hz), 1.12-1.07 (t, 3H, J= 7.14 Hz), 0.92-0.87 (t, 3H, J= 7.14 Hz) 
ppm. 
13C NMR (CDCl3, 125 Hz): 182.69 (s), 172.91 (s), 169.01 (s), 164.38 (s), 161.03 (s), 160.59 
(s), 154.71 (s), 153.73 (s), 132.18 (d), 130.91 (s), 129.16 (d, 2C), 126.67 (d, 2C), 108.18(s), 
105.98 (d), 100.57 (s), 99.87 (d), 71.29 (s), 61.10 (t), 59.49 (t), 41.04 (t), 36.07 (d), 29.98 (t), 
28.94 (t), 22.30 (t), 14.56 (q), 14.10 (q), 13.93 (q) ppm. 
LC-MS-ESI: tR = 19.59 min, m/z calcd 521.2, m/z found 522.63 [M+H]+. 
HRMS: [M+H]+, calcd 522.2127, found 522.2098. 
 
Compound 14f: Dimethyl 2-(butylamino)-5-hydroxy-6-oxo-8-phenyl-4,6-dihydropyrano[3,2-
g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 90: 10. It was obtained as a yellowish powder. Yield = 55 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf = 0.65, melting point: 77 °C. 
1H NMR (CDCl3, 500 MHz): 12.78 (s, 1H), 8.78-8.57 (br s, 1H), 8.11-8.03 (m, 2H), 7.61-7.53 
(m, 3H), 6.75 (s, 1H), 6.53 (s, 1H), 5.08 (s, 1H), 3.75 (s, 3H), 3.60 (s, 3H), 3.51-3.36 (m, 2H), 
1.63-1.58 (m, 2H), 1.45-1.38(m, 2H), 0.98-0.91 (t, 3H J= 7.34) ppm. 
13C NMR (CDCl3, 125 Hz): 182.66 (s), 172.96 (s), 169.39 (s), 164.63 (s), 161.14 (s), 160.66 
(s), 154.61 (s), 153.79 (s), 132.16 (d), 130.94 (s), 129.25 (d, 2C), 126.65 (d, 2C), 108.23 (s), 
106.11 (d),100.40 (s), 99.88 (d), 71.09 (s), 52.41 (q), 51.10 (q), 40.74 (t), 35.96 (d), 32.32 (t), 
29.67 (t), 13.71 (q) ppm. 
LC-MS-ESI, tR = 15.22 min, m/z calcd 479.16, m/z found 480.57 [M+H]+ 
 HRMS: [M+H]+, calcd 480.1658, found 480.1653. 
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Compound 15f: Diethyl 2-(butylamino)-5-hydroxy-6-oxo-8-phenyl-4,6-dihydropyrano[3,2-
g]chromene-3,4-dicarboxylate 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 85: 15. It was obtained as a yellowish powder. Yield = 33 %. 
TLC (petrol ether: ethyl acetate = 7: 3), Rf  = 0.68, melting point: 147 °C. 
1H NMR (CDCl3, 500 MHz): 12.78 (s, 1H), 8.76-8.50 (br s, 1H), 8.09-8.05 (dd, 2H, J=1.99, 
7.51 Hz), 7.58-7.53 (m, 3H), 6.76 (s, 1H), 6.53 (s, 1H), 5.08 (s, 1H), 4.27-4.21 (m, 1H), 4.19-
4.13 (m, 1H), 4.09-3.98 (m, 2H), 3.49-3.37 (m, 2H), 1.64-1.57 (m, 2H), 1.47-1.39 (m, 2H), 
1.32-1.28 (t, 3H, J= 7.07 Hz), 1.12-1.08 (t, 3H, J= 7.29 Hz), 0.96-0.92 (t, 3H, J= 7.29 Hz) 
ppm. 
13C NMR (CDCl3, 125.79Hz): 182.95 (s), 173.17 (s), 169.27 (s), 164.64 (s), 161.29 (s), 160.87 
(s), 154.97 (s), 153.98 (s), 132.43 (d), 131.17 (s), 129.42 (d, 2C), 126.93 (d, 2C), 108.44(s),  
106.24 (d), 100.83 (s), 100.13 (d), 71.55 (s), 61.37 (t), 59.75 (t), 40.97 (t), 36.32 (d), 32.62 (t), 
20.22 (t), 14.81 (q), 14.35 (q), 13.97 (q) ppm. 
LC-MS-ESI, tR = 17.78 min, m/z calcd 507.19, m/z found 508.63 [M+H]+. 
HRMS: [M+H]+, calcd 508.1971, found 508.1953. 
 
3.4. Synthesis of 5-hydroxy-2-phenyl-7-(3-(phenylselanyl)propoxy)-4H-chromen-4-
one and 5-hydroxy-2-phenyl-7-(3-(phenyltellanyl)propoxy)-4H-chromen-4-one 
 
O
OOH
OSe
Compound 1c
O
OOH
OTe
Compound 2c
 
Fig 29: Chemical structure of compounds 1c and 2c. 
 
Chapter III  Results 
93 
 
Compound 1c: 5-Hydroxy-2-phenyl-7-(3-(phenylselanyl)propoxy)-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 9: 1. It was obtained as a yellow powder. Yield = 57 %. 
TLC (petrol ether: ethyl acetate = 8: 2): Rf = 0.45, melting point: 71 °C. 
1H NMR (CDCl3, 500 MHz): 13.71 (s, 1H), 7.90-7.81 (dd, 2H, J= 1.26, 8.42 Hz), 7.56-7.49 
(m, 5H), 7.29-7.19 (m, 3H), 6.64 (s, 1H), 6.45-6.42 (d, 1H, J= 2.20 Hz), 6.33-9.29 (d, 1H, J= 
2.01 Hz), 4.14-4.08 (t, 2H, J= 5.80 Hz), 3.10-3.05 (t, 2H, J= 6.95 Hz), 2.23-2.15 (m, 2H), 
ppm. 
13C NMR (CDCl3, 125 Hz): 182.49 (s), 164.77 (s), 163.88 (s), 162.05 (s), 157.66 (s), 132.68 
(d), 131.74 (d), 131.27 (s), 129.08 (d, 2C), 129.01 (d, 2C), 126.97 (d, 2C), 126.19 (s), 105.80 
(d), 105.67 (s),  98.60 (d), 92.99 (d), 67.41 (t), 29.42 (t), 23.89 (t) ppm. 
HRMS: [M]+, calcd 452.0526, found 452.0528. 
 
Compound 2c: 5-Hydroxy-2-phenyl-7-(3-(phenyltellanyl)propoxy)-4H-chromen-4-one 
The compound was purified by column chromatography on silica gel with petrol ether: ethyl 
acetate = 9: 1. It was obtained as a yellow powder. Yield = 68 %. 
TLC (petrol ether: ethyl acetate = 8: 2): Rf = 0.45, melting point: 112 °C. 
1H NMR (CDCl3, 500 MHz): 12.67 (s, 1H), 7.90-7.81 (dd, 2H, J= 1.55, 7.49 Hz), 7.75-7.79 
(dd, 2H, J= 1.83, 1.57 Hz), 7.56-7.47 (m, 3H), 7.26-7.13 (m, 3H), 6.64 (s, 1H), 6.43-6.41 (d, 
1H, J= 2.05 Hz), 6.31-9.28 (d, 1H, J= 2.25 Hz), 4.09-4.03 (t, 2H, J= 6.09 Hz), 3.06-3.00 (t, 
2H, J= 7.05 Hz), 2.32-2.23 (m, 2H), ppm. 
13C NMR (CDCl3, 125 Hz): 182.38 (s), 164.77 (s), 163.64 (s), 162.10 (s), 157.76 (s), 138.45 
(d, 2C), 131.82 (d), 131.35 (s), 129.23 (d, 2C), 129.08 (d, 2C), 127.79 (d), 126.28 (d, 2C), 
111.04 (s), 106.00 (d), 98.90 (s), 93.00 (d), 69.40 (t), 30.91 (t), 4.01 (t) ppm. 
HRMS: [M-C6H5Te]+, calcd 295.0970, found 295.0929. 
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3.5. Cell culture 
 
The HL-60 cell line as a model to measure the antioxidant/cytotoxic activities of 
compounds in cell culture 
Human promyelocytic leukemia HL-60 cells were used in this study as a model to 
investigate the antioxidant and cytotoxic activities of natural and synthetic flavonoids in cell 
culture. The compounds were tested at six different concentrations, i.e. at 10, 40, 80, 120, 160 
and 200 µM. The cytotoxic activity was estimated by incubation of the HL-60 cells (at a 
concentration of 9 x 105 cells per mL), with the various compounds – all at different 
concentrations for 24 hours. The antioxidant power of compounds was evaluated by measuring 
the capacity of compounds to protect HL-60 cells from oxidative stress induced by exogenous 
hydrogen peroxide (H2O2). The cell suspensions (9 x 105 cells/1 mL) were treated with the 
various compounds (at different concentrations) in the presence of 5 mM of H2O2 (final 
concentration). After 24 hrs of incubation, the viability of the cells was measured by the MTT 
assay. 
The MTT cell viability assay was first described by Mosmann et al. [181]. The MTT 
assay is a colourimetric assay that measures the reduction of yellow 3-(4,5-dimethythiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate dehydrogenase. 
MTT enters the cells and passes into the mitochondria where it is reduced to an insoluble, 
coloured (dark purple) formazan product (Fig 30). The cells are then treated with an organic 
solvent (DMSO) and the released, solubilised formazan reagent is quantified photometrically 
at 550 nm. Since the reduction of MTT can only occur in metabolically active cells, the 
extend of MTT reduction is a measure of the viability of the cells [182]. 
 
 
Fig 30: The basic chemistry associated with the MTT assay: reduction of a yellow tetrazolium salt to a blue 
formazan by succinate dehydrogenase in metabolically active cells. 
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Results displayed in Table 17 and 18 summarize the cytotoxic and antioxidant activities 
of the natural and synthetic compounds when used at 200 µM concentration. The DPPH 
scavenging activity and aromatase inhibition activity are also listed. 
Quercetin and chrysin, which are the chemical precursors of the synthetic flavonoids 
were used as controls for cytotoxic and antioxidant activity as well as aromatase inhibitor 
activity. Furthermore, taxifolin, epicatechin, α-tocopherol (vitamin E), and trolox® (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid) were used as controls in the cytotoxic and 
antioxidant assay. 
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Table 17: A summary of biological activities associated with the isolated natural products. Please note that the 
viability in the two cell culture assays is set at 100 % for either the untreated cell control or the oxidatively 
stressed untreated cell control. The experimental details and discussion of these results are provided in the text. 
Compound 
Viability1 of cells after 
treatment with 200 µM of 
compounds 
Viability2 of cells after treatment with 
200 µM of compounds + 5 mM of 
H2O2 
DPPH 
scavenging 
activity 
IC50 in µM 
Aromatase 
inhibition activity
IC50 in µM 
1d 140.93 ± 7.56 240.56 ± 7.56 41.61 ± 2.27 m 
2d 127.14 ± 1.65 255.98 ± 2.82 51.66 ± 3.35 194.21 ± 9.55
3d 85.57 ± 6.75 122.60 ± 8.65 173.21 ± 3.79 m 
4d 103.50 ± 2.59 175.22 ± 6.43 88.72 ± 5.53 m 
5d 78.45 ± 2.28 210.74 ± 8.48 102.62 ± 2.85 20.90 ± 7.32 
1r 70.95 ± 4.99 137.31 ± 5.01 109.17 ± 8.16 19.99 ± 5.42 
2r 32.20 ± 0.31 63.43 ± 2.96 m m 
3r 27.93 ± 0.72 91.73 ± 3.19 m 35.24 ± 2.50 
4r 25.53 ± 0.30 77.15 ± 5.26 m 21.52 ± 1.77 
5r 26.63 ± 4.95 97.23 ± 7.29 m m 
quercetin 153.48 ± 1.15 267.03 ± 17.22 35.00 ± 1.71 105.25 ± 4.38
chrysin 25.15 ± 1.30 79.47 ± 5.42 m 11.50 ± 0.05 
taxifolin 80.19 ± 3.04 116.92 ± 3.86 86.07 ± 0.98 m 
epicatechin 114.21 ± 6.03 171.66 ± 6.82 91.15 ± 7.90 m 
vit E 133.25 ± 8.75 212.08 ± 4.54 85.36 ± 0.88 n.d. 
trolox® 111.44 ± 2.28 185.52 ± 1.77 135.12 ± 3.41 n.d. 
aminoglutethemid n.d. n.d. n.d. 36.47 ± 0.26 
1 viability of untreated cells is set as 100 %. 
2 viability of untreated cells (in the presence of 5 mM H2O2) is set as 100 %. 
m = IC50 larger than 300 µM 
n.d. = not determined  
The data is presented as a mean of at least two independent measurements ± standard deviation. 
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Table 18: A summary of biological activities associated with the synthetic compounds. Please note that the all 
viability in the two cell culture assays is set at 100 % for either the untreated cell control or the oxidatively 
stressed untreated cell control.  The experimental details and discussion of these results are provided in the text. 
Compound 
Viability1 of cells after 
treatment with 200 µM of 
compounds 
Viability2 of cells after 
treatment with 200 µM of 
compounds + 5 mM of H2O2
DPPH scavenging 
activity 
IC50 in µM 
Aromatase inhibition 
activity 
IC50 in µM 
1m 65.19 ± 7.51 85.64 ± 7.21 m 87.53 ± 7.48 
2m 39.42 ± 1.09 87.21 ± 5.76 m m 
3m 63.12 ± 0.19 101.45 ± 0.42 m 5.90 ± 1.86 
4m 87.81 ± 5.05 123.25 ± 6.19 m m 
5m 25.84 ± 1.06 90.44 ± 7.77 m 69.69 ± 9.85 
6m 86.20 ± 5.12 111.57 ± 6.01 m 178.37 ± 9.55 
7m 32.84 ± 2.62 97.30 ± 6.55 m m 
10m 57.06 ± 2.21 195.40 ± 8.72 49.42 ± 2.88 261.35 ± 3.25 
11m 54.15 ± 2.87 200.63 ± 7.51 110.01 ± 3.71 11.24 ± 1.34 
12m 35.52 ± 1.30 96.50 ± 7.34 n.d. m 
13m 22.18 ± 6.41 99.82 ± 3.27 n.d. 28.25 ± 1.99 
14m 31.99 ± 0.10 197.91 ± 4.10 58.56 ± 6.65 m 
15m 33,90±1,51 104.42 ± 5.65 m 204.86 ± 3.57 
16m 26.92 ± 1.27 112.88 ± 6.64 m 15.63 ± 3.92 
17m 88.68 ± 1.10 98.92 ± 2.70 m m 
18m 82.22 ± 3.16 108.04 ± 0.05 m m 
19m 82.00 ± 7.15 101.11 ± 4.22 m m 
20m 86.75 ± 1.95 109.69 ± 7.60 m m 
21m 88.49 ± 3.48 103.73 ± 7.38 m 193.22 ± 11.16 
1f 93.90 ± 8.88 80.30 ± 5.18 m m 
2f 28.70 ± 1.99 79.83 ± 3.24 m m 
3f 69.80 ± 4.98 n.d. n.d. m 
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Compound 
Viability1 of cells after 
treatment with 200 µM of 
compounds 
Viability2 of cells after 
treatment with 200 µM of 
compounds + 5 mM of H2O2
DPPH scavenging 
activity 
IC50 in µM 
Aromatase inhibition 
activity 
IC50 in µM 
4f 60.19 ± 3.32 n.d. n.d. m 
5f 85.07 ± 1.00 n.d. n.d. m 
6f 48.31 ± 1.68 n.d. n.d. 166.61 ± 11.33 
7f 11.88 ± 1.09 49.00 ± 2.33 m 187.44 ± 4.48 
8f 72.56 ± 1.76 85.83 ± 4.67 m 79.41 ± 4.47 
9f n.d n.d. n.d. m 
10f 64.38 ± 4.74 95.62 ± 5.04 m m 
11f 26.15 ± 2.26 n.d. n.d. m 
12f 20.69 ± 1.48 103.58 ± 7.42 m m 
13f 34.50 ± 1.64 88.62 ± 3.57 m m 
14f 22.46 ± 2.60 n.d. m 26.35 ± 1.01 
15f n.d n.d. m 36.49 ± 2.44 
1c 95.71 ± 1.23 101.61 ± 4.88 m m 
2c 88.51 ± 1.99 95.62 ± 8.92 m m 
1 viability of untreated cells is set as 100 %. 
2 viability of untreated cells (in the presence of 5 mM H2O2) is set as 100 %. 
m = IC50 larger than 300 µM 
n.d. = not determined  
The data is presented as a mean of at least two independent measurements ± standard deviation. 
 
3.6. Nematode assay 
 
Several compounds were selected (these compounds were chosen based on a distinct 
cytotoxicity profile in the cell culture assays) to investigate their nematocidal activities. The 
nematode assay was devised in order to measure the toxicity of the compounds on the intact 
complete organisms. Steinernema feltiae was used as a model for a living organism. This 
nematode belongs to the beneficial nematodes that seek out and kill the immature stages of 
harmful soil-dwelling insects before they become adults. 
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Three natural products with highly cytotoxic activity against HL-60 cell line 3r, 4r and 
5r were selected for this test, together with six synthetic flavonoids namely 2f, 7f, 11f, 12f, 
13f and 14f. 
All compounds were tested at four different concentrations, i.e. at 50, 100, 200, 400 
µM, with readings taken after 24 and 48 hrs of exposure. The results in Table 19 indicate that 
virtually none of these compounds were toxic against Steinernema feltiae at the concentration 
used. 
Table 19: Nematode viability after 24 and 48 hours of exposure to 200 and 400µM of tested compounds.  
24 hrs of exposure 
(untreated control = 100%) 
48 hrs exposure 
(untreated control = 100%) Compound 
200 µM 400µM 200 µM 400µM 
3r 99.10 ± 3.2 98.34 ± 3.3 98.17 ± 4.4 98.19 ± 3.1 
4r 96.09 ± 3.0 96.64 ± 1.6 94.37 ± 4.8 95.9 ± 0.8 
5r 95.99 ± 2.1 94.74 ± 2.5 87.15 ± 3.7 82.89 ± 4.2 
2f 99.17 ± 1.4 94.59 ± 1.3 99.58 ± 0.7 98.00 ± 1.1 
7f 100.00 ± 0.0 84.62 ± 3.1 93.22 ± 4.5 85.70 ± 3.8 
11f 94.08 ± 2.1 95.90 ± 1.6 86.72 ± 2.2 91.37 ± 3.3 
12f 99.65 ± 0.6 99.31 ± 1.2 98.62 ± 1.2 98.20 ± 3.0 
13f 98.00 ± 6.2 98.04 ± 1.4 97.81 ± 1.2 96.19 ± 3.1 
14f 94.32 ± 3.2 92.46 ± 1.7 90.56 ± 1.5 87.07 ± 2.5 
The data is presented as a mean of at least two independent measurement ± standard deviation. 
 
3.7. Aromatase assay 
 
One of the main approaches in controlling postmenopausal hormone-dependent breast 
cancer involves the reduction of plasma and tissue levels of estrogen via the inhibition of 
aromatase (a key enzyme of their biosynthetic process) [183]. Aromatase is a multi enzymatic 
complex formed by cytochrome P450 XIX (CYP19) and NADPH-cytochrome P450 
reductase. It catalyzes the conversion of androgens to estrogens through the aromatization of 
the A-ring of androgen substrates (see Introduction) (Fig 12). The enzyme has been 
considered as a particularly attractive target for the treatment of hormone-dependent breast 
cancer [183]. 
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Aminoglutethimide is an anti-steroid drug marketed worldwide under the tradename 
Cytadren® by Novartis. It blocks the production of steroids derived from cholesterol and is 
clinically used in the treatment of Cushing's syndrome and metastatic breast cancer. It is also a 
drug abused by body builders. This compound was used as benchmark and control. 
Natural and synthetic flavonoids showed a wide range of inhibition against the 
aromatase enzyme, and therefore may help us understand the structural activity features 
necessary to produce effective aromatase inhibitors. Tables 17 and 18 summarize the results 
of the aromatase assay.  
 
3.8. 2,2-dipheny-1-picryl hydrazyl (DPPH) radical scavenging activity 
 
Scavenging of the stable 2,2-dipheny-1-picryl hydrazyl (DPPH) radical by suspected 
antioxidants is a widely used method to estimate and compare antioxidant activities in a 
relatively short period of time compared to other more extensive methods. The ability of 
antioxidants to scavenge DPPH radical is thought to be related to their hydrogen donating 
abilities [184]. 
DPPH can generate stable free radicals in ethanolic solution. It has a dark purple colour 
in methanol absorbing light at 517 nm. When a suspected antioxidant is added to this DPPH 
solution, the purple colour may decolourize. Since decrease in absorbance at 517 nm is 
directly proportional to the antioxidant potency of the compounds, absorbance can be 
measured by following the colour of the sample at this wave length [185]. 
The scavenging ability of flavonoid compounds was measured at five different 
concentrations, i.e. at 10, 50, 100, 200, 400 µM. Based on the concentration of the compounds 
needed to reduce the absorbance at 530 nm, an IC50 value was estimated and summarised in 
Table 17 and 18 for the natural isolated and synthetic compounds. 
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3.9. Electrochemical results  
 
Cyclic voltametry (CV) and differancial pulse polarography (DPP) of chromene-flavone 
compounds and reference compounds were investigated on the glassy carbon working 
electrode. These compounds exhibited various oxidation and reduction potentials which are 
summarized in Table 20.  
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Table 20: Oxidation and reduction potentials of chromene-flavones were measured by CV and DPP on a glassy 
carbon electrode. Please note that only clear, visible and reproducible peak signals are listed and not all 
compounds exhibited all types of Epa1, Epa2, Epa and Epc. Although CV produces oxidation and reduction 
signals, the distance ∆E implies that these do not form a reversible or even quasi-reversible redox couple, 
therefore the redox potential E1/2 cannot be calculated. The experimental details and the discussion of the results 
are provided in the text. 
Oxididation potential [mV] 
measured by DPP 
Oxidation potential [mV] 
measured by CV Compound 
Epa1 Epa2 Epa Epc 
+340 -320 phenol +40 +520 
+800  
catechol +250 - +300 -45 
resorcinol +20 +600 +740 -260 
epicatechin +120 - +240 -45 
taxifolin +135 - +350 -35 
+200 chrysin +130 +800 
+1050 
- 
+150 quercetin +160 +990 
+970 
- 
+25 -525 cyanidin -27 +200 
+290 +170 
1f - - - - 
2f - - - - 
+245 3f -160 +830 
+1010 
- 
4f -140 +850 - - 
5f -120 +880 - - 
6f - - - - 
7f - - - - 
8f -220 +877 - - 
9f -130 +810 +900 - 
10f -120 +790 - - 
11f -140 +1230 - - 
12f -130 +920 +930 - 
13f -160 +1320 - - 
14f -210 +840 - - 
15f -160 +850 - - 
These potentials were measured either by DPP (left column) or Cyclic Voltammetry (right column). 
Epa1: first (i.e. lower) oxidation potential. 
Epa2: second (i.e. higher) oxidation potential. 
Epa: oxidation potential. 
Epc: reduction potential.
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Chapter IV: Discussion 
4.1. Structure elucidation of new natural products 
 
Two new natural compounds, i.e. 4r and 5r, were isolated from the roots of Robinia 
pseudoacacia (Black locust). Structure elucidation of the new as well as known compounds 
was confirmed by complete NMR analysis (1D and 2D) and mass spectroscopy, and also 
through comparison with published spectra of related compounds. 
 
4.1.1. Compound 4r 
 
Compound 4r was isolated from the ethyl acetate extract of Robinia pseudoacacia roots 
and was purified by column chromatography using dichloromethane: methanol (95: 5). It was 
obtained as a yellow amorphous powder with a melting point of 102 °C. 
The 1H NMR spectrum of compounds 2r, 3r and 4r revealed an AB-system (JAB around 
15.50 Hz) centred at δH 8.04-8.07 (H-α) and δH 7.84-7.98 (H-β) (Fig 31) indicating the (E)-
geometry of a trans double bond and suggesting the chalcone nature of the compounds [173, 
186]. The 1H and 13C NMR spectra of 4r in addition to DEPT spectra (Fig 31 and 32), which 
had close similarities to that of compound 2r, indicated the chalcone pattern of compound 4r 
with a hydroxyl group at position 2´ of the B-ring (Table 12 and 13). The hydrogen bonded 
phenolic hydroxyl group appeared as a singlet at δH 12.39 ppm in 1H NMR. It is strongly 
chelated by a vicinal carbonyl group, indicative of an OH group at C-2´. 
There were three aromatic proton signals for the A-ring appearing as a multiblet at δH 
7.00 ppm and integrated for two protons (H-4 and H-6), and at δH 7.12 ppm, integrated for 
one proton (H-5) with a doublet of a doublet and a coupling constant J=2.68, 6.65 Hz (Table 
12 and Fig 31). Signals for two methoxy groups appeared at δH 3.84 and δH 3.81, integrated 
for six protons were also observed in the 1H NMR of compound 4r. Their presence was also 
confirmed by 13C NMR signals at δC 61.00 (C-2) and δC 56.00 (C-3) (Table 12 and 13 and 
Fig 31 and 32). Placement of the methoxy groups at positions C-2 and C-3 of compound 4r is 
suggested by the C-2 and C-3 resonances. There are significant downfield shifts δC + 25.27 
for C-3 and upfield shifts δC -6.43 for C-1 and δC -15.57 for C-4 compared to compound 2r.  
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Fig 31: 1H NMR spectrum of compound 4r, with partial spectrum enlargement to enable the visualization 
of peak multiplicity. 
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Fig 32: 13C and DEPT NMR spectra of compound 4r. 
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Fig 33: DEPT spectra of compounds 2r, 3r and 4r. 
 
A combined analysis of 13C and DEPT NMR spectra indicates the presence of two 
primary carbons (δC 55.82 and δC 61.02 ppm), nine tertiary and six quaternary carbon atoms 
in compound 4r. There are nine tertiary and six quaternary carbon atoms in 3r, compared to 
eleven tertiary and four quaternary carbon atoms in 2r (Fig 33). This provides evidence that 
compound 4r is a chalcone with three substituents, two of them methoxy groups. 
Two dimensional NMR in conjunction with HMBC showed a strong coupling 
correlation between the methoxy proton at δH 3.84 ppm and δC 153.77 ppm (C-3), and at δH 
3.81 ppm with δC 148.51ppm (C-2) (Fig 34). 
Through interpretation of this spectral data and with additional comparison to data 
previously published [173, 174-176], the structure of compound 4r was determined to be 2´-
hydroxy-2,3-dimethoxy chalcone, and to our knowledge is a previously unknown natural 
product.  
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Fig 34: 2-D HMBC-NMR spectrum of compound 4r. 
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4.1.2. Compound 5r 
 
Compound 5r was isolated from the ethyl acetate extract of Robinia pseudoacacia roots. 
It was purified by column chromatography using petroleum benzene: ethyl acetate (80: 20). It 
gave an orange precipitate with Dragendorff’s reagent (potassium bismuth iodide, special 
precipitating reagent for alkaloids) within 24 hours. Compound 5r was obtained as a white 
amorphous powder with a melting point of 174°C. 
Compound 5r showed a molecular ion peak at 269.1[M]+ compatible with the molecular 
formula of C16H15NO3. The 1H NMR spectra of compound 5r (Fig 35) measured at 500 MHz 
exhibited the characteristic pattern of a medicarpin schaffold [177, 178]. The AB-X system of 
the two benzene rings was clearly visible due to the presence of one proton doublet at δH 7.36 
ppm, with a J = 8.50 Hz (H-5), one proton doublet of a doublet at δH 6.43 ppm,with a J = 
2.50, 8.50 Hz (H-6), one proton doublet at δH 6.38 ppm, with a J = 2.50 Hz (H-8), one proton 
doublet at δH 7.11 ppm, with a J = 8.45 Hz (H-2´), one proton doublet of a doublet at δH 6.53 
ppm, with a J = 2.20, 8.45 Hz (H-3´), one proton doublet at δH 6.43 ppm, with a J = 2.20 Hz 
(H-5´), which indicates the presence of a hydroxyl group at position C-7 and a methoxy group 
at the C-4´ position. 
The only difference between the 5r and medicarpin is the presence of one broad singlet 
proton at δH 4.99 ppm. In the two dimensional H-H COSY and H-C HMQC NMR spectra 
(Fig 38) there is no correlation between this proton and other protons or carbons within the 
compound. The chemical shift of this proton at δH 4.99 ppm and publication comparison 
suggest that this proton is attached to a nitrogen group [179, 180]. The NH proton (δH 4.99) 
correlation is clearly visible in the H-C HMBC NMR spectra (Fig 37) with C-5´, C-6´ and C-
10. This spectrum provides evidence that the NH group is attached to C-6´. 
The 13C NMR spectra of compound 5r in comparison with DEPT spectra (Fig 36) 
confirm the presence of one primary, one secondary, eight tertiary and six quaternary carbon 
atoms, and reveal a distinct pattern similarity to medicarpin except for small shifts for carbons 
C-2, C-3 and C-4. 
The spectral data of NMR, together with spectral calculation, publication comparison, 
and reaction of 5r with Dragendorff’s reagent, assigen the 5r chemical structure shown in Fig 
35 and identified compound 5r as a new natural product isolated for the first time from 
Robinia pseudoacacia. 
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Fig 35: 1H NMR spectrum of compound 5r with partial spectrum enlargement to enable the visualization of 
peak multiplicity. 
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            Fig 36: 13C NMR and DEPT NMR spectra of compound 5r. 
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Fig 37: 2-D HMBC-NMR spectrum of compound 5r. 
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Fig 38: 2-D COSY & HMQC-NMR spectra of compound 5r. 
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4.2. Mannich reaction 
 
Because the coupling of three components (chrysin or quercetin, aldehyde, and amine) 
can be achieved in a one-pot reaction, a Mannich-type aminoalkylation has been an attractive 
method for introducing a side chain to various phenols [187]. 
Chrysin and quercetin are two phenolic compounds (Fig 5) and representative flavones 
present in many plants and fruits. They are associated with important roles in the plants and 
also exhibit highly interesting biological activities in animals and humans. The benefits they 
provide such as a distinct antioxidant activity have been discussed in thousands of 
publications and in many books. 
Although there are structural similarities between chrysin and quercetin, there are also 
significant differences in biological activities. Three additional hydroxyl groups in quercetin 
make it a strong antioxidant and provide nutritive properties even towards cancerous cells (the 
viability of the HL-60 leukaemia cells was 153% after treatment with 200 µM of quercetin 
(Table 17)). Chrysin, on the other hand has been reported as a powerful aromatase inhibitor 
[65], and also has notable anticancer activity (HL-60 cells viability was just 25% (Table 17)). 
It is therefore possible that the addition of an amino alkyl moiety via a Mannich type reaction 
may enhance or decrease one of the previously mentioned biological activities. 
Structural analysis indicates that the A-ring of chrysin and quercetin, especially at 
positions C-6 and C-8, may be more reactive towards electrophiles than the C-ring (Fig 39). 
Therefore, a Mannich reaction operating under relatively mild conditions may provide a 
potential site-selective derivation procedure to achieve chrysin and quercetin aminoalkylation. 
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Fig 39: Possible sites for modification via a Mannich type reaction. 
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As part of such a Mannich reaction, carbons C-3 of chrysin and C-2´, 5´ and 6´ in 
quercetin could also potentially react (Fig 39). Previous studies on electrophilic reactions of 
chrysin, quercetin and other similar flavonoids (such as naringenin), under a variety of 
conditions, indicate that mixtures often result through substitution at different positions [188, 
189]. In order to acquire single pure Mannich adducts, one frequently adopted approach is to 
protect one or more phenolic hydroxyl groups prior to the Mannich reaction. Such an indirect 
approach, however, usually requires extensive and time consuming protection and de-
protection steps. Consequently, it would be advantageous to find a regioselective Mannich 
reaction, which would allow the addition of extended functionalized alkyl groups without the 
need for protecting groups.  
There is a distinguished chemical and electronic difference between the various 
hydroxyl groups of chrysin and quercetin. In essence, position C-6 in flavonoid substrates is 
the most reactive site for electrophillic reactions [190]. 
Regioselectivity of the Mannich reaction has been reported in the case of naringenin (a 
dihydroflavone), with the temperature and time of reaction controlling the substitution pattern 
[190]. There are many other factors we found that also affect the selectivity of the reaction 
and product yield; among these factors, the most important are the reaction solvent, and the 
type of flavonoid substrate. 
The influence of the solvent was apparent in the preparation of compounds 6m and 7m 
from chrysin, ethylglyoxalate and morpholin. When using ethanol as a solvent, product 6m 
(substitution at position C-6) was obtained with 80% yield and 7m (disubstitution at positions 
C-6 and C-8) with 12% yield (Table 15). In contrast, the yield of 6m was 45%, and 7m was 
39%, when DMF was used as a solvent (Fig 40). 
Chapter IV  Discussion 
115 
 
Eth
ano
l
DMF
 
Fig 40: Solvent effect on the Mannich reaction of chrysin with ethylglyoxalate and morpholin. 
 
Table 15 points towards a large difference in Mannich reaction conditions between 
chrysin and quercetin substrates. Reactions involving chrysin normally need a temperature 
ranging from 55 °C to 65 °C, and 8 to 24 hours reaction time. It was found that in the case of 
quercetin, the reaction conditions were less demanding (temperature ranging from room 
temperature to 40 °C, with 4 to 8 hours reaction time). It was also noted that the quercetin 
reaction produced a mixture of many products, thus increasing difficulties with the isolation 
and purification procedures. For this reason only three quercetin products, i.e. 10m, 11m, and 
14m, in yields of 72, 36 and 39 % respectively, were synthesised. The results obtained with 
quercetin may be due to the presence of a hydroxyl group at position 3 (in ring C) and the 
catechol structure of ring B, which may increase the possibility of different substitution 
patterns. These hydroxyl groups may also enhance the effect of the carbonyl group in position 
C-4 and the reaction proceeds under milder condition. 
 
The results summarized in Table 15 for compounds 15m, 16m, 17m, 18m, 19m, 20m, 
21m indicate that the use of benzaldehyde or its derivatives in the reaction leads to morpholin 
decomposition and primary amine formation. There is no clear reason for this behavior in the 
literature of Mannich reactions. One possibility is that sterical hindrance may play a role, as 
the incorporation of three bulky groups is not straight forward (Fig 41). The structures of 
these compounds were confirmed by 1H, 13C NMR spectra in addition to LC-MS and HR-MS. 
At first, it was thought that the reaction would be an Aldol condensation [191] and would not 
involve the amine at all. HR-MS spectra of compounds 15m and 16m for C22H17NO5 [M-
CH3+H]+ (calcd = 375.1106, found = 375.1076), however, suggest the presence of an amine. 
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A proton signal ranging from δH 5.04- δH 4.49 ppm indicate the attachment of a singlet proton 
to a methylene bridge between two phenyl groups (Fig 41), and proximally to an amino 
group. In contrast, proximity of the proton to a hydroxyl group instead of an amino group 
would result in a downshift of this proton to approximately δH 5.80 ppm [192,193]. 
 
Fig 41: Suggested structure of the products obtained from the reaction of chrysin with p-methoxy 
benzaldehyde and morpholin. The chemical shifts of the proton attached to the methylene carbon are shown. 
 
Aldol condensation only took place during the preparation of compound 12m. The 
secondary amine used in this reaction (phthalimide (amide)) did not participate in the product 
formation. Condensation may take place as a part of a competing reaction [191] and only 
formaldehyde was incorporated, which led to the presence of a hydroxy methyl group 
attached to chrysin (Fig 42).  
 
 
Fig 42: Reaction of chrysin with paraformaldehyde in the presence of phthalimide. Please note that 
phthalimide did not participate in this reaction. 
 
Overall, 21 compounds were obtained via the Mannich reaction pathway, with yields 
varying from 10 % (e.g. 12m), to 86 % (4m). The wide range of diverse structures that were 
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obtained via the Mannich reaction may provide a better understanding of the flavonoid 
reaction behaviours in such a Mannich reaction. They may also allow us to study the 
biological behaviour of flavonoids in more detail. 
 
4.3. Chromene-flavone reaction 
 
The three-component reaction between chrysin, isonitrile and acetylene dicarboxylate 
has been employed successfully to synthesize 15 different tricyclic chromene-flavone 
compounds 1f-15f (Fig. 27, Table 16). Different derivatives of isonitrile and acetylene 
dicarboxylate were used in the reaction and therefore products differ in the amine side chain 
and dicarboxylate ester moieties. Product yields were high in general and ranged from 25% 
(for 12f) to 85% (for 9f). The chemical structures of all compounds were confirmed by 1H and 
13C NMR in addition to LC-MS and HR-MS spectroscopy. Two dimensional NMR was used 
to identify which hydroxyl group of chrysin was involved in the reaction, and also to 
determine the site of ring closure (ring D). 
Diagnostic protons were present in all compounds. One proton singlet was found at δH 
12.50-12.75 ppm, one proton broad singlet at δH 8.96-8.25 ppm, two proton doublets of a 
doublet at δH 8.08-7.98 ppm, three proton multiplets at δH 7.59-7.50 ppm, one singlet proton 
at δH 6.75-6.73 ppm, one singlet proton at δH 6.54-6.53 ppm, and one singlet proton at δH 
5.08-4.98 ppm (Fig 44). 
When considering the structure of chrysin, there are, in theory, three different structural 
possibilities for the new chromene ring (ring D) (Fig 43).  
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Fig 43: Possible structures of the chromene-flavones, based on theoretical considerations. 
 
1H NMR spectra of all chromene-flavone compounds revealed a singlet proton at 
approximately δH 12.70 ppm that can be unambiguously assigned to the chelate proton 5-OH, 
with another singlet at δH 6.50 ppm that is better fitted to H-8 than H-6 (Fig 44). 2D, H-C 
HMBC NMR spectra of compounds 5f and 10f show a strong correlation between the proton 
at δH 12.73 ppm (5-OH) and carbon numbers C-5 at δC 164 ppm, C-10 at δC 100 ppm and C-6 
at δC 108 ppm, and another correlation between the proton at δH 6.50 (H-8) with C-6 at δC 108 
ppm, C-7 at δC 169 ppm, C-9 at δC 161 ppm and C-10 at δC 100 ppm (Fig 45), thus providing 
evidence for 6,7-annulation of the chromene ring. 
More evidence comes from the 5f structure prediction using NMR prediction software 
(ACDLabs 7.0). Predicted values (Fig 46, 47 and 48) were found to be at δH 11.7 ± 3.5 ppm 
for 5-OH and δH 6.82 ± 0.37 ppm for H-8, thereby supporting the structure of possibility 1 
(Fig 43). Prediction values for the structure in possibility 2 yield a singlet proton at δH 6.71 ± 
0.04 ppm (values for proton H-6) which is incompatible with actual spectra of compound 5f. 
Prediction of the structure in possibility 3 yields a singlet proton at δH 7.34 ± 3.15 ppm for 7-
OH and δH 6.65 ± 0.12 ppm for H-8, which is also incompatible with the actual spectra of 
compound 5f. 
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Fig 44: 1H NMR spectrum of compound 5f, with partial enlargement  
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Fig 45: HMBC spectrum of compound 5f. 
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Fig 46: 1H-NMR data predicted for the structure resulting from possibility 1. 
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Fig 47: 1H-NMR data predicted for the structure resulting from possibility 2. 
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Fig 48: 1H-NMR data predicted for the structure resulting from possibility 3. 
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4.4. Cell culture 
 
The cancer HL-60 cell line as a model to measure the antioxidant/ cytotoxic activities of 
compounds   
Cytotoxicity and antioxidant activities of isolated natural and synthetic flavonoid 
derivatives were measured using cultured human promyelocytic leukemia HL-60 cells. 
Compounds were tested at six different concentrations ranging from 10 µM to 200 µM. A 
concentration of 200 µM was found to be most suitable to differentiate between activities of 
compounds. Viability of the cells was measured in the MTT assay. The purple colour of 
formazan was determined spectrophotometrically at 550 nm (reference at 690 nm) (Fig 30). 
Chrysin, quercetin, taxifolin, epicatechin, vitamin E and trolox® were used as controls and for 
comparison. The cytotoxicity of compounds was calculated as the percentage of cell viability 
readjusted according to the negative control (viability of cells in the negative control was set as 
100 %). The antioxidant activity of compounds was calculated as the percentage of cell 
survival in the presence of hydrogen peroxide (the oxidativily stressed cell control was set as 
100 %). 
Among the natural products used, compounds 2r, 3r, 4r (natural chalcone products), 5r 
and chrysin exhibited the strongest cytotoxic activities against the HL-60 cells with a survival 
of 32, 28, 25, 27 and 25 %, respectively, as shown in Table 17. The same compounds showed 
no antioxidant activity against H2O2 induced oxidative damage on HL-60 cells. Compounds 2r, 
3r, 4r and chrysin even increased the damage caused by hydrogen peroxide by 36, 8, 23 and 20 
%, respectively (Fig 49). 
In contrast, compounds 3d, 5d, 1r and taxifolin showed a weak cytotoxicity (survival 85, 
78, 71 and 80 % respectively) combined with a relatively weak antioxidant activity (the 
survival of the oxidatively stressed cells was 122 % for 3d, 137 % for 1r and 117 % for 
taxifolin (please note that the oxidatively stressed control was set as 100 %)). Compound 5d 
showed a good antioxidant activity with a protection compared with vitamin E and trolox® 
(survival of the cells was 211, 212, 185 % respectively) (Fig 49). 
All other natural compounds showed no cytotoxic effect. Some of them, however, 
exhibited a strong antioxidant activity. In the presence of 5 mM of H2O2, the damaging effect 
of this oxidant was reduced by 240, 256, 175, 267 and 172 %, when 200 µM of compounds 1d, 
2d, 4d, quercetin and epicatechin were used respectively (Fig 49). 
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Fig 49: Cytotoxic versus antioxidant activity of natural products as well as controls at 200 µM. Please note that 
the viability in the two cell culture assays is set at 100 % for either the untreated cell control or the oxidatively 
stressed  untreated cell control. The data is presented as a mean value  ±  standard deviation. 
 
Table 17 also reflects a strong proliferative effect associated with compound 1d, 2d, 4d, 
quercetin, epicatichen, vitamin E and trolox®, with a cell survival of 141, 127, 103, 153, 114, 
133, and 111 %, respectively (Fig 49). This proliferative effect towards HL-60 cells may be 
related to a strong antioxidant activity, which reduced the level of oxidative stress and 
therefore increases the survival of the cancer cell. Alternatively, these compounds may also 
serve as a nutrient to the cells. 
Comparison of compounds 10m, 11m and 14m, which are synthetic products derived 
from quercetin, reveal a clear difference in the cytotoxic and antioxidant activities. Viability of 
the cells was 57, 54 and 32 % for 10m, 11m and 14m respectively, but 153 % for quercetin. In 
contrast, antioxidant activity of these compounds was also found to be reduced considerably 
when compared to their parent compound (195, 200 and 198 % for 10m, 11m and 14m, 
respectively, 267 % for quercetin) (Fig 50). 
Oxidatively stressed cells plus 200 µM of compounds
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Fig 50: Cytotoxic versus antioxidant activity of quercetin as well as 10m, 11m and 14m (synthetic products 
derived from quercetin) at 200 µM. Please note that the viability in the two cell culture assays is set at 100 % for 
either the untreated cell control or the oxidatively stressed untreated cell control. The data is presented as a 
mean value  ±  standard deviation. 
 
Synthetic compounds derived from chrysin exhibited a wide range of cytotoxic activities 
(Table 18): survival of HL-60 was 94 % for 1f and just 12 % for 7f. In contrast, and as 
expected, all of these compounds showed no antioxidant activity. Some of them even enhanced 
the damaging effects of H2O2 on the HL-60 cells, with cell survival of 85, 80, 80, 49 and 86 % 
for 1m, 1f, 2f, 7f and 8f, respectively. This effect may be due to an increase in the oxidative 
stress within the cancer cells triggered by these chrysin derivatives. 
The antioxidant activity observed for some of the compounds may help better understand 
the role of antioxidant flavonoid compounds in protecting human cells against oxidative stress. 
The results also indicate that there is an inverse relationship between cytotoxic activity against 
HL-60 cells on the one hand, and an increased antioxidant activity on the other. 
The results presented in Table 18 further indicate that addition of alkylamine moieties to 
quercetin by a Mannich type reaction causes a significant increase of cytotoxic activity, with a 
decrease of antioxidant activity. Chromene-flavones show large differences in cytotoxicity that 
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may be due to the presence of an alkyl chain on the nitrogen and the different dicarboxylate 
moieties. 
4.5. Nematode assay 
 
Steinernema feltiae is a beneficial nematode that seeks out and kills the immature stages 
of harmful soil-dwelling insects before they become adults. It has been used as an intact 
animal model that may provide detailed insight into the toxicity of the selected compounds.  
Steinernema feltiae nematodes were incubated with selected compounds and numbers of 
living nematodes were counted under a microscope at 0, 24 and 48 hours. The results 
presented in Table 19 indicate that most compounds exhibited no significant toxicity against 
Steinernema feltiae, when used at two different concentrations of 200 µM and 400 µM. After 
24 hours of incubation, only compounds 5r (survival was 96 % at 200 µM and 95 % at 400 
µM), and 14f (survival was 94 % for 200 µM and 92 % for 400 µM) showed a weak toxicity. 
Despite this, it can still be envisaged that the majority of these compounds have little or 
no effect on the nematodes, and therefore may not be toxic to higher animals and humans; 
further research would be required for confirmation of this in more detail. 
 
4.6. Aromatase assay 
 
Estrogens are involved in numerous physiological processes including the development 
and maintenance of the female sexual organs, the reproductive cycle and various 
neuroendocrine functions. These hormones also have crucial roles in certain disease states, 
particularly in mammary and endometrial carcinomas. Cancer is the leading cause of death 
among women between the ages of 30 and 54, with breast and uterine cancers comprising 28 
% and 10 % of cancer related deaths [111], respectively. 
Aromatase is a cytochrome P450 enzyme (CYP19), a unique member of a super-family 
of microsomal enzymes that catalyzes the aromatization of androgens (testosterone and 
androstenedione) to estrogens (estradiol and estrone, respectively) through the aromatization 
of the A-ring of androgen substrates. Not surprisingly, aromatase has been considered a 
particularly attractive target for the treatment of hormone-dependent breast cancer [183]. 
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Aminoglutethimide has been used in the studies as a comparative control. This 
compound is an anti-steroid drug marketed around the world under the trade name Cytadren® 
by Novartis. It blocks the production of steroids derived from cholesterol and is clinically 
used in the treatment of Cushing's syndrome and metastatic breast cancer. It is also a drug 
abused by body builders. 
The mechanism of aromatase inhibition by flavonoids is based on the fact that rings A 
and C of flavonoids mimic the aromatase substrate rings C and D of a genuine aromatase 
substrate (see Fig 51) [194]. The addition of another ring to the flavonoids (ring D) may 
further enhance the mimetic properties of these flavonoids, therefore increasing their 
aromatase inhibiting effect (Fig 51). 
 
Fig 51: Structural similarities between the aromatase substrates on one hand and flavonoids on the other. 
These similarities may explain the ability of flavonoids to inhibit aromatase in a competitive manner. 
 
Chrysin has been is reported to be a strong aromatase inhibitor which served as bench 
mark [65]. It was used in the experiments together with quercetin, taxifolin and epicatechin as 
controls. 
Among the natural products employed, chrysin was found to be the strongest inhibitor 
of aromatase. Most of the isolated natural products also exhibited a significant inhibiting 
activity; compounds 5d, 1r, 3r and 4r (Table 17), with an IC50 equal to 20.9 ± 7.32, 19.9 ± 
5.42, 35.2 ± 2.50 and 21.5 ± 1.77 µM, respectively, showed even stronger effects than 
aminoglutethimide and quercetin (IC50 = 36.4 ± 0.26 and 105.2 ± 4.38 µM respectively) (see 
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Fig 52). In contrast, compound 2d was a relatively weak inhibitor with an IC50 of 194.2 ± 
9.55 µM. IC50 values of the other natural products, including taxifolin and epicatechin, were 
larger than 300 µM. 
 
Fig 52: Aromatase inhibiting activity of natural products, presented as IC50. The data presented as a mean 
value ±  standard deviation. 
 
Some of the chrysin-based synthetic flavonoid derivatives proved to be stronger 
aromatase inhibitors compared to chrysin itself. Compounds 3m and 11m for instance, 
showed IC50 values of 5.9 ± 1.86 and 11.2 ± 1.34 µM respectively. Many synthetic flavonoids 
showed activities better than aminoglutethimide, such as compound 13m (IC50 = 28.2 ± 1.99 
µM), 16m (IC50 = 15.6 ± 3.92 µM), 14f (IC50 = 26.3 ± 1.01 µM) and 15f (IC50 = 36.4 ± 2.44 
µM). Some compounds only showed moderate activities, such as 1m, 5m and 8f with IC50 
values of 87.5 ± 7.48, 69.6 ± 9.85 and 79.4 ± 4.47 µM, respectively. Weak activities were 
observed for some compounds such as 6m and 6f, with IC50 values equal to 178.3 ± 9.55 and 
166.6 ± 11.35 µM, respectively. 
The results discussed previously and displayed in Tables 17 and 18 indicate that 2,3-
dihydroflavones (5d and 1d), chalcones (3r and 4r), in addition to thiomorpholin drivatized 
chrysin (3m, 11m) and some chromene-flavones (14f) exhibit good inhibitor activity against 
aromatase compared to benchmark compounds. These flavone-derivatives may have a 
potential use in breast cancer therapy. 
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4.7. DPPH radical scavenging activity 
 
The scavenging ability of compounds was examined by using the stable 2,2-dipheny-1-
picryl hydrazyl (DPPH) free radical as a model. With antioxidant compounds present in the 
solution of DPPH, the purple colour of DPPH decolourizes and this decline is measured at 
530 nm. The degree of decolourisation is directly proportional to the antioxidant potency of 
the compound tested. 
The DPPH assay was performed with all compounds that had previously shown activity 
in the antioxidant assay based on the HL-60 cell line. A few chromene-flavones were also 
tested. Our aim was to investigate the antioxidant activities of the compounds in vitro by a 
direct chemical reaction and to compare these results with the ones obtained in cell culture. 
The purple DPPH free radical reacts with flavonoids. It attracts an electron or hydrogen 
atom (H·) and converts to a stable, colourless compound, while the flavonoid is converted to a 
flavonoid radical (Fig 53). 
 
N N
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O2N
NO2 N
H
N
O2N
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NO2Flavonoid OH Flavonoid O
Purple colour Colourless
 
Fig 53: Reaction of the DPPH free radical with flavonoids. 
 
Known antioxidant compounds, such as quercetin, taxifolin, epicatechin, vitamin E and 
trolox® were also used in this assay. Out of all these compounds, quercetin exhibited the 
highest scavenging activity with an IC50 equal to 35.0 ± 1.71 µM, which is in good agreement 
with HL-60 cell protection from H2O2 (267 %) observed for this apparently antioxidant 
compound. Compounds 1d, 2d, 4d, 5d and 1r are natural products with IC50 values in the 
DPPH assay equal to 41.6 ± 2.27, 51.6 ± 3.35, 88.7 ± 5.53, 102.6 ± 2.85 and 109.1 ± 8.16 
µM, respectively, which is also compatible with the results obtained in HL-60 cell culture, 
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where these compounds act as protectants against H2O2 (240, 256, 175, 210 and 137 %, 
respectively) (Table 17). 
Among all new synthetic compounds, only compounds derived from quercetin showed 
scavenging activity against the DPPH free radical, and even then, the activity was weaker 
than that of quercetin itself (Table 18) Although these results were compatible with the results 
obtained in cell culture, they do not point towards any particulary promising antioxidant 
activity of these compounds. 
 
4.8. Antioxidant structure activity relationship 
 
Through analysis of the results obtained in cell culture (protection of the HL-60 cells 
against damage caused by H2O2 effect) and in the DPPH assay, it is possible to deduce the 
relationship between the structure of the compounds and their antioxidant potential. 
Quercetin, for instance, has an almost ideal structure to develop antioxidant activity (Table 17 
and 18). 
In addition to the presence of five free hydroxyl groups, the B-ring of quercetin has a 
catechol type 3´,4´-dihydroxy benzene structure, as well as the 3-hydroxyl and 4-keto groups 
present in the C-ring, and the double bond between C2 and C3. Together, these features may 
explain the antioxidant strength of quercetin (Fig 54). 
Taxifolin has the same number and distribution of free hydroxyl groups as quercetin, 
but differs with regard to the saturation of the C-ring (absence of a double bond between C2 
and C3). Yet this compound showed only one third of the antioxidant activity of quercetin in 
the DPPH assay. Epicatechin also has the same number of hydroxyl groups, yet it exhibited 
weak antioxidant activity in the DPPH assay, probably due to the absence of the 4-keto group 
(Fig 54). 
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Fig 54: Structures of compounds with antioxidant activity. 
 
Compounds 1d and 2d also lack the double bond between carbons 2 and 3, yet, at the 
same time, these compounds showed a higher DPPH scavenging activity (IC50 = 41 and 51 
µM, respectively) as well as better HL-60 cell protection (240 and 256 %, respectively) when 
compared to epicatechin and taxifolin. The A-rings of 1d and 2d possess ortho dihydroxy 
groups (catechol-type) which may assist in the electron or hydrogen (H·) donating properties 
of these compounds, and increase the stability of the resulting flavonoid radical (Fig 54). 
Derivatisation of quercetin with amino alkyl derivatives is found to reduce the 
antioxidant and scavenging activity. The addition of hydrocarbon chains, which do not bear 
antioxidant groups, yet that are lacking in more conjugation and free hydroxyl groups, may be 
the cause of the weak activity associated with quercetin derivatives. 
In summary, the number and positioning of free hydroxyl groups is a very important 
factor which exerts a significant effect on the antioxidant activity of individual flavonoids. 
The presence of a double bond between the C-2 and C-3 together with the keto group at 
position 4, also appear to be a significant factor of good antioxidant activity. These factors 
enable flavonoids to form stable free radicals. 
 
4.9. Electrochemical properties 
 
Differential pulse polarography (DPP) was employed to study the redox behaviour of 
the compounds and to compare them to other flavonoids of different oxidation states. Overall, 
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all chromene-flavones studied exhibit a similar redox behaviour, which is dominated by a 
major oxidation current of around +800 to +900 mV vs. SSE, with 11f and 13f at higher 
potentials (+1230 and +1320 mV, respectively). The underlying oxidation process is 
irreversible, as confirmed by the absence of a reduction current in Cyclic Voltammetry (CV). 
The electrochemical behavior of the chromene-flavones is therefore similar to that of the 
parent flavone chrysin, whose DPP also shows an oxidation signal at around +800 mV. Both 
chromene-flavones and chrysin also exibit small oxidation currents at around -150mV and 
+100 mV, respectively. The major oxidation currents observed for 1f-15f and chrysin may be 
assigned to the phenolic ring system A. Although the A-ring in chrysin is formally a 
resorcinol and not just a phenol (in contrast to 1f-15f), the meta-substitution in the resorcinol 
ring implies that its redox behaviour is more similar to the one of a phenol (oxidation to a 
phenyl radical at +520 mV) than of a hydroquinone (oxidation to ortho- or para-quinone). 
Such hydroquinone redox chemistry is present in other flavonoids, however, which contain a 
catechol moiety (B-ring) and whose redox behaviour differs from the one of chromene-
flavones. In general, these flavonoids exhibit a (mostly quasi-reversible) redox signal between 
+100 and +200 mV, which is due to catechol redox chemistry and endows these compounds 
with particular antioxidant properties. Epicatechin shows a major signal in DPP at +120 mV, 
taxifolin at +135 mV, the anthocyanidin cyanidine at +200 mV and quercetin at +160 mV, 
which turns these natural products into good electron donors and antioxidants. The catechol 
substituent and the redox chemistry associated with it (signals at around +150 to +250 mV) 
are notably absent in the chromene-flavones and in chrysin, and these compounds are quite 
cytotoxic. 
Overall the electrochemical studies therefore confirm and to some extent also rationalise 
the observations made in cell culture and in the in vitro assay. In particular, it is possible to 
explain some of the apperent “contradictions” between cytotoxicity (of chrysin derivatives) 
and antioxidant activity (of catechol-bearing derivatives). 
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Chapter V: Conclusion and Outlook 
 
Two new natural products in addition to eight well known ones have been isolated from 
the roots of two Leguminosae plants (Delonix regia, growing in Egypt, and Robinia 
pseudoacacia, growing in Germany). The isolation and purification procedures included 
extraction and successive partitions of the water soluble part with ethyl acetate and n-butanol, 
followed by silica gel and Sephadex column chromatography. 
Twenty-one chrysin and quercetin derivatives were synthesized via Mannich type 
reactions. The reaction conditions were monitored tightly to obtain the desired regioselective 
products at an acceptable yield and to avoid complications with the isolation and purification. 
Type of the flavonoid, reaction solvent, the bulk of the reactant and the reaction time and 
temperature were the most important factors affecting the yield and selectivity of these 
reactions. Our results indicate that the highly hydroxylic subistituted flavone (quercetin) is 
more reactive in the Mannich reaction. This creates problems with the synthesis of a 
regioselective product in relatively good yield, and additional problems with the isolation and 
purification of products are encountered. 
The addition of a further ring to chrysin (ring D) has been successfully achieved by the 
reaction of chrysin with an isonitrile and acetylene dicarboxylate. Fifteen new chromene-
flavone compounds have been produced by this method with a good yield ranging from 25% 
for 12f to 85% for 9f. The chromene-flavone structures were confirmed by 1D and 2D NMR 
data and mass spectroscopy (LC-MS and HR-MS), and compared to the prediction calculation 
with the computational structure prediction program ACDLabs 7.0. 
A large number of flavonoid compounds (10 natural products and 38 synthetic products 
in addition to chrysin, quercetin, epicatechin and taxifolin) were tested for antioxidant and 
anticancer potency using in vitro and in vivo assays. The diversity of these compounds was 
useful for the investigation of the structure antioxidant activity relationships of these 
compounds. In addition to comparison of the cytotoxic activity and aromatase inhibition, the 
results of the nematode assays also provided information about the selectivity and toxicity of 
the compounds towards cells and intact organisms. 
The natural product quercetin, in addition to compounds 1d and 2d, (Fig 55) exhibited 
the highest antioxidant potency in vivo (protection of the HL-60 cells against H2O2 induced 
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oxidative damage) with 267, 240 and 256 % protection respectively (please note that the  
oxidatively stressed cell control is set as 100 %). The results obtained from the in vitro DPPH 
assay also pointed towards high antioxidant potency for the aforementioned compounds (with 
IC50 values of 35.0, 41.6 and 51.6 µM respectively). The results obtained for 1d and 2d 
revealed that 2d (with a methoxy group at position 4 of the 2,3-dihydroxyflavan nucleus), has 
more protecting power in the cell culture assay compared to 1d. At the same time, 1d, with 
one more free hydroxyl group (Fig 55), showed more activity in the in vitro DPPH assay (see 
Table 17).  
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Fig 55: Structure of compounds 1d and 2d, which appear to act as promising antioxidants. 
 
Compounds 10m and 14m (Fig 56), which are quercetin derivatives, showed strong 
scavenging of the DPPH radical with IC50 values of 49.4 and 58.6 µM, respectively. 
Nonetheless, these compounds exhibited relatively weak protective effects against H2O2 
induced oxidative damage in cell culture (195 and 198 % protection, respectively). 
 
Chapter V  Conclusion and Outlook 
136 
 
 
Fig 56: Structure of compounds 10m and 14m, which is quercetin derivative. 
 
It is possible to derive a relationship between the antioxidant and the cytotoxic activity 
of the compounds: In essence, powerful antioxidant compounds appear to have little or no 
cytotoxic effects. Compound 4d and epicatechin showed moderate antioxidant activities in 
addition to cell protective effects. At the same time, these two compounds showed no 
cytotoxic activity in the HL-60 cell assay. Other examples for this “antioxidant” relation are 
quercetin, 1d and 2d, which all showed a significant increase in the proliferation of the cells 
compared to the controls. 
In contrast, 7f, a chromene-flavone was found to have the strongest cytotoxicity with a 
mortality rate of 88 % in the HL-60 cells. Compounds 3r, 4r and 5r, in addition to chrysin, 
5m, 13m, 16m, 2f, 11f, 12f and 14f, showed a strong cytotoxic activity, while most of the 
other synthetic compounds showed only a moderate cytotoxicity. Results of the nematode 
assay for some of these compounds showed a very weak nematocidal activity. Together, these 
cytotoxicity (and antioxidant) results may be useful in building a concept regarding the 
selectivity of the compounds towards the cancer cells. 
Some of the natural products showed considerable inhibiting potency towards the 
aromatase enzyme. Compounds 5d, 1r, 3r and 4r seem to be even more effective than 
aminoglutethimide. A point we must bear in mind is that compounds 5d and 1r were only 
weakly cytotoxic, which again may provide an entry point for selectivity, in this case for the 
treatment of breast cancer. 
Some of the synthetic compounds were also effective aromatase inhibitors, especially 
3m, 11m, 13m, 16m, 14f and 15f, which exhibited the highest activity among all compounds 
(some of them were even more active than chrysin). Compound 11m, a derivative from 
quercetin, showed higher activity against aromatase than quercetin itself. Although the 
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quercetin core-structure does not appear to inhibit aromatase particularly well, 11m indicates 
that more effective aromatase inhibition may still be built on the quercetin core. 
In the future, it will be important to develop a method to remove the side chain acetyl 
groups from the chromene-flavone compounds, and in doing so, perhaps enhance the 
bioavailability and solubility of these compounds. Various methods were implemented in an 
attempt to remove this ester link, but without noticeable results. Removal of parts of the 
nitrogen side chain may also be beneficial (Fig 57). 
 
 
Fig 57: Suggested removal of some side chain groups from the chromene-flavones in order to increase 
activity and improve the pharmacokinetic profile of the compounds. 
 
Removal of this nitrogen side chain from the chromene-flavones will provide a new 
type of structurally-related substances which could prove to be useful as enzyme inhibitors 
and/or anti-cancer agents. This is a possible direction to be taken in the future, which would 
combine advanced synthetic chemistry with more extensive and in-depth biological testing. 
References 
138 
 
References 
 
1. G. Di Carlo, N. Mascolo, A.A. Izzo, F. Capasso, Flavonoids: Old and new aspects of a 
class of natural therapeutic drugs, Life Sci., 1999, 65, 337–353. 
2. T. Swain, J.B. Harborne, T.J. Mabry, H. Mabry (Eds.), The Flavonoids, Chapman and 
Hall, London, UK, 1975, p. 1096. 
3. C. Remésy, C. Manach, C. Demigne, O. Texier, F. Regerat, in: J. Vercauteren, C. 
Chèze, J. Triaud (Eds.), Polyphenol 96, 18th International Conference on Polyphenols, 
INRA Éditions, (France), 1996, p. 251. 
4. M.G.L. Hertog, E.J.M. Feskens, D. Kromhout, P.C.H. Hollman, M.B. Katan, Dietary 
antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study, 
The Lancet, 1993, 342, 1007-1011. 
5. S. Renaud, M. de Lorgeril, Wine, alcohol, platelets, and the French paradox for 
coronary heart disease, The Lancet, 1992, 339, 1523-1525. 
6. B. Simini, Serge Renaud: from French paradox to Cretan miracle, The Lancet, 2000, 
355, 48. 
7. R. Brouillard, A. Cheminat, Flavonoids and plant color. Prog. Clin. Biol. Res., 1988, 
280, 93–106. 
8. J. Kuhnau, The flavanoids. A class of semi-essential food components: their role in 
human nutrition, World Rev. Nutr. Diet., 1976, 24, 117-191. 
9. H. De Groot, U. Raven, Tissue injury by reactive oxygen species and the protective 
effects of flavonoids. Fundam. Clin. Pharma. Col., 1998, 12, 249-255. 
10. J.B. Harborne, The flavonoids advanced in research since 1986, Chapman &Hall, 
London, New York, Tokyo, 1994, 499-514. 
11. J. Bruneton, Pharmacognosy, phytochemistry of medicinal plant, 2nd edition, TEC & 
DOC., London, Paris, NewYork, 1999, 316-319. 
12. J.F. Hammerstone, S.A. Lazarus, H.H. Schmitz, Procyanidin content and variation in 
some commonly consumed foods, J. Nutr., 2000, 130, 2086S–2092S. 
13. C. Santos-Buelga, A. Scalbert, Proanthocyanidins and tannin-like compounds in 
human nutrition, occurrence, dietary intake and effects on nutrition and health, J. Food 
Sci. Agr., 2000, 80, 1094–1117. 
14. D.A. Balantine, S.A. Wiseman, L.C.M. Bouwens, The chemistry of tea flavonoids, 
Crit. Rev. Food Sci. Nutr., 1997, 37, 693–704. 
References 
139 
 
15. N.C. Cook, S. Samman, Flavonoids: Chemistry, metabolism, cardioprotective effects, 
and dietary sources, J. Nutr. Biochem., 1996, 7(2), 66–76. 
16. H.J. Leese, G. Semenza, On the identity between the small intestinal enzymes 
phlorizin hydrolase and glycosylceramidase, J. Biol. Chem., 1973, 248(23), 8170–
8173. 
17. A.J. Day, F.J. Canada, J.C. Diaz, P.A. Kroon, R. McLauchlan, C.B. Faulds, M.R. 
Morgan, G. Williamson, Dietary flavonoid and isoflavone glycosides are hydrolyzed 
by lactase site of lactase phlorizin hydrolase, FEBS Lett, 2000, 468, 166–170. 
18. L.B. Daniels, P.J. Coyle, Y.B. Chiao, R.H. Glew, Purification and characterization of a 
cytosolic broad specificity beta-glucosidase from human liver, J. Biol. Chem., 1981, 
256(24), 13004–13013. 
19. V. Gopalan, A. Pastuszyn, W.R. Galey, R.H. Glew, Exolytic hydrolysis of toxic plant 
glucosides by guinea pig liver cytosolic beta-glucosidase, J. Biol. Chem., 1992, 
267(20), 14027–14032. 
20. J.P.E. Spencer, G. Chowrimootoo, R. Choudhury, E.S. Debnam, S.K. Srai, C. Rice-
Evans, The small intestine can both absorb and glucuronidate luminal flavonoids, 
FEBS Lett, 1999, 458, 224–230. 
21. G. Cao, R.L. Prior, Anthocyanins are detected in human plasma after oral 
administration of an elderberry extract, Clin. Chem., 1999, 45, 574–576. 
22. I. Erlund, G. Alfthan, J. Maenpaa, A. Aro, Tea and coronary heart disease: the 
flavonoid quercetin is more bioavailable from rutin in women than in men, Arch. 
Intern. Med., 2001, 161(15), 1919–1920. 
23. J.M. Gee, M.S. Dupont, M.J. Rhodes, I.T. Johnson, Quercetin glucosides interact with 
the intestinal glucose transport pathway, Free Radic. Biol. Med., 1998, 25(1), 19–25. 
24. K.R. Markham, L.J. Poter, flavonoids in green algae (Chlorophyta), phytochemistry, 
1969, 8(9), 1777-1781. 
25. R. Marchelli, L.C. Vining, the biosynthetic origin of chloroflavonin and flavonoid 
antibiotic from Aspergillus candidus, Can. J. Biochem., 1973, 51 (12), 1624-1629. 
26. R. Sanduja, G.E. Martin, A.J. Weinheimer, M. Alam, M.B. Hossain, D. van der Helm, 
secondary metabolite of coelenterate Echinophora labellosa, J. heterocycl. Chem. 
1984, 21, 845-848. 
27. J.B. Harborne (Ed), Phytochemical dictionary of Liguminosae, volume 1, “plant and 
their constituents”, Chapman and Hall, London, 1994. 
References 
140 
 
28. T.E. Wills, “text book of pharmacognosy” CBS publisher & distributor, India, 5th ed. 
1985, 198-199. 
29. G.E. Trease, W.C. Evans, “Pharmacognosy”, Bailliere Tindal, London, 11th ed., 1978, 
103-104. 
30. S. Al-Bahry, A.E. Elshafie, M. Deadman, A. Al Sa'di, A. Al Raeesi, Y. Al Maqbali, 
First report of Ganoderma colossum on Ficus altissima and Delonix regia in Oman, 
Plant Pathology, 2005, 54(2), 245-245. 
31. E.F. Gilman, D.G. Watson, Delonix regia –US Forest Service Fact Sheet, TS-228, 
1993, 1-3. 
32. F. Adje, Y.F. Lozano, E. Meudec, P. Lozano, A. Adima, G.A. Nzi, E.M. Gaydou, 
Anthocyanin Characterization of Pilot Plant Water Extracts of Delonix regia Flowers, 
Molecules, 2008, 13(6), 1238-1245. 
33. N.A.M. Saleh, M.S. Ishak, Anthocyanins of some leguminosae flowers and their effect 
on colour variation. Phytochemistry, 1976, 15, 835-836. 
34. A.H.S. Abou Zeid, Phytochemical and biological investigation of Delonix regia Raf. 
Leaves, Bulletin of the Faculty of Pharmacy (Cairo University), 2002, 40(3), 175-187. 
35. P.P. Joy, J.S. Mathew, B.P. Skaria, Medicinal plants. Trop. Horticult., 2001, 2, 449-
632. 
36. M.V. Jyothi, S.N. Mandayan, N.C. Kotamballi, N. Bhagyalakshmi, Antioxidative 
efficacies of floral petal extracts of Delonix regia Raffin, Int. J. Biomed. Pharmaceut. 
Sci., 2007, 1, 73-82. 
37. R.H. Sammour, A.R. El-Shanshoury, Antimicrobial activity of legume seed proteins, 
Bot. Bull. Acad. Sin., 1992, 33, 185-190. 
38. F. Aqil, I. Ahmad, Broad-spectrum antibacterial and antifungal properties of certain 
traditionally used Indian medicinal plants, World J. Microbiol. Biotechnol., 2003, 19 
(6), 653-657. 
39. L.H. Bailey, Most Commonly Grown in the Continental United States of Canada, 
Manual of Cultivated Plants, 1991, 9581, 559–560. 
40. T.B. Myron, J.T. Hugh, Root Development as a factor in the Success or Failure of 
Windbreak Trees in the Southern High Plains, Journal of Forestry, 1938, 36, 790–
803. 
41. A. Rabijns, C. Verboven, P. Rougé, A. Barre, E.J. Van Damme, W.J. Peumans, C.J. 
DeRanter, Structure of A legume Lectin From the Bark of Robinia pseudoacacia and 
its Complex with N. acetyl Galactesamine, Proteins, 2001, 44(4), 470–478. 
References 
141 
 
42. J. Wantyghem, N. Platzer, M. Giner, C. Derappe, Y. Goussault, Structure analysis of 
the carbohydrate chain of glycopeptides isolated from Robinia pseudoacacia Seed 
Lectins, Carbohydrate research, 1992, 236, 181-193. 
43. C. Baoliang, K. Junei, N. Toshihiro, Triterpene Glycosides from the Bark of Robinia 
pseudoacacia L. II, Chem. Pharm. Bull., 1993, 41(3), 553–556. 
44. A.L. Smith, C.L. Camphell, M.P. Diwakar, J.W. Hanover, R.O. Miller, Extracts from 
black locust as wood preservatives: A comparison of the methanol extract with 
pentachlorphenol and chromated copper arsenate, Holzforschung, 1989b, 43, 421–423. 
45. A.L. Smith, C.L. Camphell, D.B. Walker, J.W. Hanover, Extracts from black locust as 
wood preservatives: extraction of decay resistance from black locust heartwood, 
Holzforschung, 1989a, 43, 293–296. 
46. Trees, Structure and Function, 1996, 11 (5), 316–321. 
47. J.C. Huntley, Robinia pseudoacacia L. black locust. In: Burns, Russell M., Honkala, 
Barbara H., technical coordinators. Silvics of North America. Volume 2. Hardwoods. 
Agric. Handb. 654. Washington, DC: U.S. Department of Agriculture, Forest Service, 
1990, 755-761. 
48. Trees, Structure and Function, 1994, 8 (4), 165–171. 
49. M.D. Tindale, D.G. Raux, Phytochemical survey of the Australian species of Acacia, 
Phytochemistry, 1969, 8, 1713-1727. 
50. J.B. Harborne, Comparative Biochemistry of the Flavonoids, Academic Press, 
London, 1967. 
51. T. Iwashina, J. Kitajima, Chalcone and flavonol glycosides from Asarum canadense 
(Aristolochiaceae), Phytochemistry, 2000, 55(8), 971–974. 
52. S.E. Drewes, D.G. Roux, Condensed tannins. 15. Interrelationships of flavonoid 
components in wattle-bark extract, Biochem. J., 1963, 87, 167-172. 
53. D.G. Roux, E. Paulus, Condensed tannins. 13. Interrelationships of flavonoid 
components from the heartwood of Robinia pseudoacacia, Biochem. J., 1962, 82, 324-
330. 
54. K. Freudenberg, L. Hartmann, Inhaltsstoffe der Robinia pseudacacia, Justus Liebigs 
Annalen der Chemie, 1954, 587 (3), 207-212. 
55. H. Pachéco, Recherches sur la biochimie comparée des flavanonols dans les végétaux 
supérieurs, Bull. Soc. chim. biol., 1957, 39, 971-987. 
56. L.J. Putman, P.E. Laks, M.S. Pruner, Chemical constituents of black locust bark and 
their biocidal activity. Holzforschung, 1989, 43, 219–224 
References 
142 
 
57. L.V. Alegrio, R. Braz-Filho, O.R. Gottlieb, Diarylheptanoids and isoflavonoids from 
Centrolobium species, Phytochemistry, 1989, 28, 2359-2362. 
58. F. Tian, J.L. McLaughlin, Bioactive Flavonoids from the Black Locust Tree, Robinia 
Pseudoacacia, Pharmacutical-Biology, 2000, 38(3), 229–234 
59. K. Yongsoo, H.O. Geon-seung, M. Kim-Cheng, Y. Kwon, S.H. Geon, C.M. Kim, 
Isoflovonoids from Root Cortex of Robinia pseudoacacia, Nat. Prod. Sci., 1989, 6(3), 
139–141. 
60. J.W. McClure, Physiology of flavonoids in plants, in Plant Flavonoids in Biology and 
Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships (V. 
Cody, E. Middleton, J.B. Harborne eds), Alan R. Liss, Inc., New York, 1986, 77–85. 
61. D.A. Smith, S.W. Banks, Formation and biological properties of isoflavonoid 
phytoalexins, in Plant Flavonoids in Biology and Medicine: Biochemical, 
Pharmacological, and Structure-Activity Relationships (V. Cody, E. Middleton, J.B. 
Harborne eds), Alan R. Liss, Inc., New York, 1986, 113–124. 
62. P. Knekt, R. Jarvinen, A. Reunanen, J. Maatela, Flavonoid intake and coronary 
mortality in Finland: a cohort study, Br. Med. J., 1996, 312(7029), 478–481. 
63. L.P. Balant, M. Wermeille, L.A. Griffith, Metabolism and pharmacokinetics of 
hydroxyethylated rutosides in animals and man, Q. Rev. Drug Metab. Drug Interact., 
1984, 5(1), 1-24. 
64. P. Ferenci, B. Dragosics, H. Dittrich, H. Frank, L. Benda, H. Lochs, S. Meryn, W. 
Base, B. Schneider, Randomized controlled trial of silymarin treatment in patients 
with cirrhosis of the liver, J. Hepatol., 1989, 9(1), 105–113. 
65. R. Monteiro, I. Azevedo, C. Calhau, Modulation of Aromatase Activity by Diet 
Polyphenolic Compounds, J. Agric. Food Chem. 2006, 54(10), 3535–3540. 
66. G. Cao, E. Sofic, R.L. Prior, Antioxidant and prooxidant behavior of flavonoids, Free 
Radical Biology & Medicine, 1997, 22(5), 749–760. 
67. W. Bors, W. Heller, C. Michel, M. Saran, Flavonoids as Antioxidants, Determination 
of radical Scavenging efficiencies, Methods Enzymol, 1990, 186, 343–355. 
68. O.F. Cristián, E. de Lamirande, C. Gagnon, Positive role of reactive oxygen species in 
mammalin sperm capacitation: Triggering and modulation of phosphorylation events, 
Free Radical Biology & Medicine, 2006, 41, 528–540. 
69. A. Catherine, R. Evans, N.J. Miller, G. Paganga, Structure-Antioxidant Activity 
Relationships of Flavonoids and Phenolic Acids, Free Radic. Biol. Med., 1996, 20, 
933–956. 
References 
143 
 
70. S. Jovanovic, I. Jankovic, L. Josunovic, Electron-Transfer, Reactions of Alkylperoxy 
Radicals, J. Am. Chem. Soc., 1992, 114, 9018–9022. 
71. P. Wardman, Reduction Potentials of One-Electron Couples Involving Free Radicals 
in Aqueous Solution, J. Phys. Chem. Ref. Data. Ser., 1989, 18, 1637–1755. 
72. Y. Hanasaki, S. Ogawa, S. Fukui, The Correlation Between Active Oxygens 
Scavenging and Antioxidative Effect of Flavonoids, Free Radic. Biol. Med., 1994, 16, 
845–850. 
73. Y. Tsajimoto, H. Hashizume, M. Yamazaki, Superoxide Radical Scavenging Activity 
of Phenolic Compounds, Int. J. Biochem., 1993, 25, 491–494. 
74. S. Jovanovic, S. Steenken, Y. Hara, M. Simic, Reduction potentials of flavonoid and 
model phenoxyl radicals. Which ring in flavonoids is responsible for antioxidant 
activity?, J. Chem. Soc. Perkin., 1996, 2, 2497-2504. 
75. W. Heimann, F. Reiff, Beziehung zwischen chemischer konstitution und antioxygener 
wirkung bei flavonolen, Fette Seifen Anstr-Mittel, 1953, 55. 451–458. 
76. M. Lurdes, M.T. Fernandez, M. Santos, R. Rocha, M.H. Florencio, K.R. Jennings, 
Interactions of Flavonoids with Iron and Copper Ions: A Mechanism for their 
Antioxidant Activity, Free Radical Research, 2002, 36(11), 1199–1208. 
77. P. Dobsak, J. Siegelova, J.E. Wolf, L. Rochette, J.C. Eicher, J. Vasku, Prevention of 
apoptosis by deferoxamine during 4 h of cold cardioplegia and reperfusion: in vitro 
study of isolated working rat heart model, Pathophysiology, 2002, 9, 27–32. 
78. G. Giuseppe, J.O. Peter, Toxicity and cancer protective properties of flavonoids, Free 
Radical Biology & Medicine, 2004, 37(3), 287–303. 
79. J.A. Manthey, N. Guthrie, K. Grhmann, Biological properties of Citrus flavonoids 
pertaining to cancer and inflammation, Curr. Med. Chem., 2001, 8, 135–153. 
80. L. Bravo, Polyphenols: Chemistry, dietary sources, metabolism, and nutritional 
significance, Nutr. ReV., 1998, 56, 317–333. 
81. C. Kandaswami, E. Perkins, D.S. Soloniuk, G. Drzewiecki, E. Middleton, 
Antiproliferative effects of Citrus flavonoids on a human squamous cell carcinoma in 
Vitro, Cancer Lett., 1991, 56, 147–152. 
82. M. Piantelli, A. Rinelli, E. Macri, N. Maggiano, L.M. Larocca, A. Scerrati, R. Roselli, 
M. Iacoangeli,. G. Scambia, A. Capella, F.O. Ranelletti. Type II estrogen binding sites 
and antiproliferative activity of quercetin in human meningiomas, Cancer, 1993, 63, 
193–198. 
References 
144 
 
83. S.M. Kuo, Antiproliferative potency of structurally distinct dietary flavonoids on 
human colon cancer cells, Cancer Lett., 1996, 110, 41–48. 
84. S. Kuntz, U. Wenzel, H. Daniel, Comparative analysis of the effects of flavonoids on 
proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines, Eur. J. 
Nutr., 1999, 38, 133–142. 
85. G. Agullo, L. Gamet-Payrastre, Y. Fernandez, N. Anciaux, C. Demigne, C. Remesy, 
Comparative effects of flavonoids on the growth, viability and metabolism of a 
colonia adenocarcinoma cell line (HT29 cells), Cancer Lett., 1996, 105, 61–70. 
86. J.A. Manthey, N. Guthrie, Antiproliferative activities of Citrus flavonoids against six 
human cancer cell lines, J. Agric. Food Chem., 2002, 50, 5837–5843. 
87. G. Agullo, L.G. Payrastre, S. Manenti, C. Viala, C. Remesy, H. Chap, B. Payrastre, 
Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-
kinase: A comparison with tyrosine kinase and protein kinase C inhibition, Biochem. 
Pharmacol., 1997, 53, 1649–1657. 
88. H.C. Huang, H.R. Wang, L.M. Hsieh, Antiproliferative effect of baicalein, a flavonoid 
from Chinese herb, on vascular smooth muscle cell, Eur. J. Pharmacol., 1994, 251, 
91–93. 
89. F. Casagrande, J. Darbon, Effects of structurally related flavonoids on cell cycle 
progression of human melanoma cells: Regulation of cyclin-dependet kinases CDK2 
and CDK1, Biochem. Pharmacol., 2001, 61, 1205–1215. 
90. J.C. Le Bail, F. Varnat, J.C. Nicolas, G. Habrioux, Estrogenic and antiproliferative 
activities on MCF-7 human breast cancer cells by flavonoids, Cancer Lett., 1998, 130, 
209–216. 
91. D.M. Brownson, N.G. Azios, B.K. Fuqua, S.F. Dharmawardhane, T.J. Mabry, 
Flavonoids effects relevant to cancer, J. Nutr., 2002, 132, 3482S–3489S. 
92. H. Liu, D.C. Radisky, C.M. Nelson, H. Zhang, J.E. Fata, R.A. Roth, M. Bissell, 
Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic 
role for TSC2, Proc. Natl. Acad. Sci. U.S.A, 2006, 103, 4134–4139. 
93. S. Caltagirone, C. Rossi, A. Poggi, F.O. Ranelletti, P.G. Natali, M. Brunetti, F.B. 
Aiello, M. Piantelli, Flavonoids apigenin and quercetin inhibit melanoma growth and 
metastatic potential, J. Cancer, 2000, 87, 595–600. 
94. R.T. Greenlee, T. Murray, S. Bolden, P.A. Wingo, Cancer statistics, CA Cancer J. 
Clin., 2000, 50, 7-33. 
References 
145 
 
95. M. Stockler, N.R.C. Wilcken, D. Ghersi, Systematic reviews of chemotherapy and 
endocrine therapy in metastatic breast cancer, Cancer Treat. Rev., 2000, 26, 151-68. 
96. S.E. Bulun, E.R. Simpson, Regulation of aromatase expression in human tissues, 
Breast Cancer Res.Treat., 1994, 30, 19-29. 
97. S. Sebastian, S.E. Bulun, A Highly Complex Organization of the Regulatory Region 
of the Human CYP19 (Aromatase) Gene Revealed by the Human Genome Project, J. 
Clin. Endocrinol. Metab., 2001, 86, 4600-4602. 
98. E.R. Simpson,T. Price, J. Aitken, M. Mahendroo, G. Means, M. Kilgore, The 
aromatase enzyme: from cloning to cancer, Princess Takamatsu Symp., 1990, 21, 75-
87. 
99. G.D. Means, M.S. Mahendroo, C.J. Corbin, J.M. Mathis, F.E. Powell, C.R. 
Mendelson, E.R. Simpson, Structural analysis of the gene encoding human aromatase 
cytochrome P-450, the enzyme responsible for estrogen biosynthesis, J. Biol. Chem., 
1989, 264, 19385–19391. 
100. K. Toda, M. Terashima, T. Kawamoto, H. Sumimoto, Y. Yokoyama, I. Kuribayashi, 
Y.Mitsuuchi, T. Maeda, Y. Yamamoto, Y. Sagara, Eur. J. Biochem., 1990, 193, 559-
565. 
101. N. Harada, K. Yamada, K. Saito, N. Kibe, S. Dohmae, Y. Takagi, Structural 
characterization of the human estrogen synthetase (aromatase) gene, Biochem. 
Biophys. Res. Commun., 1990, 166, 365-372. 
102. G.D. Means, M.W. Kilgore, M.S. Mahendroo, C.R. Mendelson, E.R. Simpson, Tissue 
specific promoters regulate aromatase cytochrome P450 gene expression in human 
ovary and fetal tissues, Mol. Endocrinol., 1991, 5, 2005-2013. 
103. M.S. Mahendroo, G.D. Means, C.R. Mendelson, E.R. Simpson, Tissue-specific 
expression of human P450arom: the promoter responsible for expression in adipose 
tissue is different from that utilized in placenta, J. Biol. Chem., 1991, 266, 11276-
11281. 
104. T. Sun, Y. Zhao, D.J. Mangelsdorf, E.R. Simpson, Characterization of a Region 
Upstream of Exon I.1 of the Human CYP19 (Aromatase) Gene That Mediates 
Regulation by Retinoids in Human Choriocarcinoma Cells, Endocrinology, 1998, 139, 
1684-1691. 
105. Y. Zhao, C.R. Mendelson, E.R. Simpson, Characterization of the sequences of the 
human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose 
stromal cells and fetal hepatocytes, Mol. Endocrinol., 1995, 9, 340-349. 
References 
146 
 
106. Y. Zhao, J.E. Nichols, S.E. Bulun, C.R. Mendelson, E.R. Simpson, Aromatase P450 
Gene Expression in Human Adipose Tissue, J. Biol. Chem., 1995, 270, 16449-16457. 
107. Y. Zhao, J.E. Nichols, R. Valdez, C.R. Mendelson, E.R. Simpson, Tumor necrosis 
factor-alpha stimulates aromatase gene expression in human adipose stromal cells 
through use of an activating protein-1 binding site upstream of promoter 1.4, 
Mol.Endocrinol., 1996, 10, 1350-1357. 
108. E.R. Simpson, M.S. Mahendroo, G.D. Means, M.W. Kilgore, M.M. Hinshelwood, 
G.S. Lorence, B. Amarneh, Y. Ito, C.R. Fisher, M.D. Michael, Aromatase cytochrome 
P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev., 1994, 15, 342–
355. 
109. E.R. Simpson, M.S. Mahendroo, G.D. Means, M.W. Kilgore, C.J. Corbin, C.R. 
Mendelson, Tissue-specific promoters regulate Aromatase cytochrome P450 
expression, J. Steroid Biochem. Mol. Biol., 1993, 44, 321–330. 
110. J.T. Kellis, L.E. Vickery, Purification and characterization of human placental 
aromatase cytochrome P-450, J. Biol. Chem., 1987, 262, 4413–4420. 
111. W.R. Brueggemeier, J.C. Hackett, E.S. Diaz-Cruz, Aromatase Inhibitors in the 
Treatment of Breast Cancer, Endocrine Reviews, 2005, 26(3), 331–345. 
112. H.A. Harvey, A. Lipton, R.J. Santen, Aromatase: new perspectives for breast cancer, 
Cancer Res., 1982, 42, 3261s–3467s. 
113. L. Banting, H.J. Smith, M. James, G. Jones, W. Nazareth, P.J. Nicholls, M.J. Hewlins, 
M.G. Rowlands, Structure-activity relationships for non-steroidal inhibitors of 
aromatase, J. Enzym Inhib., 1988, 2, 215–229. 
114. R.W. Brueggemeier, Biochemical and molecular aspects of aromatase, J. Enzym 
Inhib., 1990, 4, 101–111. 
115. R.W. Brueggemeier, Aromatase inhibitors—mechanisms of steroidal inhibitors, 
Breast Cancer Res. Treat., 1994, 30, 31–42. 
116. P.A. Cole, C.H. Robinson, Mechanism and inhibition of cytochrome P-450 aromatase, 
J. Med. Chem., 1990, 33, 2933–2942. 
117. A.M. Brodie, V.C. Njar, Aromatase inhibitors and breast cancer, Semin. Oncol., 1996, 
23, 10-20. 
118. A. Brodie, Q. Lu, B. Long, Aromatase and its inhibitors, J. Steroid Biochem. Mol. 
Biol., 1999, 69, 205–210. 
119. R.J. Santen, H.A. Harvey, Use of aromatase inhibitors in breast carcinoma, Endocr. 
Relat Cancer, 1999, 6, 75–92. 
References 
147 
 
120. G. Cocconi, First generation aromatase inhibitors—aminoglutethimide and 
testololactone, Breast Cancer Res. Treat., 1994, 30, 57–80. 
121. K. Hoffken, Experience with aromatase inhibitors in the treatment of advanced breast 
cancer, Cancer Treat. Rev., 1993, 19 (Suppl B), 37–44. 
122. H. Adlercreutz, Phytoestrogens: epidemiology and a possible role in cancer protection, 
Environ Health Perspect, 1995, 103, 103–112. 
123. J.T. Kellis, L.E. Vickery, Inhibition of human estrogen synthetase (aromatase) by 
flavones, Science, 1984, 225, 1032–1034. 
124. A.R. Ibrahim, Y.J. Abul-Hajj, Aromatase inhibition by flavonoids, J. Steroid. 
Biochem. Mol. Biol., 1990, 37, 257–260. 
125. Y.C. Kao, C. Zhou, M. Sherman, C.A. Laughton, S. Chen, Molecular basis of the 
inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone 
phytoestrogens: a site-directed mutagenesis study, Environ Health Perspect, 1998, 
106, 85–92. 
126. C. Pouget, C. Fagnere, J.P. Basly, G. Habrioux, A.J. Chulia, Design, synthesis and 
evaluation of 4-imidazolylflavans as new leads for aromatase inhibition, Bioorg. Med. 
Chem. Lett., 2002, 12, 2859–2861. 
127. M. Recanatini, A. Bisi, A. Cavalli, F. Belluti, S. Gobbi, A. Rampa, P. Valenti, M. 
Palzer, A. Palusczak, R.W. Hartmann, A new class of nonsteroidal aromatase 
inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition 
of the P450 enzymes aromatase and 17-α-hydroxylase/C17,20-lyase, J. Med. Chem., 
2001, 44, 672–680. 
128. R.W. Brueggemeier, J.A. Richards, S. Joomprabutra, A.S. Bhat, J.L. Whetstone, 
Molecular pharmacology of aromatase and its regulation by endogenous and 
exogenous agents, J. Steroid Biochem. Mol. Biol., 2001, 79, 75–84. 
129. D.J. Manglesdorf, C. Thummel, M. Beato, P. Herrlich, G. Shutz, K. Umesono, B. 
Blumberg, P. Kastner, M. Mark, P. Charmbon, R.M. Evans, The nuclear receptor 
superfamily: the second decade, Cell, 1995, 83, 835-839. 
130. J.M. Beekman, G.F. Allan, S.Y. Tsai, M.J.O. Tsai, B.W. Malley, Transcriptional 
activation by the estrogen receptor requires a conformational change in the ligand 
binding domain, Mol. Endocrinol., 1993, 267, 19513-19520. 
131. D. Barton, C. Loprinzi, D. Wahner-Roedler, Hot flashes: aetiology and management, 
Drugs Aging, 2001, 18(8), 597-606. 
References 
148 
 
132. S.C. Manolagas, S. Kousteni, R.L. Jilka, Sex Steroids and Bone, Recent Prog. Horm. 
Res., 2002, 57, 385-409. 
133. M.J. Stampfer, G.A. Colditz, W.C. Willett, J.E. Manson, B. Rosner, F.E. Speizer, C.H. 
Hennekens, Postmenopausal estrogen therapy and cardiovascular disease. Ten-year 
follow-up from the nurses' health study, N. Engl. J. Med., 1991, 325, 756. 
134. D.A. Shewmon, J.L. Stock, C.J. Rosen, K.M. Heiniluoma, M.M. Hogue, A. Morrison, 
E.M. Doyle, T. Ukena, V. Weale, S. Baker, Tamoxifen and estrogen lower circulating 
lipoprotein(a) concentrations in healthy postmenopausal women, Arterioscler. 
Thromb., 1994, 14, 1586-1593. 
135. M.A. Limouzin-Lamothe, N. Mairon, C.R. Joyce, M. Le Gal, Quality of life after the 
menopause: influence of hormonal replacement therapy, Am. J. Obstet. Gynecol., 
1994, 170, 618-624. 
136. I.H. Russo and J. Russo, Role of hormones in mammary cancer initiation and 
progression, J. Mamm. Gland Biol. Neoplasia, 1998, 3, 49–61. 
137. P. Cos, T. De Bruyne, S. Apers, D. Vanden Berghe, L. Pieters, A.J. Vlietinck, 
Phytoestrogens: recent developments, Planta Med., 2003, 69, 589–599. 
138. S.B. Katzenellenbogen, J.A. Katzenellenbogen, Estrogen receptor transcription and 
transactivation: estrogen receptor-alpha and estrogen receptor beta–regulation by 
selective estrogen receptor modulators and importance in breast cancer, Breast Cancer 
Res., 2000, 2, 335–344. 
139. E. Minami, M. Taki, S. Takaishi, stereochemistry of cis and trans-hinokiresional and 
their estrogen like activity, Chem. Pharm. Bull., 2000, 48(3), 389-392. 
140. J.C. Le Bail, Y. Champavier, A.J. Chulia, G. Habrioux, Effects of phytoestrogens on 
aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human 
breast cancer cells, Life Sci., 2000, 66(14), 1281–1291. 
141. Y.J. Moon, X. Wang, M.E. Morris, Dietary flavonoids: effects on xenobiotic and 
carcinogen metabolism, Toxicol. In Vitro, 2006, 20(2), 187–210. 
142. C.R. Sirtori, A. Arnoldi, S.K. Johnson, Phytoestrogens: end of a tale?, Ann. Med., 
2005, 37(6), 423–438. 
143. J. Allan, R. Robinson, Accessible derivative of chromonol, J. Chem. Soc., 1924, 2192–
2194. 
144. H.S.Mahal, K.Venkataraman, Curr. Sc., 1933, 4, 214—216. 
145. T.S. Wheeler, “Organic Syntheses,” Collective Vol. IV, 2nd ed. By N. Rabojohn, John 
Wiley & Sons, New York, 1967, p. 478—481. 
References 
149 
 
146. M. Iinuma, K. Iwashima, S. Matsuura, Synthetic Studies on Flavone Derivatives. XIV. 
Synthesis of 2',4',5'-Trioxygenated Flavones, Chem. Pharm. Bull., 1984, 32(12), 
4935—4941. 
147. A. Hercouet, M. LeCorre, A simple synthesis of chromene, Synthesis, 1982, 597—
598. 
148. T.S. Kukhareva, V.A. Karsnova, M.P. Koroteev, Electrophilic subistitution in 
dihydroquercetin system. Aminomethylation, Russian journal of organic chemistry, 
2004, 40(8), 1190-1193. 
149. T.G. van Aardt, P.S. van Heerden, D. Ferreira, The First Direct Synthesis of 
Pterocarpans via Aldol Condensation of Phenylacetates with Benzaldehydes, 
Tetrahedron Letters, 1998, 39, 3881-3884. 
150. A.R. Ibrahim, Y.J. Abul-Hajj, Microbiological transformation of chromone, 
chromanone, and ring A hydroxyflavones, Journal of Natural Products, 1990a, 53, 
1471–1478. 
151. A.R. Ibrahim, Y.J. Abul-Hajj, Microbiological transformation of flavone and 
isoflavone, Xenobiotica, 1990b, 20, 363–373. 
152. A.R. Ibrahim, A.M. Gatal, J.S. Mossa, F.S. El-Feraly, Glucose- conjugation of the 
flavones of Psiadia arabica by Cunninghamella elegans, Phytochemistry, 1997, 46, 
1193–1195. 
153. I.O. Anyanwutaku, E. Zirbes, J.P.N. Rosazza, Isoflavonoids from streptomycetes: 
origins of genistein, 8-chlorogenistein, and 6,8-dichlorogenistein, Journal of Natural 
Products, 1992, 55, 1498–1504. 
154. P. Janeiro, O. Corduneanu, A. Maria, O. Brett, Chrysin and taxifolin electrochemical 
mechanisms, Electroanalysis, 2005, 17(12), 1059-1064. 
155. S.V. Jovanovic, S. Steenken, M.G. Simic, Y. Hara, in Flavonoids in Health and 
Disease (Eds: C. A. Rice-Evans, L. Packer), Marcel Dekker, New York 1998, p 137. 
156. A.S. Pannala, T.S. Chan, P.J.O. Brien, C.A. Rice-Evans, Flavonoid B-ring chemistry 
and antioxidant activity: Fast reaction kinetics, Biochem. Biophys. Res. Comm., 2001, 
282, 1161-1168. 
157. H. Hotta, S. Nagano, M. Ueda, Y. Tsujino, J. Koyama, T. Osakai, Higher radical 
scavenging activities of polyphenolic antioxidants can be ascribed to chemical 
reactions following their oxidation, Biochim. Biophys. Acta, 2002, 1572(1), 123-132. 
References 
150 
 
158. H. Hotta, H. Sakamoto, S. Nagano, T. Osakai, Y. Tsujino, Unusually large numbers of 
electrons for the oxidation of polyphenolic antioxidants, Biochim. Biophys. Acta, 
2001, 1526(2), 159-67. 
159. P. Zuman, J.J.M. Holthuis, Recueil des Travaux Chimiques des Pays-Bas, 1988, 107, 
403. 
160. A. Maria, O. Brett, M.E. Ghica, Electrochemical Oxidation of Quercetin, 
Electroanalysis, 2003, 15, 1745-1750 
161. G. Konig, H. Rimpler, Iridoid glucosides in Avicennia marina, Phytochemistry, 1985, 
24, 1245–1248. 
162. C. Mannich, W. Krosche, Ueber ein Kondensationsprodukt aus Formaldehyd, 
Ammoniak und Antipyrin, Archiv der Pharmazie, 1912, 250, 647–667. 
163. P.M. Dewick, Medicinal Natural Products “A Biosynthetic Approach”, John Wiley & 
Sons, Ltd, 2002, 18-19. 
164. E.R. Alexander, E.J. Underhill, Studies on the Mechanism of the Mannich Reaction. I. 
Ethylmalonic Acid, A Methynyl Compound, J. Am. Chem. Soc., 1949, 71(12), 4014–
4019. 
165. A. Ouchi, S. Liu, Z. Li, S.A. Kumar, T. Suzuki, T. Hyugano, H. Kitahara, Factors 
Controlling Photochemical Cleavage of the Energetically Unfavorable Ph−Se Bond of 
Alkyl Phenyl Selenides, J. Org. Chem., 2007, 72(23), 8700-8706. 
166. E.A. Thompson, P.K. Siiteri, Utilization of oxygen and reduced nicotinamide adenine 
dinucleotide phosphate by human placental microsomes during Aromatization of 
Androstenedione, J. Biol. Chem., 1974, 249, 5364-5372. 
167. J. W. Clark-Lewis, I. Dainis, Flavan derivatives. XI. Teracacidin, melacacidin, and 
7,8,4'-trihydroxyflavonol from Acacia sparsiflora, and extractives from Acacia orites, 
Australian Journal of Chemistry, 1964, 17 (10), 1170-1173. 
168. W. Jyh-Horng, T. Yu-Tang, C. Shih-Chang, W. Sheng-Yang, K. Yueh-Hsiung, S. Lie-
Fen, C. Shang-Tzen, Effect of Phytocompounds from the Heartwood of Acacia 
confusa on Inflammatory Mediator Production, J. Agric. Food Chem., 2008, 56, 1567–
1573. 
169. S.K. Sadhu, P.M. Phattanawasin, S.K. Choudhuri, T.O.M. Ishibashi, A new lignan 
from Aphanamixis polystachya, J. Nat. Med., 2006, 60, 258–260.  
170. B. Nay, V. Arnaudinaud, J. Peyrat, A. Nuhrich, G. Deffieux, J. Merillon, J. 
Vercauteren, Total Synthesis of Isotopically Labelled Flavonoids, 13C-Labelled (±)-
Catechin From Potassium [13C]Cyanide, Eur. J. Org. Chem., 2000, 1279-1283. 
References 
151 
 
171. M.J. Jung, S.S. Kang, H.A. Jung, G.J. Kim, J.S. Choi, Isolation of Flavonoids and a 
Cerebroside from the Stem Bark of Albizzia julibrissin, Arch. Pharm. Res., 2004, 
27(6), 593-599. 
172. M.J.C. Falcao, Y.B.M. Pouliquem, M.A.S. Lima, N.V. Gramosa, L.V. Costa-Lotufo, 
G.C.G. Militao, C. Pessoa, M.O. De Moraes, E.R. Silveira, Cytotoxic flavonoids from 
Platymiscium floribundum, J. Nat. Prod., 2005, 68 (3), 423-426. 
173. N. De Tommasi, S. Piacente, C. Pizza, Flavonol and Chalcone Ester Glycosides from 
Bidens, J. Nat. Prod., 1998, 61, 973-977. 
174. Y.H. Kim, J. Kim, H. Park, H.P. Kim, Anti-inflammatory Activity of the Synthetic 
Chalcone Derivatives: Inhibition of Inducible Nitric Oxide Synthase-Catalyzed Nitric 
Oxide Production from Lipopolysaccharide-Treated RAW 264.7 Cells, Biol. Pharm. 
Bull., 2007, 30(8), 1450—1455. 
175. C. Franco, B. Adriana, M. Fedele, S. Daniela, C. Paola, G. Arianna, B. Olivia, T. 
Paola, C. Roberto, T.L. Francesco, A. Stefano, O. Francesco, L. Thierry, T.L.A. 
Francesco, Synthesis, Biological Evaluation and 3D-QSAR of 1,3,5-Trisubstituted-
4,5- Dihydro-(1H)-Pyrazole Derivatives as Potent and Highly Selective Monoamine 
Oxidase A Inhibitors., Current Medicinal Chemistry, 2006, 13, 1411-1428. 
176. M. Sanchez-Gonzalez, J.P.N. Rosazza, Microbial Transformations of Chalcones: 
Hydroxylation, O-Demethylation, and Cyclization to Flavanones, J. Nat. Prod., 2004, 
67, 553-558. 
177. A. Major, M. Nogradi, B. Vermes, M. Kajtar-Peredy, Synthese der naturlichen 
Tsoflav-3-ene Haginin A, B und D., Liebigs Ann. Chem., 1988, 555–558. 
178. Y. Goda, F. Kiuchi, M. Shibuya, Inhibitor of prostagland biosynthesis from Dalbergia 
odorifera, Chem. Pharm. Bull., 1992, 40(9), 2452-2457.  
179. J.S. Yadav, B.V. Subba Reddy, G. Kondaji, Intermolecular imino-Diels-Alder reaction 
in [bmim] BF4 ionic medium: Green protocol for the synthesis of 
tetrahydrochromanoquinolines, J. of molecular catalysis A: Chemical, 2006, 258, 361-
366. 
180. G. Sabitha, E.V. Reddy, J.S. Yadav, Bismuth(III) chloride-Catalyze intramolecular 
hetro Diels-Alder reaction: Application to the synthesis of tetrahydrochromano[4,3-
b]quinoline derivative, Synthesis, 2001, 10, 1979-1984. 
181. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays, J. Immunol. Methods, 1983, 65, 55-63. 
References 
152 
 
182. L.M. Green, J.L. Reade, C.F. Ware, Rapid Colormetric Assay for Cell Viability: 
Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines, J. 
Immunol. Methods, 1984, 70(2), 257-268. 
183. S. Gobbi, A. Cavalli, A. Rampa, F. Belluti, L. Piazzi, A. Paluszcak, R.W. Hartmann, 
M. Recanatini, A. Bisi, Lead Optimization Providing a Series of Flavone Derivatives 
as Potent Nonsteroidal Inhibitors of the Cytochrome P450 Aromatase Enzyme, J. 
Med. Chem., 2006, 49, 4777-4780. 
184. J. Baumann, G. Wurn, F.V. Bruchlausen. Prostaglandin synthetase inhibiting O-2 
radical scavenging properties of some flavonoids and related phenolic compounds. 
Deutsche Pharmakologische Gesellschaft Abstracts of the 20th spring meeting, 
Naunyn-Schmiedebergs Abstract No: R27 cited in Arch. Pharmacologia, 1979, 307, 
R1–R77. 
185. M. Hosny, A.J. Holly, K.U. Amanda, J.N.P. Rosozza, Oxidation, reduction and 
methylation of carnosic acid by Nocardia, J. Nat. Prod., 2002, 65, 1266–1269. 
186. T. Iwashina, J. Kitajima, Chalcone and flavonol glycosides from Asarum canadense 
(Aristolochiaceae), Phytochemistry, 2000, 55, 971–974. 
187. Y. Omura, Y. Taruno, Y. Irisa, M. Morimoto, H. Saimoto, Y. Shigemasa, 
Regioselective Mannich reaction of phenolic compounds and its application to the 
synthesis of new chitosan derivatives, Tetrahedron Letters, 2001, 42, 7273–7275. 
188. X. Zheng,, W. Meng, Y. Xu, J. Cao, F. Qing,  Synthesis and anticancer effect of 
chrysin derivatives, Bioorganic & Medicinal Chemistry Letters, 2003, 13(5), 881-884. 
189. P. Yaipakdee, L.W. Robertson, Enzymatic halogenation of flavanones and flavones, 
Phytochemistry, 2001, 57, 341-347. 
190. L. Chen, T.S. Hu, J. Zhu, H. Wu, Z.J. Yao, Application of a Regioselective Mannich 
Reaction on Naringenin and its Use in Fluorescent Labeling, SYNLETT, 2006, 8, 
1225–1229. 
191. M.M. Garazd, Y.L. Garazd, A.S. Ogorodniiehuk, V.V. Shilin, A.V. Turov, V.P. 
Khilya, Mannich reaction in the series of 7-hydroxy-3-phenoxychromones and their 
derivatives, Chemistry of Natural Compounds, 1998, 34,(4), 442-447. 
192. M. Fontes, X. Verdaguer, L. Sola, M.A. Perica, A. Riera, 2-Piperidino-1,1,2-
triphenylethanol: A Highly Effective Catalyst for the Enantioselective Arylation of 
Aldehydes, J. Org. Chem., 2004, 69, 2532-2543. 
References 
153 
 
193. K. Suzuki, K. Kondo, T. Aoyama, Asymmetric Synthesis of Diarylmethanols by 
Rh(I)-Catalyzed Arylation of Aromatic Aldehydes with Arylboronic Acid, 
SYNTHESIS, 2006, 8, 1360–1364. 
194. R. Monteiro, I. Azevedo, C. Calhau, Modulation of Aromatase Activity by Diet 
Polyphenolic Compounds, J. Agric. Food Chem., 2006, 54, 3535-3540  
 
Curriculum Vitae 
 
Hamdoon Mohammed 
 
Personal Information: 
 
           Date of birth      : 6/1/1975 
 
           Nationality         : Egyptian 
 
           E-mail               : h.mohammad@mx.uni-saarland.de 
                                        hamdoonhmdn@yahoomail.com 
                           
Objectives: 
It is my ambition to investigate the chemical and biological properties of natural products, 
with particular focus on compounds extracted from plants.  
The importance of Flavonoids and phenolic natural products in plant defense is widely 
acknowledged. There is also significant potential for the beneficial application of these natural 
products in agriculture and medicine. Research into the structural modification of flavonoids 
could provide knowledge that could be implemented in the development of treatments against 
modern diseases such as AIDS, Hepatitis and certain types of Influenza.     
Synthetic chemistry is often necessary for the reproduction of naturally-occurring 
compounds in cases where there are difficulties in isolation, extraction and purification, or if the 
natural product is very rare. Through synthetic chemistry it is also possible to enhance or modify 
these natural compounds, thus producing novel drugs for further investigation. 
Isolation of natural products, biological assays and synthesis of active compounds or 
modification to improve their biological activity will be the main focus of my work in the future.   
 
Education:  
August 1998: Bachelor of the pharmaceutical sciences, Faculty of pharmacy, Al-Azhar 
University, Cairo, Egypt. 
July 2004: Master degree “Antioxidant activities of some plants belong to family 
leguminosea”, Faculty of pharmacy, Al-Azhar University, Cairo, Egypt. 
 
 
Work Experience: 
1) Five years as a demonstrator in the Department of Pharmacognosy, Faculty of pharmacy, 
Al-Azhar University, from 2000 to 2004.  
2) Assistant Lecturer in the Department of Pharmacognosy, Faculty of pharmacy, Al-Azhar 
University, from 2004 to 2007. 
3) Ph D student in the Department of Bioorganic Chemistry, Faculty of Pharmacy,   Saarland 
University, Germany, from 2007 up to now. During which I have developed my practical 
knowledge of synthetic chemistry and biological assays (for example, Aromatase assays and 
estrogen receptor binding assays) and have also gained important experience in handling 
advanced scientific equipment and instruments e.g. NMR, LC MS, Beta counter and HPLC. 
It is perhaps in the isolation and purification of natural products that I have developed my 
skills most effectively, largely due to the prevalence of these chromatographic techniques in 
my Masters Thesis and PH D project. 
 
International Conferences  
Poster presentation “Selenium, Tellurium and Transition Metals as Chemical Ingredients 
of Intelligent Antioxidants” in EUROBIC9 - 9th European Biological Inorganic Chemistry 
Conference, 2-6 September 2008, Wroclaw, Poland, Europe 
 
Publication 
Hamdoon A. Mohammed, Lalla A. Ba-Bernardi, Torsten Burkholz, Elena Gurevich, Britta 
Diesel, Josef Zapp, Alexandra K. Kiemer, Rolf W. Hartmann, Mohammed Hosny and Claus 
Jacob. Facile synthesis of tricyclic chromene-flavones with cytotoxicity against HL-60 cells and 
distinct activity as aromatase inhibitors. Under preparation. 
 
References 
                                       1- Dr. Claus Jacob, Junior Professor Bioorganische Chemie, University 
of Saarland, Saarbrücken, Germany 
                                        Tel.: +49 (0)681 302 3129 
Fax: +49 (0)681 302 3464 
c.jacob@mx.uni-saarland.de 
 
                                       2- Dr. Mohammed Hosny, Professor and head of Pharmacognosy Dept.  
                                         Faculty of pharmacy, Al-Azhar Uni. Cairo, Egypt, 
                                         mohmmedhosny@hotmail.com 
                                        3- Dr. Lalla Aicha Ba, PostDoc., Bioorganic Chemistry, University of     
Saarland, Saarbrücken, Germany 
                                         Tel.  +49 (0)681 302 3 339 
 Fax: +49 (0)681 302 3464 
 la.ba-Bernardi@mx.uni-saarland.de 
 
 
 
 
 
 
 
